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Abstract 
 
Our current understanding of the host response to pathogenic insult is in constant flux. The 
long term goal is to better understand the host response so as to design better therapeutics 
with higher efficacies and less side effects. Thus, the current work sought to increase our 
understanding the immune response to viral and bacterial perturbation of host signalling 
pathways. The TIR-domain containing adaptor TRAM is a relatively understudied protein 
with regard to TLR signalling, particularly with respect to type-I inferferon production. A re-
evaluation of the role of TRAM in TLR7 signalling showed that TRAM is required for 
maximal levels of TLR7 mediated RANTES, CXCL10 and IFNβ cytokine secretion but not 
TNFα production. TLR7 signalling was shown to activate IRF3 and NFκB in murine bone 
marrow derived macrophages. However, while TLR7 mediated IRF3 activation was TRAM 
dependent, NFκB activation was not. TRAM was also shown to mediate signalling via a 
physiological activator of TLR7, human rhinovirus 16 (HRV16). TRAM’s role in TLR7 is 
hypothesised to be dependent on its ability to membrane localise as overexpression of a 
TRAM myriostoylation mutant which is incapable of membrane localisation dose 
dependently inhibited  TLR7 mediated activation of RANTES, IFNβ, IFNα but not NFκB 
reporter genes. Furthermore, TRAM was shown to co-immunoprecipitate with the TLR7 
adaptor molecule MyD88 upon TLR7 activation.  This is first time that either IRF3 or TRAM 
has been shown to play role in TLR7 signalling. The second part of this project focused on 
the characterisation of the proteomic response to two respiratory pathogens, HRV16 and 
Bordetella pertussis (B. pertussis) in a lung epithelial cell line using mass spectrometry. 
Significant alternations were observed in the host proteome in response to both pathogens 
with proteins involved in the immune response, redox signalling, cancer related pathways, 
metabolism and DNA binding being particularly well represented. There was also a 
significant overlap between proteins identified in response to both infections with immune 
11 
 
response proteins being responsible for a third of the overlap. Supression of endogenous 
levels of a number of protein hits prior to infection with either HRV16 or B. pertussis did not 
affect levels of cytokine secretion. However, suppression of two proteins, the microtubule 
regulator stathmin 1 and the protein phosphatase PPP1Cα led to a significant decrease in 
TLR4 mediated IL-6 production.  Thus the current work has indicated novel roles for a 
number of proteins in the host response to pathogen challenge.  TRAM is required for 
maximal TLR7 mediated anti-viral cytokine secretion and both stathmin 1 and PPP1Cα are 
required for maximal TLR4 mediated IL-6 production. 
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1.1 Innate Immunity and Toll-like receptors 
The innate immune system encompasses an array of systemic defences whose principle role 
is to clear an infection or, failing that, to keep it in check until the pathogen can be recognised 
and cleared by the adaptive immune response. These defences range from relatively simple 
yet effective physical barriers such as the body’s epithelia or the respiratory tract’s cilia to 
those at the molecular level such as the production of nitric oxide by macrophages to degrade 
phagocytosed pathogens [1]. It is at this molecular level of innate immunity where an 
explosion of research has occurred over the past fifteen years allowing for the discovery and 
characterisation of several intrinsic classes of proteins and their associated signalling 
pathways in exquisite detail [2]. Toll-like receptors (TLRs) are one such class.  Belonging to 
an evolutionary ancient molecular recognition and signalling system, these type 1 
transmembrane glycoproteins represent a link between the innate and adaptive immune 
responses [3].  
 
1.1.1 TLRs 
The transmembrane Toll protein was first discovered in the fruit fly Drosophila melanogaster 
and was originally known only for its function in embryogenesis [4]. It took over a decade for 
proof of its role in defence against fungal and bacterial infections in the fruit fly to become 
apparent [5, 6]. A similar role in the mouse was also discovered where defects in the bacterial 
cell wall component lipopolysaccharide (LPS), mediated immune responses were attributed 
to mutations in the tlr4 gene [7]. TLRs have since been described in insects and vertebrates 
including humans and the chicken [8-10]. Structurally similar proteins which include the 
functionally crucial toll/interleukin-1 receptor (TIR) domain and leucine-rich repeats (LRR) 
(Figure 1.1A) have also been reported in plants [11], emphasising their broad conservation 
throughout evolution and thus their fundamental importance in defence against pathogens.   
22 
 
TLRs function by recognizing conserved structural motifs, or pathogen associated molecular 
patterns (PAMPs) which are inherent to infectious organisms and rarely found in the host. 
These are unique to pathogens and allow the host immune system to distinguish non-self 
from self and thus initiate an intracellular signalling cascade which can bring about the 
appropriate innate and adaptive immune response (Figure 1.1B).  
There are 10 functional human TLRs, each with their own particular ligand(s) specificity and 
effector function. For example, TLR2 can heterodimerise with either TLR1 or TLR6 to 
recognise triacylated or diacylated lipopeptides respectively [12]. TLR4 recognises the gram-
negative bacterial cell wall component LPS, whereas TLR3 and TLR9 recognise signature 
double stranded RNA (dsRNA) and unmethylated -cytosine-phosphate-guanine- (CpG) 
motifs respectively [13]. TLR5 senses flagellin, a component of bacterial flagella [14] and 
TLR 7 and TLR8 sense viral single stranded RNA (ssRNA) [15]. Mysteries remain however, 
as the ligand for TLR10 has yet to be discovered [16]. TLRs are also activated by host 
derived, sterile inflammatory mediators known as danger-associated molecular pattern 
(DAMPs), for example hyaluronan - an extracellular matrix fragment [17]. Thus each 
member of the TLR family senses different PAMPs and DAMPs, leading to the activation of 
TLR signalling.   
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Figure 1.1: Basic TLR structure and signalling. (A) The divergent ligand binding 
ectodomain of all TLRs consists of multiple leucne rich repeats (LRRs) interspersed with 
cysteine-rich regions. There is a short transmembrane domain linking the ectodomain to the 
highly conserved intracellular TIR domain which bears close resemblance to the IL-1R 
intracellular domain. (B) Recognition of a conserved pathogen associated molecular pattern 
(PAMP) by TLR4 causes TLR activation, typically by dimerisation and subsequent TIR-TIR 
domain interactions and autophosphorylation. This induces a downstream signalling process 
involving a MyD88 dependent or MyD88 independent pathway which culminates in the 
transcription of inflammatory and anti-viral cytokines. Adapted from [15, 18]. 
 
1.1.2 TLR adaptor proteins  
The downstream dissemination of TLR signalling involves the recruitment of appropriate 
adapter proteins which bind to the cytoplasmic TIR-domain of the TLRs via their own 
intrinsic TIR-domains. There are four activating TLR adaptor proteins: myeloid 
differentiation factor 88 (MyD88), MyD88 adaptor-like (MAL); also known as Toll-IL-1 
adaptor protein (TIRAP), TIR-domain-containing adaptor inducing IFN-β (TRIF; also known 
as TICAM-1) and TRIF related adaptor molecule (TRAM; also known as TICAM-2 and 
TIRP) [12]. These adapter proteins couple to downstream protein kinases that ultimately lead 
to the activation of transcription factors such as nuclear factor-κB (NF-κB) and members of 
the interferon (IFN)-regulatory factor (IRF) family. The critical domain common to all five of 
the TLR adaptors as well as to the TLRs themselves is the TIR domain. This is located on the 
cytoplasmic portion of all TLRs and allows binding to the reciprocal TIR-domain on the 
A B 
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exposed surface of the adaptor molecule. The IL-1 receptor (IL-1R) also contains a TIR-
domain hence the existence of the TLR/IL-1R superfamily [13]. Despite the TLRs having 
somewhat similar signal transduction pathways, there is specificity with regard to their 
adaptor usage (Figure 1.6) [19]. MyD88 is the common downstream adaptor that is recruited 
by all TLRs, except TLR3 [20]. MAL is required for TLR4, and to a lesser extent, TLR2 
signalling [21, 22]. TRIF mediates TLR3 and TLR4 signalling [23]. Finally, TRAM mediates 
TLR4 signalling exclusively, acting as a bridging adaptor to recruit TRIF to the TLR4 
complex [23, 24]. In addition, an inhibitory TLR adaptor protein called sterile alpha and TIR 
motif-containing protein (SARM) has also been identified which negatively regulates TRIF 
mediated signalling (Figure 1.6) [25].  
TLR4 is the only TLR whose activation utilises all five TLR adaptor proteins and as a result, 
its signalling is split into two broad categories according to its use of the MyD88 adaptor. 
The ‘MyD88 dependent’ pathway is used by all TLRs except TLR3.  TLR3 utilises TRIF 
only (Figure 1.6) [12]. However, loss of MyD88 does not completely abolish TLR4 
signalling as is the case with other TLRs. The ‘MyD88 independent’ pathway uses the 
adapters TRAM and TRIF in the case of TLR4 signalling to activate anti-viral and late-stage 
inflammatory responses. Thus, the function of the adaptor proteins is to provide specificity to 
TLR signalling in order to tailor the resulting cytokine profile to best defend against the 
infectious agent. To summarise, TLR engagement in response to a PAMP or DAMP 
instigates the recruitment of the relevant TLR adaptor protein(s) which provides a docking 
platform for downstream effector signalling molecules. This culminates in the production of 
proinflammatory cytokines, chemokines, and antimicrobial type I IFNs (IFN-β and IFN-α) 
which serve to trigger an inflammatory and/or antimicrobial immune response to limit the 
infectious agent. The remainder of this section will provide a more detailed discussion of the 
functionality of each of the TLR adaptors. 
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1.1.3 MyD88 
 
 
Figure 1.2: Schematic illustrating domain segmentation of MyD88. MyD88 is 296 amino 
acids (aa) in length and contains two domains. At the C terminus (aa 1–110) is the death 
domain (DD) and at the N terminus (aa 155–296) is the TIR domain. Adapted from [26]. 
 
Human myeloid differentiation factor 88 (MyD88) was first identified in 1990 as the 88 th 
gene that was induced during the terminal differentiation of myeloid precursor cells in 
response to IL-6 [27]. It is 296 amino acids (aa) in length and contains three domains: an N-
terminal death domain (DD) which enables interactions with downstream DD containing 
proteins, an interdomain, and a C-terminal TIR domain which facilitates homotypic 
interaction with other TIR-containing proteins (Figure 1.2) [28]. Early studies indicated that 
its 5’ upstream sequences contained an interferon regulatory factor 1 (IRF-1) binding site and 
in 1997, it was identified as an adaptor in the IL-1R complex that was required for IL-1 and 
IL-18 signalling [29-32]. Almost immediately after these discoveries, the fundamental 
importance of MyD88 in an immunological setting was becoming evident as mice deficient 
in the protein were shown to be unresponsive to the bacterial cell wall component endotoxin, 
a critical mediator of septic shock [33, 34]. It was eventually shown to be the master adaptor 
molecule in mediating TLR2 signalling and subsequently also in TLR4, TLR5, TLR7/8, 
TLR9, TLR13 but not TLR3 [35-42].  
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1.1.3.1 MyD88 mediated signalling 
MyD88 exists primarily in the cytoplasm of resting cells wherein it is thought to exist in a 
weak and reversible oligomerised form [43, 44].  Upon TLR activation and consequent TIR-
dimerisation, MyD88 binds to the TLR complex via its TIR-domain, thus stabilising its 
oligomeric form to provide a platform for downstream molecules to bind via DD-DD 
interactions. Interleukin-1 receptor-associated kinase 4 (IRAK4), is the critical molecule 
downstream of MyD88, being absolutely required for MyD88 dependent signalling and for 
the recruitment of further downstream molecules, IRAK1 and IRAK2 (Figure 1.3) [45]. A 
crystal structure has been generated of the MyD88, IRAK4, IRAK2 DD complex which has 
shown that a left-handed helical oligomer is formed consisting of 6 MyD88, 4 IRAK4 and 4 
IRAK2 molecules [43]. Complex formation is hierarchical whereby MyD88 first recruits 
IRAK4. This complex, but not its individual parts, is required to recruit IRAK2 or the related 
IRAK1. The resulting structure has been termed the Myddosome and serves to bring the 
kinase domains of the IRAK molecules into close proximity to drive their 
autophosphorylation [43, 44]. Phosphorylation of the IRAKs recruits the E3 ubiquitin ligase, 
TNFR-associated factor -6 (TRAF6) which ubquitinates itself [46]. TRAF6 utilises its E3 
ubiquitin ligase activity to ubiquitinate a scaffolding protein, NFκB essential modulator 
((NEMO) [47] (Figure 1.3). The combination of TRAF6 mediated ubiquitin chain formation 
and NEMO functions to recruit TGF-β activated kinase 1 (TAK1) which itself recruits the 
TAK-1 binding proteins 1 (TAB1) and TAB2. TAK1 phosphorylates IKKβ as well as 
initiating a MAP kinase cascade leading to activation of the transcription factor CREB. IKKβ 
phosphorylates the inhibitors of κB (IκB) α and IκBβ leading to NFκB release and nuclear 
translocation to bind the promoter regions of pro-inflammatory cytokines such as TNFα and 
IL-12 (Figure 1.3).  
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Figure 1.3: MyD88 dependent TLR signalling pathway. MyD88 binds to the intracellular 
protion of a TLR via TIR-TIR domain interactions. Upon TLR activation, IRAK-1, IRAK-4 
and TRAF-6 are recruited to the receptor causing MyD88-IRAK-1 interactions via death 
domain (DD) interactions. IRAK-4 phosphorylates IRAK-1 which phosphorylates TRAF-6. 
TRAF-6 then dissociates and interacts with TAK1, TAB1, and TAB2 which in turn recruits 
Ubc13 and Uev1A. This induced TAK1 activation which in turn activates the IKK complex 
consisting of IKKα, IKKβ and IKKγ/NEMO. The MAP kinase JNK is also activated. These 
then activate the transcription factors NFκB and AP-1 respectively which induce pro-
inflammatory gene expression. Adapted from [48].       
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1.1.4 MAL 
 
 
 
Figure 1.4: Schematic illustrating domain structure of MAL. Mal is 256 aa long. At the N 
terminus, there is a PIP2-binding domain (aa 15–35). This is followed by the TIR domain (aa 
86–188) and a TRAF6 domain (aa 188–196). There are two phosphorylation sites at positions 
86 and 187. Located at position 180 is the serine/leucine site linked to the genetic 
susceptibility to several diseases including TB and malaria. At position 198 is the aspartic 
acid indicating the presence of the caspase-1 cleavage site. Adapted from [26]. 
 
 
 
MAL, or TIRAP, the second TLR adaptor to be identified, was simultaneously discovered by 
two independent labs in 2001 [22, 49]. Having observed late stage NF-κB and Jun N-terminal 
kinase (JNK) activation in MyD88 deficient mice, Fitzgerald and colleagues [22], speculated 
that another, as yet unidentified TIR domain-containing adaptor protein was mediating this 
effect. High-throughput sequencing of a human DC expressed sequence tag cDNA library 
identified MAL – a TIR domain-containing protein, 235 aa in length (Figure 1.4), that was 
capable of activating NF-κB (via IRAK2) and JNK as well as extracellular signal-regulated 
kinase (ERK) -1 and -2. MAL was shown to homodimerise and heterodimerize with MyD88. 
It was also shown that a dominant-negative form of Mal inhibited TLR4 (but not IL-1R or IL-
18R) mediated NF-κB activation [22, 49]. It is generally accepted that MAL acts a bridging 
adaptor between MyD88 and TLR4 and TLR2 [15]. 
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1.1.4.1 MAL Localization 
MAL is localised primarily to the plasma membrane, although MAL-positive, actin-negative 
vesicles can be found throughout the cell [50]. MAL is concentrated at the leading edge of 
murine embryonic fibroblasts (MEFs) and in macrophages, MAL is localised to discrete 
regions of the plasma membrane called membrane ruffles which are biochemically similar to 
the leading edge of fibroblasts [50]. MAL interacts with the TIR domain of TLR2 and TLR4. 
This association is facilitated by the phosphatidylinositol 4,5-bisphosphate (PIP2)-binding 
domain contained within the N-terminal region of MAL. This allows MAL to target to PIP2-
rich regions of the plasma membrane which contain high levels of TLR2 and TLR4, thus 
facilitating their association with MAL [12, 50]. Notably, MAL is not involved in the 
recruitment of MyD88 to other compartments, including endosomal compartments devoid of 
PIP2. Further, in MAL/MyD88 double-deficient cells, transfection of a mutant construct 
which incorporates a PIP2 binding site to the C-terminus of MyD88 directs MyD88 to the 
plasma membrane and restores lipopolysaccharide (LPS) signalling via TLR4 [50]. Surface 
charge distribution models of MAL, MyD88, and TLR4 have shown that the TIR domains of 
TLR4 and MyD88 are electropositive – and would thus be expected to repel each other under 
normal circumstances. However, the TIR domain of MAL is electronegative which would 
facilitate binding of TLR4 to MyD88 in order to transduce TLR4 signalling [12, 51]. 
Moreover, molecular docking experiments have suggested that MAL binds to a homodimer 
of TLR4 and that MAL binds to the same region of the TLR4 dimer interface [52]. 
 
 1.1.4.2 Mal and TLR4 Signalling 
Ligand engagement of TLR4, for example, binding of LPS via MD-2 and cluster of 
differentiation 14 (CD14), causes TLR4 dimerisation and nonexclusive interaction with MAL. 
Docking experiments have predicted that the MAL (and TRAM) interaction surfaces on the 
TLR4 dimer interface are at either side of the structure rather than at the top, a region that 
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would be sterically hindered by the membrane [52]. The TLR4 dimer:MAL complex 
provides a platform allowing MyD88 to bind which then facilitates the recruitment of IRAK1 
and IRAK4. Tumour necrosis factor (TNF)-receptor-associated factor 6 (TRAF6) is 
subsequently recruited and activated via an oligomerisation/auto-ubiquitination event. 
Activated TRAF6 then recruits transforming growth factor activated kinase 1 (TAK1) and 
TAK1 binding protein 2 (TAB2). This complex interacts with the inhibitor of NF-κB kinase 
(IKK) complex, which consists of IKKα, IKKβ, and IKKγ (also known as NEMO), leading to 
the activation of NF-κB and subsequent activation of NF-κB-dependent genes, including the 
proinflammatory cytokines IL-1β, IL-6 and TNFα (Figure 1.6) [53]. 
 
1.1.4.3 MAL and TLR2 Signalling 
The role of MAL in TLR2 signalling is complicated by the fact that TLR2 can heterodimerise 
with both TLR1 and TLR6 to recognize tri- and diacylated lipopeptides, respectively. 
Overexpression studies have shown that MAL interacts with TLR1 and TLR2, but not TLR6 
[21]. Although MAL was originally suspected to be essential for TLR2 signalling, more 
recent studies have shown that MAL plays a lesser role here when compared to TLR4 [21, 
49]. Specifically, whilst MAL is required for TLR2 signalling when exposed to low levels of 
Salmonella typhimurium (S. typhimurium), MAL is redundant at high concentrations of 
ligand or in response to high levels of S. typhimurium [21]. This suggests that the 
physiological role of MAL in the context of TLR2 signalling is to prime or amplify low 
strength bacterial signals. 
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1.1.4.4 Modulators of MAL Functionality 
Additional levels of specificity and control are added to TLR signalling by virtue of the fact 
that the TLR adaptors themselves are subject to a myriad of regulatory mechanisms. MAL 
contains a proline, glutamic acid, serine, and threonine (PEST) domain, located at amino 
acids 32–72 in human MAL [54]. PEST domains are found in short-lived proteins which 
undergo phosphorylation, polyubiquitination of lysine residues, and subsequent degradation 
via the 26S proteasome. The presence of a PEST domain in MAL would therefore suggest 
that it may be a target for degradation. Interestingly, suppressor of cytokine signalling 1 
(SOCS-1), has been shown to inhibit LPS signalling by ubiquitinating MAL and thus 
targeting it for proteosomal degradation [55] . The ubiquitination of MAL is facilitated by 
Bruton’s tyrosine kinase (Btk) – a protein which is the case of MAL, performs two important 
functions. Specifically, Btk induces tyrosine phosphorylation of MAL, thus potentiating 
TLR2/4-driven NF-κB signalling [56]. However, the same phosphorylation event provides a 
platform for the aforementioned SOCS-1 mediated ubiquitination/degradation of MAL – thus 
serving to limit the over-activation of the inflammatory immune response [12]. IRAK1 and 
IRAK4 have also been shown to phosphorylate MAL, thereby facilitating its TLR4-ligand-
mediated ubiquitination and degradation; IRAK1 and IRAK4 inhibitors blocked this effect 
[57]. MAL has also been shown to interact with caspase-1, with cleavage of MAL by 
caspase-1 being required to modulate MAL functionality [58]. A number of studies have been 
carried out on a variant of MAL that contains a leucine at position 180 instead of a serine [59-
61]. It has been reported that MAL Ser180Leu does not associate with TLR2 and confers a 
protective phenotype in malaria and tuberculosis by inhibiting the inflammatory response. 
Other groups dispute this claim [28]. Overall, the studies to date indicate an association 
between heterozygosity at MAL Ser180Leu and protection against multiple infections. 
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1.1.5 TRIF 
Initially, MAL was thought to mediate the MyD88-independent pathway following TLR4 
engagement, leading to IRF3 activation and delayed activation of NF-κB [12]. However, 
given that MAL was instead shown to act as a bridging adaptor in the MyD88-dependent 
pathway which was activated following TLR4/TLR2 engagement, it remained unclear how 
TLR4 might mediate the MyD88 independent production of IFN-β [12]. In 2003, a third TLR 
adaptor, TRIF, also known as TICAM-1, was identified by two separate groups. One 
employed a database screen to identify novel TIR-domain containing proteins with the other 
employing a yeast two-hybrid screen using TLR3 as bait [41, 62]. It was found that 
overexpression of TRIF, 712 aa in length (Figure 1.5), leads to the induction of the IFN-β 
promoter. In TRIF-deficient mice, whilst impaired TLR3 and TLR4 mediated IRF3 activation 
and concomitant IFN-β induction was observed, TLR2, TLR7 and TLR9 signalling were 
unaffected [63]. Notably, TLR4 mediated NF-κB activation is completely abolished in cells 
deficient in both MyD88 and TRIF and a germline TRIF mutation in mice termed Lps2 
confirmed TRIF’s essential role in mediating ‘MyD88-independent’ pathway [28, 63, 64].  
 
Figure 1.5: Schematic illustrating domain segmentation of TRIF. TRIF is 712 aa in 
length. It consists of a TRAF6-binding domain (aa 230–235), the TIR domain (aa 380–530) 
and a receptor-interacting protein (RIP) homotypic interaction motif (RHIM) (aa 661–699). 
Adapted from [26]. 
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1.1.5.1 TRIF Localisation 
TRIF is expressed at low levels in most tissues and cells and is diffusely localised in the 
cytoplasm of resting cells [65].  When endosomal TLR3 is activated by dsRNA, TRIF 
transiently colocalises with TLR3 and then dissociates from the receptor forming speckled 
structures that localise with downstream signalling molecules. Upon stimulation of TLR4 
with LPS, TRIF is activated by endosomal TRAM, which associates with the internalised 
TLR4 complex [65]. Thus, TRIF is indirectly recruited to TLR4 via TRAM (Figure 1.6). 
Also, overexpression of TRIF leads to homo-oligomerisation through the TIR-domain and the 
C-terminus, forming a complex called the TRIF signalosome [28, 65].   
 
1.1.5.2 TRIF and TLR3/4 Signalling 
TRIF has consensus TRAF-6 and TRAF-2 binding motifs in the N-terminal region as well as 
a C-terminal receptor-interacting protein (RIP) homotypic interaction motif (RHIM) domain 
[12, 65]. The TIR domain of TRIF is essential for binding to the TIR domain of TLR3 [62]. 
These domains serve to facilitate TRIF-mediated signalling, with each domain playing a 
distinct role. The N-terminal region of TRIF participates in IRF3/7 activation by recruiting 
the IRF3-activating kinases, TANK-binding kinase 1 (TBK1), and inhibitor of NF-κB kinase 
ε (IKKε, also known as IKKi) [12]. NAK-associated protein 1 (NAP-1) forms part a kinase 
complex activating IRF3 and also serving to facilitate the association of TRIF with TBK1 and 
IKKε (Figure 1.6) [66]. Upon TBK1/IKKε-mediated phosphorylation of the IRF3/7 complex, 
the IRFs homo and heterodimerise followed by their translocation to the nucleus. Here, they 
bind to both the IFN-β enhanceosome and the IFN-stimulated response elements (ISREs) to 
induce the transcription of responsive genes including the type-I IFN and RANTES, 
otherwise known as CCL5, genes [67]. TRAF3 plays a crucial role in TLR3 signalling as 
various independent studies show that TRAF3 forms a complex with NAP-1 and TRIF 
(Figure 1.6) [68, 69]. Two separate NF-κB activation pathways bifurcate from TRIF, and 
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these map to distinct sites at the N- and C-termini. The binding motifs in the N-terminal 
region of TRIF serve to recruit TRAF6, although its role in TRIF signalling remains 
controversial [12]. Studies suggest that the participation of TRAF6 in TRIF-mediated NF-κB 
induction is cell type specific as TRAF6 is essential for NF-κB activation in mouse 
embryonic fibroblasts (MEFs), whereas TLR3 induced NF-κB activation is not impaired in 
TRAF6-deficient macrophages [70, 71]. There is a separate route to NFκB activation 
involving the RHIM domain of TRIF which facilitates the recruitment of both RIP1 and RIP3 
through this domain (Figure 1.6) [72]. Adding credence to the importance of RIP1 and RIP3 
in TRIF signalling is the fact that poly(I:C)-induced NF-κB activation is completely blocked 
in RIP-1-deficient MEFs [73]. In contrast, RIP3 has been shown to negatively regulate the 
TRIF–RIP1–NF-κB pathway [72]. TRIF also mediates the induction of apoptosis through 
TLR3 and TLR4. This is facilitated by direct recruitment of RIP1 to the C-terminal RHIM 
domain of TRIF, and involves activation of a complex containing TNFR1 associated death 
domain protein (TRADD), Fas-associated protein with death domain (FADD), and caspase-8 
(Figure 1.6) [74]. This apoptotic pathway is believed to be responsible for bacterial-induced 
apoptosis of infected DCs [12]. 
  
1.1.5.3 TRIF and TLR5 Signalling 
Although it was thought that TRIF mediated TLR3 and TLR4 signalling only, a number of 
recent studies have shown that TRIF also plays an important role in TLR5 signalling (Figure 
1.6) [75, 76]. Stimulation of human colonic epithelial cells with the TLR5 ligand flagellin, 
allows TLR5 and TRIF, but not TRAM, to interact and mediate TLR5-induced NF-κB and 
mitogen-activated protein kinase (MAPK) activation in intestinal epithelial cells (IEC). 
TRIF-deficient IECs stimulated with flagellin exhibit decreased inflammatory cytokine 
expression compared to their wildtype counterparts. Furthermore, TRIF deficient mice are 
resistant to flagellin-mediated exacerbation of colonic inflammation and dextran sulphate 
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sodium–induced experimental colitis [75]. In contrast, studies by the same group have shown 
that TRIF-induced caspase activity causes the degradation of TLR5 indicating that TRIF can 
participate in the proteolytic modification of TLR functionality at the posttranslational level 
[76]. These recent findings therefore suggest that TRIF plays an important role in regulating 
host-microbial communication via TLR5 in the gut epithelium.    
 
1.1.5.4 TRIF and Cytosolic dsRNA Detection 
A further role for TRIF in innate immune signalling, independent of the TLRs, has recently 
been identified whereby TRIF appears to be an essential component of a novel dsRNA 
sensing pathway in DCs [77]. Specifically, the RNA helicases DEAD box helicase 1 (DDX1), 
DDX21, and DEAH box helicase 36 (DHX36) form a complex which enables the 
sequestration of cytosolic dsRNA. This complex then binds to TRIF to initiate the production 
of type I IFN and inflammatory cytokines. It has been shown that DDX1 binds dsRNA via its 
helicase A domain, with DHX36 and DDX21 binding to TRIF via their HA2-DUF and PRK 
domains respectively. The resulting complex triggers the innate antimicrobial response [77]. 
 
1.1.5.5 Negative Regulation of TRIF 
Numerous strategies exist to curtail TRIF signalling, either directly, or via inhibition of 
downstream signalling molecules.  A number of molecules have been identified that directly 
inhibit TRIF. For example, the inhibitory TLR adaptor protein SARM contains a TIR domain 
and serves to inhibit TRIF mediated signalling. SARM has been shown to interact with TRIF 
and both the TIR and SAM domains of SARM are vital for SARM’s functionality in this 
regard. While the exact mechanism of inhibition has not been elucidated, it is suspected that 
SARM and TRIF interact via their TIR domains, thus preventing the binding of downstream 
effector molecules such as RIP1 (Figure 1.6) [25]. Alternatively, the SAM domain of SARM 
may facilitate recruitment of an as yet unidentified inhibitory molecule. Consistent with a role 
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for TRIF in restricting viral replication through type I IFN induction, at least two viruses have 
been shown to contain proteins that antagonize TRIF. Vaccinia virus (VACV) encoded 
proteins, A46R and A52R, differentially affect TRIF signalling. A46R interacts directly with 
TRIF and inhibits TRIF mediated TLR3 signalling. Notably, A46R also interacts with the 
other TLR adaptors and also inhibits TLR4 signalling [78]. In contrast, A52R acts 
downstream of the adaptors by targeting TRAF6 and IRAK2-containing complexes to inhibit 
TLR4, TLR2 and TLR5 signalling [79]. Hepatitis C virus (HCV) contains a serine protease 
NS3-4A that causes the proteolysis of TRIF. The cleavage of TRIF by NS3-4A inhibits both 
NF-κB and IRF3 activation by TLR3, thus disabling the innate immune response to the virus 
[80]. These examples illustrate the importance of TRIF in mediating the anti-viral signalling 
pathway such that specific inhibition by VACV and HCV confers an advantage to the viruses 
in vivo. 
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Figure 1.6: Overview of TLR signalling the role of the TIR-domain containing adaptors. MyD88 is the central adaptor in TLR signalling, 
capable of transducing signals mediated by all TLRs except TLR3. MyD88 does however negatively regulate TLR3-induced IRF3 activation. 
Regarding TLR1/2, TLR2/6, TLR4, and TLR5 signalling, MyD88 interacts with the each TLR though their TIR domains (red). IRAK4 is then 
recruited to the complex which in turn recruits IRAK1 and/or IRAK2 via death domain (DD) interactions. TRAF6 is then recruited to activate 
TAK1, leading to subsequent activation of MAPK and NF-κB. In the case of TLR7/8/9 signalling, the MyD88 complex can also recruit TRAF3 
which activates IRF7. TRIF is the sole adaptor involved in TLR3 signalling and recruits NAP1 and TRAF3 to activate the noncanonical IKKs, 
TBK1, and IKKε. These in turn phosphorylate IRF3 and IRF7 causing their translocation into the nucleus where they bind to the type I IFN 
(IFNα and IFNβ) gene promoters. TRIF is also required to mediate maximal TLR5-induced NF-κB and MAPK activation by binding directly to 
TLR5. As part of a suspected negative feedback loop, TRIF can also mediate caspase-dependent TLR5 degradation. MAL acts as a bridge to 
allow TLR4 and to a lesser extent TLR2, to signal via the MyD88 pathway. MAL also negatively regulates TLR3-mediated IRF7 activation. 
TRAM, like MAL, is another bridging adaptor and links TLR4 to the TRIF pathway. The Mal-MyD88 and TRAM-TRIF complexes facilitate 
bifurcation of the TLR4 pathway to allow for the synthesis of both inflammatory cytokines and type I IFN, respectively. The fifth adaptor 
SARM interacts with TRIF and impairs TRIF signalling 
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1.1.6 TRAM 
In 2003, the fourth TIR-domain-containing adaptor, TRAM, 235 aa in length, was identified 
following a bioinformatic search of the human genome database [23, 81]. It was initially 
thought that TRAM was involved in both TLR and IL-1R mediated NF-κB activation, but not 
IFN-β induction [81]. Subsequently, a more definitive description of TRAM showed that it 
interacts with TLR4 and TRIF to regulate TLR4-mediated IRF3 and IRF7 activation [23]. 
TRAM deficient cells have impaired TLR4-mediated cytokine production and B cell 
activation, as was observed with TRIF [24]. It is now accepted that TRAM acts as bridging 
adaptor between TLR4 and TRIF in the ‘MyD88-independent’ pathway [12].   
 
1.1.6.1 TRAM localisation and involvement in TLR4 signalling 
TRAM exclusively mediates TLR4 signalling. It activates the ‘MyD88-independent’ pathway 
by facilitating the association of TRIF with TLR4 - similar to the way in which MAL links 
TLR4 and MyD88 (Figure 1.6). To date, it serves no other known role in TLR signalling [15]. 
Regarding localisation, the N-terminal region of TRAM is constitutively myristoylated on its 
glycine at position two, which facilitates its association with the plasma membrane. Indeed, 
mutation of TRAM’s myristoylation motif abolishes its ability to signal [82]. A distinct 
requirement for TRAM signalling to occur is its phosphorylation on serine 16 by protein 
kinase C epsilon (PKCε) [83]. TRAM has also been shown to contain a bipartite sorting 
signal that modulates its trafficking between the plasma membrane and the endosomes. In 
fact, TRAM must be delivered to the endosomes in a complex with TLR4 to facilitate the 
activation of IRF3 [84]. Thus, activation of TLR4 sequentially induces two signalling 
pathways from two different cellular locations. The ‘MyD88-dependent’ pathway is induced 
from the plasma membrane, whereas the ‘MyD88-independent’ pathway is induced from 
endosomes (Figure 1.6).  
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1.1.6.2 Negative Regulation of TRAM 
VACV is capable of modulating TRAM functionality. An 11-aa-long peptide derived from 
the VACV protein A46R, termed viral inhibitor peptide of TLR4 (VIPER), has been shown 
to interact with TRAM (and MAL), towards inhibiting TLR4 signalling. Mechanistically, it 
has been postulated that masking of the critical binding sites on MAL and TRAM by VIPER 
specifically inhibits their ability to interact with the cytoplasmic TIR-domain of TLR4 - thus 
inhibiting its signalling [85]. A splice variant of TRAM, termed TRAM adaptor with Golgi 
dynamics (GOLD) domain (TAG), has been shown to competitively bind TRAM and 
displace TRIF during LPS signalling, leading to decreases in RANTES cytokine production 
without affecting NF-κB activation [86]. A second related protein, transmembrane emp24 
domain-containing protein 7 (TMED7), which sits next to TRAM and TAG on chromosome 
five, is also a TRAM inhibitor and thus a negative regulator of TLR4 signalling. Is it is 
believed that TMED7 interacts with both TAG and TRAM and is required for TAG’s ability 
to displace TRIF from TRAM [87]. 
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1.1.7 SARM 
Figure 1.7: Schematic illustrating domain segmentation of SARM. SARM is 690 aa in 
length and is made up of several domains. There are two SAM motifs between amino acid 
375 and 515 followed by the TIR domain between 515 and 660. Adapted from [26]. 
 
SARM was initially identified in 2001 as a human gene conserved across multiple taxa [88]. 
Structurally, SARM is 690 aa in length and contains two sterile alpha motifs (SAM) domains 
as well as a HEAT/Armadillo repeat motif (ARM) domain. Both the SAM and ARM 
domains are known to be involved in the formation of protein complexes [88]. It was initially 
shown that the Caenorhabditis elegans SARM homologue, TIR1, was important in the 
efficient immune response against fungal and bacterial infection [89]. However, in human 
cells, it was shown that unlike the other TIR-domain adaptors, overexpression of SARM 
failed to induce NF-κB or activate IRF3-dependent reporter genes and in fact inhibited their 
activation and expression [25]. In contrast, a later study showed that macrophages from 
SARM knockout mice responded normally to TLR3, TLR4, and TLR9 ligands, suggesting 
that mouse SARM has a redundant role in regulating macrophage responses to these TLR 
ligands [28]. Further research must be undertaken to definitively assign a role for SARM in 
TLR signalling. 
 
1.1.7.1 SARM and TLR3/4 Signalling 
Although disputed, it appears that in humans, SARM inhibits TRIF-mediated TLR3 and 
TLR4 signalling by selectively targeting TRIF. In unstimulated cells, SARM and TRIF are 
weak interactors, but stimulation with LPS or poly(I:C) induces SARM protein expression 
and enhances the interaction between SARM and TRIF [25]. SARM overexpression serves to 
inhibit TRIF-dependent, but not MyD88- or MAL dependent NF-κB activation. SARM also 
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inhibits poly(I:C)-mediated RANTES and IFN-β promoter activity (Figure 1.6). The exact 
mechanism utilized by SARM to impair TRIF functionality requires further investigation, 
however it is speculated that SARM may use its TIR domain to bind TRIF and use its SAM 
domains to recruit an as-yet-unidentified inhibitor. Alternatively, SARM may competitively 
block the ability of TRIF to directly interact with downstream signal transducers such as 
TBK1, RIP1, and TRAF6 [25]. 
 
1.1.7.2 SARM in the central nervous system 
A study conducted in SARM deficient mice has indicated a role for SARM in protection from 
death after central nervous system (CNS) infection with vesicular stomatitis virus (VSV) [90]. 
This was associated with reduced CNS injury and significantly reduced inflammatory 
cytokine production which would suggest that at least in the murine CNS, SARM is in fact a 
positive regulator of the innate immune response. Moreover, a seperate study conducted in 
SARM -/- mice also indicated its requirement for inflammatory cytokine production in the 
reponse to infection with West Nile virus (WNV) [91]. WNV replication was increased 
specifically within the brain stem of SRAM deficient mice compared to WT and this was 
associated with decreased levels of TNFα, decreaeed microglia activation and increased 
neuronal death [91]. 
 
1.1.8 Negative Regulation of TLR Signalling by TLR Adaptors 
A number of recent studies have highlighted the role of the TLR adaptors themselves in the 
curtailment of TLR signalling. For example, MyD88 has been shown to negatively regulate 
TLR3-TRIF-induced corneal inflammation through a mechanism involving JNK 
phosphorylation, but not p38, IRF3, or NF-κB and to inhibit TLR3-dependent IL-6 induction 
[21, 92]. MyD88 has also been shown to inhibit TLR3-dependent phosphorylation of IRF3 
and thus curtail TLR3-mediated IFN-β and RANTES production [93]. Furthermore, MAL 
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has been shown to inhibit TLR3 dependent IFN-β production through a mechanism that is 
distinct from MyD88, instead inhibiting TLR3 mediated IRF7 activation [94]. As already 
stated, SARM has been shown to inhibit TRIF-dependent TLR3 and TLR4 signalling (Figure 
1.6) [25]. 
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1.2 Proteomics and its applications in immunology 
The ability to compare the different functional states of a biological system has led to many 
major biological discoveries, a prime example being ubiquitination, having resulted from 
comparisons between stressed and normal cells [95]. Comparative genomics has fulfilled this 
need for the past decade and indeed led to many seminal discoveries particularly in genomic 
medicine [96].  However, proteins are typically the effector entities in biological systems and 
transcript analysis often poorly predicts the level of mature, activated protein [97]. A typical 
example is the inflammatory protein IL-1β whose function is dependent upon a bi-phasic 
regulatory process. An initial signal, termed signal 1, induces initial IL-1β mRNA 
transcription and subsequent translation to produce a zymogenic form called pro-IL-1β. A 
second signal is required to cleave pro-IL-1β into its active, secreted form [98]. Reliably 
defining the levels of this secreted, bioactive form of IL-1β would be impossible to detect by 
monitoring transcription levels alone. Therefore, proteomics can provide insights into key 
biological processes from a different and ultimately more functional perspective.   
By definition, proteomics is the global study of organismal proteins and can include their 
structure, isoforms, modifications, interactions, ordering and in essence, anything relating to 
proteins that is post-genomic. Genomics is however, of central importance in proteomics as it 
provides the blueprint of possible gene products from which we can readily identify and 
comprehend the proteome [99].  
 
1.2.1 Technique and Evolution 
Mass spectrometry is an analytical technique that measures ionised molecules in a gas phase 
in order to qualitatively and quantitatively study proteins and their modifications. At its core, 
a mass spectrometer (MS) consists firstly of an inlet system, for example, liquid or gas 
chromatography which performs an initial separation of complex protein mixtures prior to 
injection into the MS. Immediately prior to their entry into the MS, the samples are ionised 
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by what is known as an ion source. Sample ionisation is critical for analysis as MS mediated 
protein identification essentially occurs by measuring the mass:charge ratio (m/z) of 
incoming molecules and these sample molecules must therefore be charged or ionised for this 
to occur. Biological samples such as proteins and peptides are thermolabile and are thus best 
suited to soft ionisation techniques such as electrospray ionisation (ESI) and matrix-assisted 
laser desorption/ionisation (MALDI). Non thermolabile samples can be ionised using 
electron impact or chemical ionisation. ESI ionises the proteins from solution and is therefore 
easily combined with liquid chromatography for complex sample analysis. MALDI uses laser 
pulses to first sublimate and then ionise samples from a dry crystalline matrix and is more 
suited to analysis of less complex sample mixtures. The contribution of sample ionisation 
techniques such ESI and MALDI to mass spectrometry is illustrated by the awarding of the 
2002 Nobel Prize in Chemistry for their development. ESI was used exclusively in the 
current project.   
There are many different types of mass analyser with the most used being ion trap, time-of-
flight, quadrupole and Fourier transform ion cyclotron and orbitrap. Ion-trap and orbitrap 
were used in the current study. 
 
1.2.1.1 2D PAGE and 2D DIGE 
The study of proteomics was originally based upon two-dimensional polyacrylamide gel 
electrophoresis whereby protein lysates, solubilised from a cell population, tissue or 
biological fluid, are separated first according to their isoelectric point (first dimension) and 
secondly according to their molecular mass by SDS-PAGE (second dimension). Resolved 
proteins are then visualised by silver staining and the protein spot size between different gels 
(representing different biological conditions) could be visually, or as the technology matured, 
electronically compared. Protein spots with significant variations in expression between 
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biological conditions are then excised, destained, fragmented into peptides and analysed by 
mass spectrometry (MS) to identify the parent proteins based on peptide-protein databases 
(Figure 1.8). Problems with this technique included the large volumes of protein required (a 
particular drawback when analysing clinical samples), inter-gel variability which plagued 
reliability and most pressingly, the relatively limited cross-section of proteins visualised – 
typically consisting of only highly abundant proteins. Resolution was increased by 
fractionating the proteins over a narrower pH range in the first dimension thereby increasing 
resolution, albeit at the expense of proteins outside the pH. This advance was aided by the 
introduction of precast immobilised pH gradient (IPG) strips for the first dimension 
seperation in which the pH gradient is fixed within the acrylamide matrix.  A further 
innovation was the development of a technique termed differential in-gel electrophoresis 
(DIGE) which utilised highly sensitive, fluorescent labelling of protein samples with up to 
three independent dyes to enable multiple biological samples to be subjected to 
electrophoresis on a single gel (Figure 1.9). This effectively eliminated the problem of inter-
gel variability and greatly reduced the amount of sample required.  2D-DIGE was used 
extensively in the current work. 
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Figure 1.8: Schematic outlining 2-dimensional gel electrophoresis (2-DE). Protein is 
solubilized in rehydration buffer. The proteins are then immobilized on IPG strips of different 
pH ranges depending on the requirement of the experiment. In the first-dimension, the 
proteins are separated on the basis of their isoelectric points (pI) and are further resolved 
according to their molecular weight in the second-dimension. Finally, protein spots of interest 
are excised and subjected to tryptic digestion followed by MS. Adapted from [100]. 
 
 
Figure 1.9: Schematic outlining 2D-DIGE experimental procedure. Whole cell lysates are 
from unstimulated and stimulated samples are labelled with different fluorophores (Cy 3 for 
sample 1, Cy 5 for sample 2, and Cy 2 for the pooled internal standard). All samples are 
resolved on the same 2D gel (this eliminating gel-to-gel variation) followed by protein spot 
pattern detection by scanning the gel at the wavelength corresponding to each Cy dye. The 
images are analyzed for significantly up or down regulated proteins which are then excised 
from the gel, trypsin digested and identified by MS. Adapted from [100]. 
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1.2.1.2 SILAC and label-free quantitation 
In the past 10-20 years, major advances have occurred in mass spectrometer instrumentation, 
sample preparation and computational analysis that have rapidly enabled proteomics to 
realise at least part of its potential and put it on a more equal footing with genomics in terms 
of scientific impact. Novel protocols have emerged enabling the use of much smaller amounts 
of biological samples whilst extracting more information and this, combined with the 
entwining of MS fragmentation spectra and sequence databases has greatly accelerated 
protein identification [97]. Quantitatively speaking, both labelled and label-free protein 
quantitation have allowed for the measurement and thus comparison of protein levels 
between samples [100]. Label-based, gel-free protein quantitation involves the differential 
labelling of separate biological conditions with stable isotopes. The most widely used method 
incorporating this strategy is termed stable isotope labelling by amino acids in cell culture 
(SILAC) [101]. Proliferating cells in culture, representing different biological states, are 
metabolically labelled with either light or heavy isotope versions of essential, stable amino 
acids. Labelled cells are then lysed, combined in a 1:1 stoichiometric ratio and trypsin 
digested followed by MS analysis. Assuming that isotopes are incorporated with equal 
efficiency across the different biological states, differences in isotopic incorpororation into 
particular proteins, again measured by the m/z ratios, must be due to differnces in abundance 
of these proteins between different biological states (Figure 1.10). In vivo labelling is also 
possible by feeding mouse populations with either natural or light isotope-lysine labelled 
food over four generations. Benefits of quantitative labelling such as SILAC include high 
accuracy and low error rate. However, it cannot be applied to human tissue and reagents are 
expensive [100] 
Label-free quantitation (LFQ) is based on the assumption that the area of a peptide peak on a 
MS chromatogram is proportional to its concentration [102]. LFQ MS can be applied in 
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different forms: spectral counting and signal intensity. Spectral counting logs the number of 
spectra obtained between biological samples for a given peptide and integrates these into the 
total numbers of peptides detected for a given protein in each sample. Signal intensity 
determines the relative intensities of the extracted ion chromatograms to generate correlating 
protein intensities which can then be statistically compared between biological samples. The 
advantages of LFQ are many. It is considerably less cumbersome than label-based techniques 
and can provide robust and highly sensitive protein quantitation at a very low cost. 
Limitations include redundancy in detection as some peptides are shared between proteins. 
Moreover, this approach is not as accurate and therefore measurements of protein fold 
changes in lower with lower values are not as reliable and thus require repeat analysis. LFQ 
MS was used in the current study. 
 
Figure 1.10: Schematic overview of SILAC. Cells are grown in medium containing light 
and heavy versions of essential amino acids for 6 generations to achieve maximal 
incorporation. Protein is extracted from both populations of cells and mixed in equal 
proportion and subjected to either in-gel or in-solution digestion. Relative abundance of the 
digested peptides is determined from the ratio of heavy to- light peptide signals as obtained 
by MS. Adapted from [100]. 
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1.2.2 Applications to immunology and disease 
Historically, the application of proteomics has been directed more frequently towards the 
identification of disease biomarkers rather than pure immunology.  This approach primarily 
relied on the combination of 2D-PAGE with MS and later, on 2D-DIGE with MS. Despite 
the aforementioned limitations of these technologies, some successes were achieved, for 
example, in the classification of leukaemia subsets [103]. Online data troves of myocardial 
proteins associated with human heart failure similarly allowed researchers to establish 
standards to classify the myriad of pathological conditions associated with heart disease, 
particularly regarding onset [104-106]. 2D-DIGE has identified potential biomarkers of 
oesophageal carcinoma [107]. Proteomics has also been applied to the study of infectious 
pathogens. The arrival of increasing numbers of antibiotic resistant strains of bacteria has 
hastening research into prophylactic and remedial therapy [108].  Again, the genome 
sequencing of a particular pathogen is key to providing the blueprint for subsequent 
proteomic analysis, an example being the malaria parasite, Plasmodium falciparum. 
Comparative proteomic studies on both the parasite’s innate proteome and life-cycle 
proteome have produced a number of novel drug and vaccine targets [109-111]. Indeed, the 
applications of proteomics to pathogen study are varied, as summarised in table 1.1. 
Table 1.1: Proteomic approaches to the study of pathogenic organisms. Adapted from 
[104]. 
 
 
Despite these successes, proteomics has, until very recently, consistently remained in a 
distant second place when compared to the state-of-the-art advances and measurable 
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achievements associated with genomics [112-115]. Only in the past 5-6 years have radical 
new technologies encompassing both labelled and label free quantitation combined with MS 
become available to push immunologically-based proteomics into the top-tier scientific 
journals [97, 116, 117]. Notably, a recent study analysed the protein secretome of LPS 
stimulated, primary wild-type (WT), MyD88 deficient (
-/-
) and TRIF 
-/-
 macrophages using 
LFQ on an Orbitrap MS [117]. The time-resolved release of 775 proteins was detected with 
low picogram sensitivity from only 1.5x10
5 
cells per condition. Fold changes in protein 
abundance upon stimulation ranged up to 10,000. A separate study utilised a similar approach 
to characterise differences in the proteome between different subsets of conventional 
dendritic cells (cDCs). Newly developed, quantitative algorithms permitted proteomic 
sequencing across subsets to an average depth of 5000 proteins with 99 % certainty in 
identification. Identification was also reliable across biological replicates with correlations 
between normalised protein intensities between 0.84 and 0.96 [116]. This study assigned key 
viral recognition abilities to CD4
+
 and CD4, CD8 double negative cDC subsets but not to 
CD8α+ cells. Moreover, relatively few cells were required to achieve accurate reliable results 
(approximately 1.5x10
6
/condition), equivalent to a 1-5 micrograms of protein. Studies such as 
these foretell the potential application of proteomics towards the expansion of our knowledge 
base in areas such as immunology, disease pathologies, drug development and many other 
fields. 
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1.3.1 Bordetella genus  
B. pertussis is a gram negative coccobacillus from the Bordetella genus of proteobacteria. It 
is the best known member of the Bordetella genus which consists of eight other members: B. 
ansorpii, B. avium, B. bronchiseptica, B. hinzii, B. holmesii, B. parapertussis, B. petrii and B. 
trematum [118].  
B. parapertussis, B. bronchiesptica and B. pertussis are known as the ‘classical’ Bordetella 
species as they were the first to be successfully isolated and were therefore the defining 
members of the Bordetella family. They are also closely related morphologically, 
physiologically and antigenically and as such are referred to as a subspecies or as a strain of 
one species, known as the B. bronchiesptica cluster [118]. There are several similarities 
between the three. Infection occurs in the respiratory tract of humans, the resulting disease is 
whooping cough, or a variation of, with pathology resulting from infection and killing of 
ciliated tracheal epithelial cells [119]. Their genome contains a GC content of approximately 
67 % with optimal growth for each occurring at a temperature between 35 °C and 37 °C 
(Table 1.2) [118]. 
 
1.3.2 B. pertussis: initial isolation and description 
B. pertussis is aerobic, non-motile and is the cause of pertussis or whooping cough in humans. 
It is not known to infect any other species and as a result, humans are its sole reservoir 
[120]. It was first isolated in 1900 by Jules Bordet and Octave Gengou from a child upon 
which it was described it as a “small ovoid gram negative bacterium” [121]. Their first 
publication on the method of isolation was published six years later in 1906 [122].  Indeed 
the genus name Bordetella is derived from its cofounder, Jules Bordet [123]. The bacterium, 
whilst difficult to isolate from patients, (possible only within a very short timeframe during 
the initial period of infection called the catarrhal phase) was found to grow well on a medium 
consisting of blood, potato extract and glycerol, created by Bordet and Gengou and since 
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termed Bordet Gengou (BG) medium [121]. Transfer and subculture of the bacterium causes 
it to change both morphologically and physiologically turning from a bright yellow colour 
(Figure 1.11A) to white (Figure 1.11B) whilst also causing it to lose its haemolytic ability 
[121, 124].  
 
Table 1.2: Individual characteristics of members of the Bordetella family.  Adapted 
from [118]. 
 
 
 
Figure 1.11: Bordetella pertussis on Bordet-Gengou medium. (A) Freshly isolated B. 
pertussis isolate. (B) Subcultured isolate. Adapted from [121].  
 
B 
A 
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1.3.3 Pathogenesis of B. pertussis 
Initially, B. pertussis was considered an exclusively extracellular pathogen whose 
pathogenesis was derived from its secretion of several potent toxins. Local cytotoxic effects 
helped derive systemic metabolic disturbances which combine to generate characteristic 
symptoms [125, 126]. However, following several hints that B. pertussis could reside 
intracellularly [127-129] it was definitively shown that it could infect HeLa cells and that this 
was dependent to varying degrees on the presence of virulence factors such as filamentous 
hemagglutinin (FHA) and cell bound pertussis toxin (PTx) in the bacterium as well as host 
microfilament mediated phagocytosis [130]. It is generally accepted that there are four main 
factors pertaining to B. pertussis infection and disease which are: attachment, host defence 
evasion, local damage and systemic damage [131].  B. pertussis bacteria attach to cilia of the 
upper respiratory tract via adherence factors such as FHA, fimbriae, PTx and pertactin (PRN) 
[132-135]. FHA is the major adhesin expressed on the cell surface and its role in mediating B. 
pertussis binding is believed to involve host upregulation of intracellular adhesion molecule-
1 (ICAM-1) [136]. It initiates host phagocytosis by binding to and activating leukocyte 
integrin complement receptor 3 on multiple cell types [137]. Once inside the cell, the 
majority of bacteria are destroyed by the cells defence mechanisms, particularly by 
endosomal acidification [138]. However, approximately 25 % of bacteria taken up into the 
cell survive by residing in non-acidic compartments and begin to replicate. It is believed that 
this process occurs by inhibiting endosomal maturation and thus acidification [138]. The 
ability of B. pertussis to exist within the host’s cells is believed to play a key role in its ability 
to evade the host’s immune response for extended periods [139].  
1.3.4 Immune Response to B. pertussis 
Respiratory infection of mice with B. pertussis drives a large inflammatory cell infiltration 
into the lungs and particularly to the alveolar spaces with large numbers of macrophage, 
neutrophils and lymphocytes taking up residence (Figure 1.12) [140]. Resident macrophages 
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and DCs are first to arrive, followed by neutrophils, natural killer cells and T cells (Figure 
1.12) [139]. Lymphocyte populations are composed primarily of CD4+ T cells with a smaller 
number of CD8+ cells [141]. Infiltration of small populations of gamma delta (γδ) T cells has 
also been noted in both animal models and in the very early stages of infection in children 
(Figure 1.12) [141]. 
 
 
Figure 1.12: Time dependent kinetics of innate and adaptive immune cell recruitment to 
lungs following B. pertussis infection. Relative cell numbers are indicated by hypothetical 
curves. CD4 T cell: recruitment of CD4
+
 T cells to lungs and response to B. pertussis 
antigens. IgG: anti-B. pertussis immunoglobulin G in serum. IgA: anti-B. pertussis 
immunoglobulin A in in lungs. Bp CFU: B. pertussis burden in lungs. DC: dendritic cells. 
Mac: macrophage. NK: natural killer cell. γδ: gamma-delta T cells. Adapted from [139]. 
 
 
Macrophages, whilst internally harbouring populations of bacteria, are also required for 
protection as depletion of resident airway macrophages enhances B. pertussis infection. They 
can be induced to kill intracellular bacteria by T-cell derived cytokines such as IFN-γ and IL-
17 [142, 143]. Neutrophils reach the lungs of infected mice approximately five days post 
infection (Figure 1.12). Like macrophages, neutrophils are capable of phagocytosing and 
killing of intracellular bacteria but are considered unlikely reservoirs due to their relatively 
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short half-life [139]. NK cells are the early providers of the crucial cytokine IFN-γ which 
ensures macrophage mediated bacteria killing and promotes TH1 responses. Depletion of NK 
cells results in bacterial escape from the lungs to the liver [144]. Specific antibody responses 
take much longer to develop in mice after B. pertussis challenge, only appearing in 
significant amounts when most bacteria have been cleared approximately five weeks post-
infection. This would indicate that they are not of major importance the clearance of a 
primary infection however antibodies are important in vaccine-induced adaptive immunity to 
B. pertussis [139]. 
 
1.3.5 Vaccination  
Vaccines using inactivated whole B. pertussis organisms followed by acellular pertussis 
vaccines have been in use since the 1940s and have led to a marked decline in resulting 
disease [145]. Being an exclusively human pathogen, the introduction of wide-spread 
vaccination programs have been twinned with the expectation of disease eradication, at least 
in industrialised countries. However, despite significant investment and high uptake, many 
first world countries have experienced a striking resurgence in the past decade, particularly 
amongst older children and adults [146, 147]. In Europe, a surveillance programme termed 
EUVAC-NET recorded a 115% increase in incidence rates in children over 14 between 1998 
and 2002 [148]. An approximate doubling in incidence has also been reported in the US 
between 2001 and 2003 [145].  Possible explanations for the current epidemiology of B. 
pertussis infection include:  
1. Waning immunity and shorter protection following vaccination: Duration of 
protection resulting from whole cell pertussis (wP) vaccination ranges from 4-14 
years and between 5-6 years for acellular B. pertussis (aP) vaccination. 
2. Strain polymorphism: Studies have indicated that certain strains of B. pertussis have 
adapted to express PT and PRN different from that contained within current vaccine 
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preparations with suspected links to observed reductions in vaccine effectiveness in 
The Netherlands and Finland [145, 149].  
3. Increased diagnosis and reporting: It is generally accepted that improved awareness 
and diagnostic methodology are responsible for some, but not all of the increases in 
incidences. For example, a significant increase in observed disease Canada in 2006 
was associated with a similarly significant increase in the number of tests carried out 
[145]. 
 
 
1.3.6 Application of proteomics to the study of B. pertussis 
Several proteomic studies have been carried out on the B. pertussis bacterium in order to 
monitor its response to various infection relevant scenarios as well as to characterise potential 
novel antigens for future vaccine design. For example, one study utilised 2D gel 
electrophoresis combined with MALDI-TOF MS to profile protein expression in both whole 
cell lysates and outer membrane fractions of bacteria grown in either iron starvation or iron 
excess conditions [150]. Iron starvation is a common obstacle to overcome by many bacteria 
including B. pertussis during an infection and protein signatures linked to its ability to 
scavenge host iron are believed to be critical to its survival and therefore a source of potential 
therapeutic targets. The study identified multiple iron dependent proteins, four of which 
reacted strongly with sera from infected individuals and one which was highly immunogenic 
in vivo thus providing a potential vaccine target [150]. A further 2D gel electrophoresis study 
examined the protein signature of B. pertussis bacteria upon biofilm formation [151]. 
Biofilms allow pathogens to exhibit phenotypic traits that allow for increased resistance to 
host defences and antibiotics. It is also believed that adults carrying B. pertussis biofilms act 
as infection reservoirs by periodically shedding active bacteria [131]. The study identified 
significant alternations in proteins involved in cell attachment and bacterial virulence 
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indicating the impact biofilm formation likely has on B. pertussis pathogenesis [151]. Clinical 
isolates have also been examined using similar proteomic techniques [152]. To date however, 
despite a slew of proteomic studies having been conducted on the B. pertussis bacterium 
itself, a proteomic study as yet to be conducted which examines the response of host cells to 
B. pertussis infection. Evaluation of this host proteomic response to infection is important for 
a number of reasons. One is that studying the proteome itself, as opposed to the genome is a 
more reliable method of detecting crucial host effector mechanisms engaged to fight the 
infection as proteins, not genes, are responsible for this. Another is that novel host proteins 
subverted by the bacterium to acquire resources, for example transferrin for iron scavenging 
[150], could be identified and whose expression again, may not be detected by genetic studies. 
Identification of host protein signatures specific to certain functions or even cellular 
compartments could shed new light on B. pertussis infection and resilience strategies and in 
turn uncover multiple new targets for perturbation of the host immune response when the 
need to treat pathogenesis resulting from an acute inflammatory response arises.  
To this end, it was decided to conduct a comparison of the proteomes of B. pertussis infected 
and uninfected lung-epithelial cells (BEAS-2B cells). 2D-DIGE combined with LC/MS as 
well as LFQ MS were used to identify and quantify dynamic regulation of proteins resulting 
from whole cell lysates from different cell treatments. Protein hits of interest were selected, 
verified by western blot and subjected to further analysis of their role in the host immune 
response to B. pertussis infection. 
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1.4.1 Human rhinovirus 
Human rhinoviruses (HRVs) were first discovered in 1956 and were immediately associated 
with clinical disease in humans with symptoms almost identical to that of the common cold 
[153]. They are a member of the genus enterovirus within the picornavirus family and as 
such, exhibit characteristics synonymous with picronaviruses such as being non-enveloped, 
positive-sensed and single-stranded RNA viruses. To date, 102 serotypes have been 
documented and they are believed to be the major cause of common cold symptoms in adult 
humans [154, 155]. The serotypes can be organised into three ‘receptor groups’ based on the 
cellular receptor they bind to. These are classified as the major group, which bind to 
intracellular adhesion molecule-1 (ICAM-1) and account for 91 of the serotypes; the minor 
group, which bind to members of the low density lipoprotein receptor (LDLR) family and 
account for 10 serotypes; and finally, the remaining serotype, HRV87, which does not attach 
to receptors of the major or minor group and attaches to an unknown glycoprotein that unlike 
any other serotype, requires the presence of sialic acid [156].  
 
1.4.2 Structure of HRV 
Rhinoviruses are composed of sixty copies of each of four viral capsid proteins (VPs) which 
are arranged such that they form an icosahedral shell surrounding a single stranded RNA at 
the centre (Figure 1.13). VP1-3 are external whilst VP4 lines the internal surface and is 
therefore thought to contact the packaged RNA (Figure 1.13) [157]. Amino acid differences 
across these capsid proteins confer the antigenic differences between the HRV serotypes with 
VP1 exhibiting the greatest sequence variability and VP4 responsible for the least [158].  
VP1 contains a hydrophobic pocket, often referred to as a canyon which serves as the binding 
site for ICAM-1 in the case of the major group of HRVs (Figure 1.13) [159]. Whilst still not 
completely understood, it is believed that during the initial stages of viral infection, HRV 
binds ICAM-1 followed by a loss of the viral capsid with VP4 first being externalised and 
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VP1 being lost next. This process ultimately leads to viral RNA internalisation via 
endocytosis or macropinocytosis through the host cell’s plasma membrane [160-162]. 
 
Figure 1.13: HRV structure. RV is a non-enveloped virus consisting of a protein shell 
surrounding the naked RNA genome. The protein capsid is composed of four polypeptides, 
viral capsid protein 1 (VP1), VP2, VP3 and VP4 in an icosahedral structure. A hydrophobic 
canyon exists within VP1 which is believed to contain the ICAM-1 binding site. VP4, unlike 
the other VPs, is contained within the viral internal surface. Adapted from [163].  
 
 
 
1.4.3 HRV Replication 
The picnoravirus genome is comprised of a single stranded RNA which itself consists of 3 
distinct regions. At the 5’ end is a single untranslated region (UTR), followed by an open 
reading frame (ORF) encoding the structural VPs 1-4 and non-structural proteins such as 
proteases and finally a short 3’UTR and poly(A) tail (Figure 1.14) [164]. Upon entry into the 
cell, HRVs follow a similar replication strategy to other picornaviruses. The previously 
packaged RNA functions as an mRNA and is translated by the host’s translation machinery 
into a large polypeptide which is cleaved to yield mature viral proteins (Figure 1.15). The 
viral RNA is then transcribed into a negative sense complementary RNA which in turn serves 
as a template to transcribe complementary positive sense RNA and thus complete one cycle 
of replication (Figure 1.15).  
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Figure 1.14: HRV genomic structure. HRV is 7.2 kb in length with a single open reading 
frame linkned to a 5’ untranslated region (5’UTR). Protein P1 is translated into the HRV 
capsid. P2 and P3 are translated into VPg, protease and RNA-dependent RNA polymerase 
(RDRP). Adapted from [162]. 
 
 
 
 
Figure 1.15: HRV replication in tracheal epithelial cells. Virus uptake can occur via 
clathrin-dependent endocytosis or macropinocytosis. Lowering of pH leads to viral uncoating. 
Negative strand RNA is replicated and translated into structural and non-structural proteins. 
Virions are packaged prior to export via cell lysis. LDLR, low density lipoprotein receptor; 
ICAM1, intracellular adhesion molecule 1. Adapted from [162]. 
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1.4.4 HRV Pathogenesis 
HRV is believed to preferentially infect and replicate in the upper respiratory tract of non-
asthmatic individuals [163]. Although other respiratory viruses such as influenza and 
respiratory synthetical virus are associated with the destruction of airway epithelial cells, 
HRV is not, with nasal biopsies from patients both naturally and experimentally infected 
showing intact epithelial cell linings [165, 166]. However, HRV has been shown to disrupt 
epithelial cell tight-junctions thus reducing barrier function and allowing transmigration of 
bacteria [167]. Lower respiratory infections typically occur in those with pre-existing asthma 
or chronic lung disease [163] and are known to exacerbate asthma symptoms [168]. 
Rhinorrea (nasal filling with mucous) and consequent nasal obstruction are common 
symptoms of upper respiratory tract infections and are associated with a neutrophilic 
inflammatory response causing increased vascular permeability and mucus secretion [163]. 
 
1.4.5 Immune Response to HRV 
HRV ssRNA , once internalised is known to be endosomally recognised by TLR7 and TLR8 
[162]. During its replication cycle, dsRNA is generated which can then be recognised by 
cytosolic RIG-I and MDA5 (Figure 1.16) [169, 170]. The engagement of these PRRs leads to 
secretion of IFN-β, IFN-γ, RANTES, IL-6, TNF-α and IL-8 (Figure 1.16) [162]. Levels of 
IL-8 have been shown to correlate with HRV induced rhinorrea and nasal obstruction in 
experimentally inoculated individuals [171]. The vasodilators bradykinin and lysylbradykinin 
are also released in significant quantities upon HRV infection however histamines are not, 
which would suggest that basophils and mast cells play no role in HRV pathogenesis [172]. 
The humoral response is also important as evidenced by the observation that those with 
hypogammaglobulinemia, a condition in which levels of immunoglobulins are abnormally 
low, suffer from increased recurrence and severity of HRV infections [173]. Infection of 
patients with HRV is followed by generation of serotype specific neutralising IgG and IgA 
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antibodies with 1-2 weeks [174]. T cell infiltration of the airway epithelium and submucosa 
has also been observed [175].  
 
Figure 1.16: HRV recognition by various PRRs and signal transduction. HRV dsRNA 
and ssRNA in the endosome are recognised by TLR3 and TLR7/8 respectively to drive NFκB 
and IRF activation. This increased production of pro-inflammatory and anti-viral cytokines. 
TLR3 activation also upregulates expression of cytosolic PRRs RIG-I and MDA5 which 
sense cytosolic HRV ssRNA and dsRNA respectively. These PRRs also drive pro-
inflammatory and anti-viral cytokine production. These cytokines can further act on T and B 
cells to activate the adaptive immune response. Adapted from [162]. 
 
 
1.4.6 Application of proteomics to HRV infection studies 
Similar to B. pertussis, there has been no previous attempt to characterise the changes in a 
cell’s proteome upon infection with any serotype of HRV. This therefore leaves a 
considerable gap in our knowledge about how HRV’s modulate the host’s intracellular 
environment and also how the host itself responds to infection. It was therefore decided to 
conduct a proteomic study examining the changes induced in the host cellular proteome in 
response to HRV infection. To achieve this aim, HRV serotype 16 (HRV16) was used as it is 
a member of the major group of ICAM-1 sensing HRVs and thus a good indicator of how the 
majority of known HRV serotypes modulate the cell. Also, as HRV16, like B. pertussis is 
primarily a respiratory pathogen, the same cell line, BEAS-2B, was used for the infection. 
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These cells have been used previously as an in vitro model for studying HRV infection in 
respiratory cells [93, 176, 177] but also carry the additional advantage in this case of allowing 
a comparison between the proteomes of a virally infected cell (HRV16) and a bacterially 
infected cell (B. pertussis). As in our opinion, the 2D-DIGE – B. pertussis study produced 
more hits that were of interest to an immunological setting compared to the LFQ MS, it was 
decided to also analyse the HRV16 infection proteome by 2D-DIGE also.  
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1.3 Project Aims 
 
1.3.1 Project Aim 1 
The current state of our knowledge of TLR signalling is in constant flux with systems that 
seemed impressively simple less than a decade ago, becoming increasingly complex. Taking 
the TIR-domain containing adaptors as an example, the current accepted dogma is that 
MyD88 is involved in signalling from all TLRs except TLR3, that TRIF is required for only 
TLR3 and TLR4 signalling or that MAL mediated only TLR2 and TLR3 signalling [15]. 
These claims, whilst once true, have been shown to be in need of updating. MAL and MyD88 
negatively regulate TLR3 mediated type-I IFN production, whilst TRIF is required for TLR5 
signalling [21, 75, 76, 93, 94]. TRAM, whose only known cellular function was to mediate 
TLR4 signalling, has been shown to also mediate IL-18R signalling and is believed to play a 
role in TLR2 signalling [178, 179].  With this is mind, we questioned whether there were 
additional unknown roles for the adaptor molecules in TLR signalling, with a focus on 
TRAM. A factor in the dissemination of the initial characterisation data from knockout mice 
specific to TRAM is a lack of strenuous controls that eliminate the role of TRAM in 
alternative TLR pathways. For example, whilst cells from TRAM deficient mice have had 
NFκB dependent pathways from multiple TLRs examined, not once have IRF mediated 
cytokines been examined apart from those mediated by TLR3 and TLR4 [23, 24]. A major 
aim of the current work was therefore to:  
Characterise the role of the adaptor TRAM in both NFκB and IRF mediated pathways 
derived from multiple TLRs. 
 
65 
  
1.3.2 Project Aim 2 
The advances in proteomics technology discussed herewith have made the direct study of the 
proteome pre and post infection faster and cheaper as well as bringing increased protein 
identification accuracy, reliability and depth [97]. Characterisation of the proteome following 
infection with human-relevant pathogens remains an understudied field of study. Whilst there 
have been reports of the application of transcriptomics to the field [180, 181], the application 
of proteomics is still lacking. Two pathogens of relevance to human health, both currently 
and historically, are the human rhinoviruses and the gram negative bacterium, Bordetella 
pertussis (B. pertussis). Proteomic profiling of the cellular response to infection with these 
two respiratory pathogens has never been completed and therefore represents a missing link 
in our knowledge of what proteins are involved in tailoring and modulating the immune 
response to these significant human health pathogens.  
Therefore, the second major aim of the project is to define the proteome of lung epithelial 
cells following infection with two pathogens of significance to human health, namely human 
rhinovirus 16 and B. pertussis. 
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Chapter 2 
 
 
Materials and Methods 
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2.1 General methods:  
 
2.1.1 Mamalian cell culture techniques 
All mammalian cells were maintained in a humidified atmosphere, with 5 % CO2 at 37 °C. 
Wild-type (WT), TRAM 
-/-
 and MAL 
-/-
 immortalised bone marrow derived macrophage 
(iBMDM) cell lines, human embryonic kidney 293 (HEK293) cells stably transfected with 
human TLR3 (HEK293-TLR3), HEK293-TLR4, HEK293-TLR7, HEK-Blue™ TLR4 and 
bronchial epithelial cells, strain AS-2B (BEAS-2B) were grown in Dulbecco's Modified 
Eagle's Medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS), 1 % (v/v) 
penicillin/streptomycin  solution and 1% (v/v) sodium pyruvate.  Difficulties were 
experienced using the iBMDM cell lines with differing growth rates and unreliable 
phenotypes often observed. Efforts were made to source primary cells direct from WT and 
TRAM 
-/-
 mice however the cells did not survive the international shipping process. HEK293-
TLR3 and HEK-Blue™ TLR4 cells were additionally supplemented with blasticidin (25 
μg/ml). HEK293-TLR4 and HEK293-TLR7 cells were additionally supplemented with G418 
(250 μg/ml).  HEK-Blue™ IFN-α/β cells and the human leukemic monocyte cell line, THP-1 
were grown in Roswell Park Memorial Institute 1640 (RPMI 1640) medium supplemented 
with 10 % (v/v) FBS, 1% (v/v) penicillin/streptomycin solution and 1% (v/v) sodium 
pyruvate. HEK-Blue™ IFN-α/β cells were additionally supplemented with Normocin™ (100 
μg/ml) and Zeocin™ (50 μg/ml). Adherent cell monolayers were detached from tissue culture 
flasks using trypsin/ ethylenediaminetetraacetic acid (EDTA) upon 90% confluency and re-
cultured at a 1:5 or 1:10 dilution depending upon growth rate. Non-adherent cells were 
similarly re-cultured upon 90% confluency at a 1:5 or 1:10 dilution.  
2.1.2 Cell stock freezing and resuscitation 
Adherent cells were trypsinised, re-suspended in complete growth medium, and centrifuged 
at 306 g-force (g) for 5 min. Pelleted cells were re-suspended in freezing medium (90 % (v/v) 
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growth medium, 10 % (v/v) DMSO) and aliquoted into cryovials. Typically, a confluent 
T175 flask would be split into 3 cyrovials with 1ml per vial. Cryovials were stored at -80 °C 
in a NALGENE™ Cryo 1 °C Freezing Container to achieve a -1 °C/min rate of cooling for a 
minimum of 4 hours before long-term storage in liquid nitrogen.  
To resuscitate cells, cryovials were removed from liquid nitrogen storage and rapidly thawed 
in a water bath heated to 37 °C. Cells were immediately re-suspended in complete growth 
medium before centrifugation at 306 g for 5 min. Medium containing DMSO was removed 
and the cell pellet was re-suspended in complete growth medium and transferred to a T75 
culture flask in the appropriate incubation conditions (see section 2.2.1).  
 
2.1.3 Transformation of competent cells  
Plasmid DNA (1-2 μl corresponding to 100-800 ng) was added directly to 20 μl of thawed E. 
coli DH5α competent cells (Invitrogen) and incubated on ice for 30 min. Thereafter, cells 
were heat shocked for 20 sec at 37 °C before being immediately returned to ice for a further 2 
min. Cells were re-suspended in 0.5 ml lysogeny broth (LB) and agitated in a shaker at 10 g 
and at 37 °C for 1 hour. Approximately 100 μl of the transformed bacteria were plated out 
onto LB-agar plates supplemented with antibiotic to select for plasmid containing bacteria. 
Plates were inverted and incubated at 37 °C overnight. 
 
2.1.4 Preparation of plasmid DNA  
Note: All centrifugations carried out chilled at 4,503 g. Single colonies were inoculated into 
100 ml of LB (preheated to 37 °C) supplemented with appropriate antibiotic and incubated at 
37 °C with gentle shaking for approximately 16 hr. Bacterial cells were subsequently pelleted 
by centrifugation for 30 min. DNA was extracted from the cells using a QIAGEN Plasmid 
Midi Kit as described by the manufacturer.  Briefly, the bacterial pellet was resuspended in 4 
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ml Buffer P1, followed immediately by 4 ml Buffer P2, inversion 5 times and incubation for 
5 min at RT. Chilled buffer P3 was added, the bacteria inverted 5 times and incubated on ice 
for 15 min followed by centrifugation for 30 min. Supernatant containing plasmid was 
removed, transferred to a fresh tube and re-centrifuged, chilled for 15 min. The supernatant 
was then applied to an equilibrated QIAGEN-tip 100 and allowed to empty by gravity flow. 
The tip was washed twice with 10mls of Buffer QC before elution into a fresh falcon with 
5mls Buffer QF. DNA was precipitated using 3.5 ml 100% isopropanol, mixed and 
centrifuged for 30 min. The supernatant was discarded and the DNA pellet washed with 2 ml 
70 % ethanol, before centrifugation for 10 min.  
The DNA concentration determined in ng/μl using the NanoDrop 2000 spectrophotometer 
(Thermo Scientific). Note that centrifugations were carried out at 4,503 g at 4 °C. 
 
2.1.5 Plasmid glycerol stock preparation 
A 500 μl aliquot of transformed cells was mixed with 500 μl of 50 % glycerol and stored at       
-80 °C. A ‘stab’ of this secondary culture was used to inoculate 100 ml liquid cultures as 
necessary. 
 
2.1.6 Transfection of cells with plasmid DNA:  
On day 1, confluent cells were plated in complete growth medium in a 6-well plate at a 
density of 0.4x10
6
 cells/ml (3 ml/well) and incubated for 24 hr at 37 °C. On day 2, a solution 
of plasmid DNA was prepared containing DNA in a maximum of 250 μl Opti-MEM® 
Reduced Serum Medium (hereafter referred to as Opti-MEM®). Separately, a solution 
containing 1 μl lipofectamine/μg DNA was prepared in a total volume of 250 μl Opti-MEM®. 
Solutions were the incubated for 5 min at RT before combining, mixing and incubating for a 
further 20 min at RT. At this point, 1 ml of medium was removed from each well in the cells 
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plated previously. After 20 min, the DNA-lipofectamine-Opti-MEM® solution was added 
drop-wise to the cells and the tissue culture plate was incubated for 24 hr at 37 °C. 
 
2.1.7 Transfection of cells with siRNA: 
On day 1, confluent THP1 monocytes were plated in complete growth medium in a 12-well 
plate at a density of 0.7x10
6
 cells/ml (2 ml/well) containing 40 nM Phorbol 12-myristate 13-
acetate (PMA)/well and incubated for 48 hr at 37 °C. On day 3, separate solutions of human 
TRAM (200 nM) or scrambled siRNA (200 nM) were prepared in total volume of 125 μl of 
Opti-Mem®. In a fresh eppendorf, a solution containing 4 μl lipofectamine/sample was 
prepared to a total volume of 125 μl Opti-MEM®. Solutions were incubated for 5 min at RT 
before adding 125 μl lipofectamine solution to each individual siRNA mix followed by 
incubation for 20 min at RT. At this point, 250 μl of medium was removed from each well in 
the cells plated previously. After 20 min, the individual siRNA-lipofectamine-Opti-MEM® 
solutions were added drop-wise to the cells and the tissue culture plate was incubated for 48 
hr at 37 °C. 
 
2.1.8 Transfection of cells with esiRNA: 
On day 1, confluent BEAS-2B cells were plated in complete growth medium in a 6-well plate 
at a density of 0.4x10
6
 cells/ml (1 ml/well) and incubated for 24 hr at 37 °C. On day 2, 
separate solutions of target specific esiRNA (200 ng) or negative control GFP esiRNA (200 
ng) were prepared in a total volume of 250 μl Opti-Mem®. In a fresh eppendorf, a solution 
containing 3.5 μl lipofectamine/sample was prepared in a total volume of 250 μl with Opti-
MEM®. Solutions were incubated for 5 min at RT before adding 250 μl lipofectamine 
solution to each individual esiRNA mix followed by incubation for 20 min at RT. After 20 
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min, the individual esiRNA-lipofectamine-Opti-MEM® solutions were added drop-wise to 
the cells and the tissue culture plate was incubated for 24 hr at 37 °C. 
2.1.9 B. pertussis culture and infection 
Pre-warmed, Bordet-Gengou (BG) agar plates (3 % (w/v) BG agar base, 1 % (v/v) glycerol, 
17 % (v/v) defibrinated horse blood), containing 100 μg/ml streptomycin, were inoculated 
with a streptomycin resistant, B. pertussis Tohama I derivative strain (BPSM) using a sterile 
spreader and incubated inverted at 37 °C for 72 hr. Using a sterile inoculation loop, colonies 
were harvested and transferred to a sterile, 200 ml conical flask containing 100 ml of pre-
warmed Stainer and Scholte (S&S) medium (per 500 ml: 10.72 g L-Glutamic acid, 0.24 g L-
Proline, 2.5 g NaCl, 0.5 g KH2PO4, 0.2 g KCl, 0.1 g MgCl2.6H2O, CaCl2.2H2O) and 1 ml 
supplement medium (per 90 ml: 0.1 g iron sulphate, 0.2 g ascorbic acid, 0.04 g nicotinic acid, 
1 g glutathione and 0.4 g L-Cysteine). The flask was then placed in a 37 °C shaker for a 36 hr 
at 9 g. 100 μl of the liquid culture was removed, placed in a quartz cuvette and the number of 
colony forming units (CFU)/ml was estimated by spectrophotometry at 595 nm. Typically, an 
OD of 1 equalled approximately 2x10
10
 CFU/ml. BEAS-2B cells were infected by directly 
pipetting the required volume of bacterial liquid culture into the mammalian cell culture 
media to achieve an MOI of 200. Cells were incubated for 12 hr before harvesting.  
 
2.1.10 HRV16 infection 
Human rhinovirus 16 (HRV16) containing stock solution was removed from -80 °C storage 
and rapidly thawed in a 37 °C incubator. Mammalian cells were infected by pipetting the 
HRV16 containing solution directly into the mammalian cell culture medium (MOI of 3). 
Cells were incubated at 33 °C for 72 hr to permit infection and viral replication to occur.  
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2.1.11 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was performed based on the Laemmli method [182] and carried out using the 
mini-gel system (Bio-Rad). Polyacrylamide gels were cast in two layers with a lower, 
resolving layer containing 10 % acrylamide and an upper, stacking layer containing 5 % 
acrylamide.  After solidification, gel plates were transferred from the casting rig to the 
electrophoresis chamber (Bio-Rad) which was filled with 1x SDS running buffer (25 mM 
Tris-Base, 192 mM Glycine, 0.1 % SDS (w/v)). Samples to be analysed were mixed with 5x 
Laemmli sample buffer (300 mM Tris-HCl, 50 % (v/v) Glycerol, 10 % (w/v) SDS, 0.02 % 
(w/v) Bromophenol Blue, 10 % (v/v) β-Mercaptoethanol, 20 %), followed by boiling at 
100 °C for 5 min. Samples and standard protein marker (Bio-Rad) were loaded into 
individual wells and electrophoresis was performed at 90 V for the first 30 min followed by 
100 V for approximately 1 hr.  
 
2.1.12 Western blot  
Proteins were transferred to polyvinylidene difluoride membrane (PVDF; Santa Cruz), using 
a wet transfer apparatus (Owl VEP-2, Thermo Scientific). Briefly, PVDF membranes were 
cut to the required size and activated by soaking in 100 % methanol for 1 min followed by 
washing in 1x transfer buffer (25 mM Tris-HCl (pH 7.6), 192 mM glycine, 20% methanol) 
for a further 1 min. A transfer sandwich was assembled as follows: one sponge, two pieces of 
Whatman™ chromatography paper, gel containing electrophoresed samples, PVDF 
membrane, a further two pieces of Whatman™ chromatography paper and a final sponge. 
The transfer sandwiches were then clamped, placed in the transfer chamber containing 1x 
transfer buffer and transferred at 100 V for 70 min at 4 °C. At this point, the PVDF 
membrane was blocked in either 5 % (w/v) fat free dry milk or 5% (w/v) bovine serum 
albumin (BSA) in 1x TBST for a minimum of 50 min at RT. Primary antibodies against the 
target protein were appropriately diluted in 5 % (w/v) fat free dry milk in 1x TBST or 5 % 
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(w/v) BSA in 1xTBST and incubated on the membrane overnight at 4 °C with gentle 
agitation. Following this, membranes were washed three times with 1x TBST, before addition 
with a horseradish peroxidase (HRP)-conjugated secondary antibody raised against the 
appropriate species, diluted 1:2500 in 5 % (w/v) fat free dry milk in 1x TBST for 1 hr. 
Unbound antibody was removed by washing the membrane three further times with TBST 
before visualisation of immunoreactive bands protein bands by electrochemiluminescence 
(ECL). Visualised bands were recorded using autoradiography film (Santa Cruz) which was 
exposed in developer solution (Devalex M™, Champion Photochemistry), washed in H2O, 
fixed (Fixaplus™, Champion Photochemistry) and washed again prior to electronic image 
scanning.  
 
2.1.13 RNA isolation  
The medium was removed from experimental cells followed by washing in ice-cold 
phosphate buffered saline (PBS) and centrifugation at 161 g for 5 min. Supernatant free 
pellets were lysed in 0.5 ml of TRI Reagent (Sigma) and left for 5 min at RT.  Next, 100 μl of 
100 % chloroform was added, followed by mixing and incubation for 3 min at RT. Samples 
were centrifuged at 16,464 g for 15 min at 4 °C to separate the lysates into three phases: an 
upper, aqueous phase containing the RNA, a DNA containing interphase and a lower organic 
phase containing proteins. The upper aqueous phase was pipetted into a fresh eppendorf, to 
which 250 μl of 100 % isopropyl alcohol was added and incubated for 10 min at RT to 
precipitate the RNA. Samples were centrifuged at 16,464 g for 10 min at 4 °C at which point 
the supernatant was removed and 500 μl of 70 % ethanol added to the RNA pellet. The 
samples were subjected to centrifugation at 16,464 g for 5 min at 4 °C, after which, the 
ethanol was removed and the pellet air dried for 10 min at RT. The RNA pellet was 
resuspended in 25-50 μl RNAase free water (Fisher), depending upon the original number of 
cells. Samples were heated at 59 °C for 10 min to aid RNA resuspension and immediately 
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placed on ice. The RNA concentration was determined using a NanoDrop ND-1000 
spectrophotometer (Thermo Scientific). Samples were stored at -80 °C until required for first 
strand cDNA synthesis.  
2.1.14 First-strand cDNA synthesis  
Total cellular RNA was used as a template for first stand cDNA synthesis. Additional 
reagents and volumes used are summarised in Table 2.1. All samples and reagents were kept 
on ice unless otherwise indicated. Final reaction volume was 25 μl in 0.2 ml PCR grade 
eppendorfs (Corning). Upon preparation, the samples were placed in a thermocycler 
(Eppendorf) and cDNA synthesis was performed according to the cycling conditions in Table 
2.2.  
 
Table 2.1: Reagents and volumes required for first-strand cDNA synthesis  
Component Volume (μl) 
RNA X μl equivalent to 1 μg 
Random hexamer primers (500 ng/μl) 3 
H2O Make to 17 
70 °C for 5 min followed by pulse centrifuge 
5x Buffer 5 
dNTP (10 mM) 1.3 
Reverse Transcriptase (200 units/μl) 0.5 
RNase Inhibitor (40 units/μl) 0.5 
Gentle mix and centrifuge 
 
 
 
 
Table 2.2: Thermal cycler conditions for first-strand cDNA synthesis 
Temperature (°C) Time (min) 
85°C – Lid 
37 40 
42 40 
80 10 
4 ∞ 
 
75 
  
2.1.15 Polymerase chain reaction (PCR) 
Template cDNA was diluted 1:5 in nuclease-free H2O (Fisher). To 0.2ml PCR grade 
eppendorfs (Corning), additional reagents were added as per Table 2.3. Samples were gently 
mixed, pulse centrifuged and loading into a thermal cycler (Eppendorf) and ran according to 
the conditions in Table 2.4. 
 
Table 2.3: Reagents for PCR 
Component Volume (μl) 
cDNA 1 
Forward primer (4pM) 1 
Reverse primer (4pM) 1 
dNTP (10nM) 2 
Taq DNA Polymerase (5 units/μl) 0.2 
10x Buffer A 5 
Nuclease free H2O 15.8 
 
 
 
 
 
Table 2.4: Thermal cycler conditions for PCR 
Step Temperature (°C) Time (min) 
Lid 100 
1 95 3 
2 94 1 
3 60 0.5 
4 72 1 
Repeat steps 2-4 for 35 cycles 
5 72 7 
6 80 10 
7 4 ∞ 
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2.1.16 Quantitative real time-PCR (qRT-PCR)  
Template cDNA was thawed, diluted 1:25 in nuclease free H2O (Fisher) and set aside. 
Additional reagents were aliquotted into eppendorfs to make master-mix solutions as per the 
required target gene, according to Table 2.5.  
 
Table 2.5: qRT-PCR reagents and volumes. 
Component Volume per sample (μl) 
Nuclease free H2O 1.25 
Forward primer (4pM) 1.25 
Reverse primer (4pM) 1.25 
SYBR® Green JumpStart™ Taq ReadyMix™ 5 
Template cDNA (1:25) 1.25 
 
 
Samples were loaded in duplicate into a FrameStar™ LC half-skirted, 96 well plate and 
sealed with an optically clear adhesive cover (Rainin Instrument, LLC). Plates were pulse 
centrifuged to ensure complete sample collection within wells. QRT-PCR was performed 
using a Roche Lightcycler® 480 system according to parameters specified in Table 2.6. 
Table 2.6: Cycler conditions for qRT-PCR 
Step Temperature (°C) Time (min) 
1 94 2 
2 94 0.25 
3 60 1 
Repeat steps 2-3 for 40 cycles 
4 65-95 10 
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Table 2.7: Primer sequences for qRT-PCR 
Primer Sequence 
Murine TNF-α Forward 5’-CATCTTCTCAAAATTCGAGTGACAA-3’ 
Murine TNF-α Reverse 5’-TGGGAGTAGACAAGGTACAACCC-3’ 
Murine RANTES Forward 5’-GGAGATGAGCTAGGATAGAGGG-3’ 
Murine RANTES Reverse 5’-TGCCCATTTTCCCAGGACCG-3’ 
Murine GAPDH Forward 5’-GCACAGTCAAGGCCGAGAAT-3’  
Murine GAPDH Reverse 5’-GCCTTCTCCATGGTGGTGAA-3’ 
Human IFN-β Forward 5’-AACTGCAACCTTTCGAAGCC-3’ 
Human IFN-β Reverse 5’-TGTCGCCTACTACCTGTTGTGC-3’ 
Human TNF-α Forward 5’-CACCACTTCGAAACCTGGGA-3’  
Human TNF-α Reverse 5’-CACTTCACTGTGCAGGCCAC-3’ 
Human RANTES Forward 5’-TGCCTGTTTCTGCTTGCTCTTGTC-3’ 
Human RANTES Reverse 5’-TGTGGTAGAATCTGGGCCCTTCAA-3’ 
Human TPI Forward 5’-TGGTTTGTGCTCCCCCTACT-3’ 
Human TPI Reverse 5’-CACAGCAATCTTGGGATCTAGCT-3’ 
Human SOD1 Forward 5’-GGTGTGGCCGATGTGTCTAT-3’ 
Human SOD1 Reverse 5’-CCTTTGCCCAAGTCATCTGC-3’ 
Human NME2 Forward 5’-CCATGGCCAACCTGGAG-3’ 
Human NME2 Reverse 5’-CTTCAGGTGTTCTTCAGAGGC-3’ 
Human TRAM Forward 5’-AAGGAAGACAGAAAAGCCGC-3’ 
Human TRAM Reverse 5’-ATCCAAGGCAGAAGAGGAAAACT-3’ 
Human Ferritin HC Forward 5’-GCCAGAACTACCACCAGGACT-3’ 
Human Ferritin HC Reverse 5’-GCCACATCATCGCGGTCAAA-3’ 
Human Ferritin LC Forward 5’-CAACCTCCGGGACCATCTTC-3’ 
Human Ferritin LC Reverse 5’-TGGGAGCTCATGGTTGGTTG-3’ 
Human IL-6 Forward 5’-AGCCACTCACCTCTTCAGAACGAA-3’ 
Human IL-6 Reverse 5’-CAGTGCCTCTTTGCTGCTTTCACA-3’ 
Human IFNα Forward 5’-GAAATACTTCCAAAGAATCACTCT-3’ 
Human IFNα Reverse 5’-GATCTCATGATTTCTGCTCTGACA-3’ 
Human CXCL10 Forward 5’-ATTATTCCTGCAAGCCAATTTTG-3’ 
Human CXCL10 Reverse 5’-TCACCCTTCTTTTTCATTGTAGCA-3’ 
Human NLRP12 Forward 5’-TGTTGGTGCAGCTCAGACCAG-3’ 
Human NLRP12 Reverse 5’-ATCAGTGTGAGAATCCAGCA-3’ 
Human DJ-1 Forward 5’-CTGTTGGCTATGAAATAGG-3’ 
Human DJ-1 Reverse 5’-GTGTAATGACCTCCATTCATC-3’ 
Human STMN1 Forward 5’-AGATGTACTTCTGGACTCAC-3’ 
Human STMN1 Reverse 5’-GATCAGACCAGGTAATCAATG-3’ 
Human GSTO1 Forward 5’-GGTGGCAATTCTATCTCTATG-3’ 
Human GSTO1 Reverse 5’-GTGGTCTACACACTCATTTACA-3’ 
Human PPP1Cα Forward 5’-TGCTGGCCATAAGATCAAG-3’ 
Human PPP1Cα Reverse 5’-CTTGCACTCATCGTAGAAAC-3’ 
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2.1.17 Reporter assays  
HEK293-TLR7 cells were seeded into 96 well plates (2x10
5
 cells/ml – 200 μl/well). After 48 
hr, cells were transfected with vectors encoding a reporter gene for either the IFNα promoter 
(p125), IFNβ, NF-κB, or RANTES promoters (60 ng/well) and co-transfected with either 
empty vector (EV) or increasing amounts of an expression vector encoding mutated versions 
of the human TLR adaptors TRAM (TRAM G2A), TRIF (TRIF ΔCΔN), or MAL (MAL 
P126H) using Lipofectamine 2000 (Invitrogen), according to the manufacturer’s instructions. 
A total of 20 ng/well Renilla-luciferase reporter gene was transfected simultaneously to 
noramlise transfection efficiency. After 24 hr, cells were stimulated with 5 μg/ml of CLO97 
for an additional 24 hr. Thereafter, cell lysates were prepared and reporter gene activity was 
measured using the Dual-Luciferase Assay system (Promega). Data were expressed as the 
mean fold induction relative to the control.  
2.1.18 Enzyme-Linked Immunosorbent Assay (ELISA)  
Appropriate capture antibody was plated onto Maxisorp 96-well plates (NUNC) (1 μg/ml for 
TNFα and RANTES, 2 μg/ml for IL-6) overnight at RT. The following day, plates were 
washed four times with wash buffer (sterile 1x PBS containing 0.05 % (v/v) Tween-20) 
followed by blocking with blocking buffer (PBS containing 1 % (w/v) BSA) for minimum 2 
hr. The plates were then washed four times with wash buffer. Next, serial dilutions of the 
standards (ranging from 0 to 4000 pg/ml; 100 μl/well) and samples were added (100 μl/well) 
followed by incubation at 4 °C overnight. Plates were washed again four times with wash 
buffer followed by the addition of the appropriate biotinylated detection antibody (0.2 μg/ml 
for IL-6, 0.25 μg/ml for RANTES and 0.5 μg/ml for TNFα) for 2 hr at RT. Plates were 
washed four times with wash buffer followed by the addition of Avidin-HRP conjugate 
(1:2000 for RANTES, TNFα and IL-6) for 30 min. Thereafter, plates were washed five times 
with wash buffer followed by addition of citric acid substrate buffer (100 μl/well) 
supplemented with o-Phenylenediamine (Sigma) and 30 % hydrogen peroxide (Sigma). 
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Plates were incubated in the dark with gentle shaking with the absorbance measured at 
various intervals at 490 nm using a spectrophotometer (BioTek). 
 
 
2.1.19 Nuclear Extraction  
Cellular nuclear extracts were prepared according to the manufacturer’s instructions (Nuclear 
Extraction Kit, Cayman Chemical). Briefly, experimental cells were washed in ice-cold PBS, 
harvested and pelleted by chilled centrifugation in PBS. Cell pellets were resuspended in 
PBS/Phosphatase Inhibitor Solution and re-centrifuged. This was repeated once, after which, 
250 μl Hypotonic Buffer solution was added to the pellets, mixed gently by pipetting, 
transferred to a fresh, chilled eppendorf and incubated for on ice for 15 min. Next, 50 μl 
Nonidet P-40 Assay Reagent was added to lyse the plasma membrane and the samples were 
pulse centrifuged at 16,464 g for 30 sec. The supernatant was discarded and the nuclear pellet 
was resuspended in Complete Nuclear Extraction Buffer, vortexed for 15 sec and incubated 
on ice with gentle shaking for 15 min. Samples were vortexed again for 30 sec and incubated 
on ice with gentle shaking for an additional 15 min. Samples were centrifuged at 16,464 g for 
a final 10 min and the nuclear fraction-containing supernatant was removed to a fresh 
eppendorf and stored at -80 °C.    
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2.2 Methods in Proteomics: 2D-DIGE and LC/MS 
 
2.2.1 Sample lysis 
Experimental cell culture samples were washed in 10 ml ice-cold PBS, harvested and 
subjected to centrifugation at 4°C for 5 min at 161 g. Pelleted samples were then lysed in 2D 
lysis buffer (7 M Urea, 2 M Thiourea, 100 mM DTT, 4% (w/v) CHAPS, 1% (v/v) Triton X-
100, 0.06 % (v/v) ampholytes pH4-7, 0.06 % (v/v) bromophenol blue) with repeated pipetting 
until all cell clumps were solubilised. Samples were incubated on ice for a further 30 min 
with frequent pipetting to aid lysis before chilled centrifugation at 16,464 g for 10 min. 
Whole cell lysate-containing supernatants were removed to fresh, chilled eppendorfs and 
frozen at -80 °C prior to a ‘clean-up’ step to remove impurities.  
 
2.2.2 Sample Clean-up 
Sample clean-up was undertaken using a 2D Clean-Up Kit according to the manufacturer’s 
instructions (General Electric (GE) Healthcare). Briefly, to each sample, 300 μl precipitant 
was added, followed by vortexing and incubation on ice for 15 min. A further 300 μl of co-
precipitant was then added, followed by mixing. Samples were centrifuged at 16,464 g for 8 
min followed by removal of the supernatant (Note: all centrifugation steps were carried out at 
4 °C.) Next, 40 μl of co-precipitant was added to the sample followed by incubation on ice 
for 5 min and centrifugation at 16,464 g for 5 min. Supernatants were removed and 25 μl 
distilled H2O was added followed by sample vortexing to disperse the pellet. Next, 1 ml ice-
cold wash buffer, containing 5 μl wash buffer additive, was added followed by vortexing for 
30 sec every 10 min for a total of 40 min. Samples were then centrifuged at 16,464 g for 5 
min after which, the supernatant was removed. The samples were allowed to air dry for 5 min 
on ice. Approximately 100 μl 2x DIGE labelling buffer (8 M urea, 30 mM Tris, 4% CHAPS, 
pH 9) was then added followed by pipetting and water bath sonication to aid resuspension.  
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2.2.3 Protein Quantification  
Proteins were quantified using a Bradford assay [183]. Protein standards ranging from 0 – 2 
mg/ml were prepared by diluting a BSA stock (5 mg/ml) in 0.1 M HCl, 2D lysis buffer and 
dH2O in 4 ml polystyrene cuvettes (Sarstedt). In separate cuvettes, samples were prepared by 
mixing 10 μl whole cell lysate with 10 μl 0.1 M HCl plus 80 μl dH2O. To both samples and 
standards, 3.5 ml of Protein Assay solution (Bio-Rad) (diluted 1:4 with dH2O) was added and 
incubated at room temperature for 5 min. The protein content of both standards and samples 
was measured by spectrophotometric analysis at 595 nm. A standard curve was plotted 
according to the known standards and the line equation calculated. Sample protein 
concentrations were calculated by inputting their spectrophotometric readings into the line 
equation. 
 
2.2.4 DIGE Labelling 
Quantified protein samples were labelled with CyDye DIGE Fluor minimal dyes according to 
the manufacturer’s instructions (GE Healthcare). Briefly, Cy2, Cy3 and Cy5 DIGE dyes were 
reconstituted to a concentration of 1 mM in fresh dimethylformamide (DMF) (Sigma) and 
stored at -20 °C when not in use. Stock dye solutions were then further diluted to a working 
concentration of 400 μM using DMF immediately prior to labelling. Next, 50 μg of protein 
from each unstimulated and stiulated biological replicate was quantified and minimally 
labelled with 400 pmol of Cy3 and Cy5 working solution respectively. A further 25 μg of 
protein from unstimulated and stimulated samples corresponding to each  biological replicate 
were pooled and minimally labelled with 400 pmol Cy2 as the internal standard. Samples 
were immediately mixed, pulse centrifuged and incubated on ice in the dark for 30 min. 
Labelling was quenched by adding 1 μl of 10 mM lysine with mixing and incubation for 10 
min in the dark on ice. At this point, labelled samples corresponding to each biological 
replicate were pooled in single eppendorfs. For example, Cy2, Cy3 and Cy5 labelled labelled 
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samples from biological replicate one were pooled into one eppendorf followed by gentle 
mixing and centrifugation. To this mix, an equal volume of 2x lysis buffer (7 M urea, 2 M 
thiourea, 4 % CHAPS, 0.04 % bromophenol blue) was added and made to 450 μl with 
rehydration buffer (8 M urea, 2 % CHAPS, 0.5 % IPG 4-7 buffer, 0.002% bromophenol blue). 
 
2.2.5 IPG strip rehydration 
Each sample was pipetted into a re-swelling tray (Amersham Bioscience) and overlaid with 
individual, 24 cm linear pH 4-7 IPG strips (GE Healthcare). The IPG strips were overlaid 
with 3 ml of mineral oil (Sigma) per strip. The re-swelling tray was then placed in darkness at 
RT for a minimum of 14 hr to allow passive strip rehydration to occur.  
 
2.2.6 1
st
 Dimension isoelectric focusing (IEF) 
Rehydrated IPG strips were loaded gel-side up on an Amersham Ettan IPG-phor manifold 
and overlaid in mineral oil in order to keep the IPG gel matrix moist and aid conduction. 1
st
 
dimension IEF was performed in darkness using the Amersham IPG-phor IEF system 
according to table 2.8.  
 
Table 2.8: 1
st
 dimension IEF running conditions.  
 Step Voltage (V) Time 
1 Hold 250 3 hr 
2 Gradient 8,000 4 hr 
3 Hold 8,000 80,000 Vhr 
4 Hold 500 24 hr 
 
2.2.7 Gel Casting 
Acrylamide gels (250 x 200 x 1 milimetre (mm), 10 % acrylamide) for 2
nd
 dimension SDS-
Page were prepared 24 hr prior to running to allow time for complete gel polymerisation. Gel 
composition was as follows: 10% Acrylamide, 0.38 M Tris-HCl pH 8.8, 0.1 % SDS (v/v), 
APS 0.05 % (v/v) and TEMED 0.04 % (v/v). Gels were poured to 98 % capacity, overlaid 
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with 30 % isopropanol and allowed to set at RT overnight. Immediately prior to IPG strip 
loading, the 30% isopropanol was removed. 
 
2.2.8 2
nd
 Dimension Gel Electrophoresis 
Following 1
st
 dimension IEF, proteins within the IPG strips were reduced by overlaying with 
DTT equilibration solution (6 M urea, 30 % (w/v) glycerol, 2 % (w/v) SDS, 100 mM DTT) 
for 15 min at RT with gentle agitation. This solution was removed and the proteins were 
alkylated by overlaying with iodoacetamide equilibration solution (6M urea, 30 % (w/v) 
glycerol, 2 % (w/v) SDS, 100 mM DTT, 0.25 M iodoacetamide) for a further 15 min, again 
with gentle agitation. The IPG strips were briefly washed in 1x SDS running buffer and 
applied, gel-side out, to the resolving gels. The interface between the IPG strip and the 
resolving gel was sealed with melted 0.5 % agarose sealing solution (25 mM Tris base, 192 
mM glycine, 0.1 % SDS, 0.5 % agarose, 0.002 % bromophenol blue) and allowed to solidify 
at RT for 5 min. Sealed glass plates were then loaded into an electrophoresis tank (Ettan 
DALTtwelve Separation Unit, GE Healthcare) and filled to 75 % capacity with 7 L of 1x SDS 
running buffer. Remaining slots were filled with artificial plates and the tank was topped off 
with 2 L of 2x SDS running buffer. For 2
nd
 dimension separation, electrophoresis was 
performed in darkness at 0.5 watt/gel for 1 hr followed by 1 watt/gel until the tracking dye 
reached the bottom of the plate. 
2.2.9 Image Acquisition 
Gel images were scanned using the Typhoon Trio Variable Mode Imager (Amersham 
Biosciences/GE Healthcare). The photomultiplier tube (PMT) voltage values for gels 
analysed were between 500 V and 700 V and the maximum pixel volume was between 
85,000 and 95,000. Scanning was performed at 50 mm resolution and saved in the .gel file 
format.  
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2.2.10 Image Analysis  
Gel images were analysed using Progenesis Same Spots software version 3.2.3 (NonLinear 
Dynamics). Images were categorised according to their label: Cy3 (unstimulated), Cy5 
(stimulated) and Cy2 (internal standard) for later protein abundance comparisons and 
normalisation. To ensure correct protein spot alignment between replicate gels, all images in 
an experiment were virtually overlaid through a combination of manual and automatic 
alignments against a manually determined ‘reference gel’ that displayed optimal spot 
separation across all dimensions. Spots were automatically detected and filtered to eliminate 
false detections (typically by size exclusion). Next, the images were separated into control 
and stimulated groups and individual spots were analysed to detect changes in abundance 
between the two sets and across their biological replicates. A spot list was generated 
displaying those with significant protein abundance fold changes between biological 
conditions. Only spots with a fold change <1.3 and a P value less than 0.05 were taken into 
consideration. Further manual analysis was carried out to eliminate false detections. Spots 
that met these criteria were subsequently visualised, excised and prepared for LC/MS.  
 
2.2.11 Protein Visualisation 
As DIGE labelled spot patterns are invisible to the human eye, the proteins must be visualised 
to facilitate manual excision. Therefore, the reference gel was subjected to silver staining in 
order to visual the proteins within the gel. Briefly, the reference gel was removed from its 
plate and gently placed in 500 ml fixing solution (30 % ethanol, 10 % glacial acetic acid) and 
gently rocked for 60 min. This step was repeated once with fresh fixing solution. The fixing 
solution was removed and the gels were sensitised using 250 ml sensitising solution (30 % 
ethanol, 0.2 % (w/v) sodium thiosulphate and 6.8 % (w/v) sodium acetate for 2 hr. Sensitising 
solution was removed and gels were washed 5 x 8 min in Milli-Q water. Gels were 
impregnated with silver by addition of 250 ml silver solution (0.25 % silver nitrate) for 1 hr. 
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Silver solution was removed and gels were washed 4 x 1 min in Milli-Q water. Developing 
solution (2.5 % sodium carbonate, 0.08 % (v/v) of 37 % (w/v) formaldehyde) was then added 
for approximately 5-10 min until protein spots became visible. Before high background 
development, the developing solution was removed and replaced with fixing solution (4 % 
Tris, 2 % acetic acid) for 10 min. Finally, gels were washed for 2 x 30 min in Milli-Q water 
and stored in plastic film at 4 °C in 5 % acetic acid solution prior to spot excision. 
 
2.2.12 Spot Excision  
Protein spots selected for mass spectrometry analysis were manually excised from the silver 
stained gel using a cut pipette tip and transferred to a 1.5 ml eppendorf tube. 
 
2.2.13 Gel Destaining 
Silver stained gel pieces were destained using a standard lab protocol. Briefly, 10 ml each of 
30 mM potassium ferricyanide and 100 mM sodium thiosulphate were freshly prepared and 
mixed.  Next, 50 μl of this solution was added to each excised gel piece and incubated at RT 
with gentle shaking until the brown, silver nitrate residue disappeared from the gel. The gel 
pieces were washed with Milli-Q water until the yellow potassium ferricyanide residue was 
removed. Gel pieces were incubated in 100 μl of 200 mM ammonium bicarbonate (Ambic) 
for 20 min with gentle shaking. The solution was then removed and 100 μl of a 2:3 ratio of 
200 mM Ambic/100 % acetonitrile was added and placed at 37 °C for 10 min. The solution 
was removed and 100 μl of 50 mM Ambic added to each tube and placed at 37 °C for 10 min. 
This solution was removed and 100 μl of 100 % acetonitrile was added and placed at 37 °C 
for 10 min.  This final solution was removed. The gel piece was now ready for trypsin 
digestion. 
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2.2.14 In-gel Trypsin Digestion 
Following de-staining of the individual gel plugs, protein digestion was performed as per 
Mann et al., [184]. Briefly, the trypsin digestion solution was prepared by resuspending 20 µg 
sequencing grade trypsin (Promega) in 1.5 mL 10mM Ammonium Bicarbonate containing 
10 % (v/v) acetonitrile. Next, 50 µl of trypsin solution was incubated with each gel piece on 
ice for 2 hr followed by the layering of 10 µl of a 10 mM AmBic, 10 % Acetonitrile solution 
on top of the gel pieces to prevent drying out. At this point, gel pieces were incubated at 37 
o
C overnight. Peptides were extracted from the gel plugs using 100 µl extraction buffer (1:2 
(v/v) 5% formic acid (FA)/acetonitrile) followed by incubation at 37
 o
C for 15 min with 
shaking. The solution containing the extracted peptides was then removed from each sample 
and placed in a fresh eppendorf. Samples were vacuum dried using a concentrator (Eppendorf) 
and stored at -20 °C prior to MS analysis. 
 
2.2.15 LC/MS/MS  
All peptide identifications were carried out using the Ion Trap 6340 LC/MS/MS system 
supplied by Agilent. Digested samples were resuspended in 20 µl 0.1 % (v/v) trifluroacetic 
acid (TFA) in Milli-Q water. Samples were then filtered in 0.22 μm spin filters (Corning) and 
5 µl of the trypsin digested sample was loaded onto a C18 chip (G4240-62006) (Agilent) at a 
rate of 0.6 µl/min in 0.1 % FA. The mobile phases were aqueous solutions of 0.1 % (v/v) FA 
and an acetonitrile solution of 0.1 % (v/v) FA. A 10 min gradient was carried out to increase 
the acetonitrile concentration to 100 % linearly. Charged ions were generated using an 
electrospray ionisation source. Spray voltage was set to 2000 V. 
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2.3.16 Protein Identification 
All peptides were submitted to the Mascot search engine (Matrix Science) to identify proteins. 
All peptides were searched in both the NCBinr and Swiss-Prot databases. The enzyme used 
was selected as trypsin and up to 2 missed cleavages were allowed. Peptide mass tolerance 
was set at ±2 for precursor ions and a tolerance of ±1 for fragment ions. Variable 
modifications allowed for were carboxymethyl (C) and oxidation (M). Taxonomy was 
selected as mammalian. When using the NCBinr database individual ion scores >54 indicate 
protein identity or extensive homology. Only peptides matched with an ion score above 54 
were accepted as significant. When using the Swiss-Prot database individual ion scores >40 
indicate protein identity or extensive homology. Only peptides matched with a score >40 
were accepted as significant.  
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2.3 Methods in Proteomics: Label Free Quantitative Mass Spectrometry 
(LFQ MS) 
 
2.3.1 Sample Clean-up 
Protein samples were cleaned and desalted using a 2D clean-up kit (GE Healthcare, UK) 
according to the manufacturer's instructions. Protocol was carried out as per section 2.2.2 
with one modification: the final protein pellet was resuspended in 300 μl of resuspension 
solution (50 mM Ambic, 1 mM calcium chloride (CaCl2)). 
2.3.2 Sample Quantification 
Cleaned protein samples were quantified for protein concentration using the Qubit® Quant-
IT™ Protein Assay Kit (Invitrogen, UK) on a Qubit® flourometer v.2.0 according to the 
manufacturer’s instructions. Briefly, three protein standards equivalent to 0 ng/μl, 200 ng/μl 
and 400 ng/μl were prepared by diluting the supplied protein reagent (10 μl) in Qubit® 
Protein Buffer (190 μl). Equivalent volumes of Protein Buffer were also mixed with the 
samples to be analysed followed by incubation of both samples and standards at RT for 15 
min. Finally, the fluorometer was calibrated using the prepared standards before measuring of 
the samples. 
2.3.3 Sample Acetlyation and Trypsin Digestion 
Following sample quantification, 50µg from each was pipetted into a fresh 1.5 ml 
microcentrifuge tube.  Next, 10 µl of 200 mM dithiothreitol (DTT) suspended in 100 mM 
Ambic solution was added to each sample followed by incubation at 95 °C for 15 min. 
Protein acetylation was performed by adding 4 µl of 1 M iodoacetamide (IAA) suspended in 
100 mM Ambic to each sample followed by incubation at 25 °C for 45 min. The acetylation 
reaction was stopped by adding 20 µl of 200 mM DTT with incubation at 25 °C for 45 min. 
Samples were quantified again for protein concentration and 10 µg was removed from each 
sample and transferred into a fresh 1.5 ml microcentrifuge tube. To these, 0.5 µl of 0.5 µg/µl 
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trypsin was added. To ensure maximal tryspin digestion, samples were incubated at 37 °C 
overnight followed by speed vacuuming to concentrate the peptide preparation.  
 
2.3.4 Peptide Purification  
Lyophilised, trypsin digested protein peptides were further purified for MS using the ZipTip 
procedure (Millipore) according to the manufacturer’s instructions. Briefly, trypsin digested 
peptides were resuspended in 20 µl Resuspension Buffer (0.5 % TFA in LC/MS grade H2O). 
The protein samples were sonicated for 2 min to aid resuspension followed by a pulse 
centrifugation. The ZipTips were wetted by aspirating and dispensing 10 µl of Wetting 
Solution (0.1 % TFA in 80 % acetonitrile) five times. Tip equilibration was carried out by 
aspirating and dispensing 10 µl Equilibration Solution (0.1 % TFA in LC/MS grade H2O) 
five times. To bind the peptides, 10 µl of each sample was aspirated and dispensed into the 
ZipTips. This was repeated a further 9 times, each time aspirating and dispensing into the 
same eppendorf. The sample containing tips were then washed by aspirating and dispensing 
10 µl of Washing Solution (0.1 % TFA in 80 % acetonitrile) from the tip to waste five times 
in total. Elution of the peptide samples was achieved by aspirating and dispensing 10 µl of 
Elution Solution (0.1 % TFA, 60% acetonitrile) from the tip into a 1.5 ml eppendorf tube five 
times. The resulting peptide solution was speed vacuumed and resuspended in 12 µl of 
loading buffer (0.05 % TFA, 98 % LC/MS grade H2O, 2 % LC/MS grade acetonitrile). 
Finally, samples were transferred to MS compatible vials ensuring no bubbles were present in 
the solution.  
 
2.3.5 Label-Free Mass Spectrometry 
Peptide samples were run on a Thermo Scientific Q Exactive mass spectrometer connected to 
a Dionex Ultimate 3000 (RSLCnano) chromatography system in the University College 
Dublin, Conway Institute of Biomolecular and Biomedical Research, Mass Spectrometry 
Resource unit. Each sample was loaded onto Biobasic Picotip Emitter (120 mm length, 75 
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μm ID) packed with Reprocil Pur C18 (1.9 μm) reverse phase media and was separated by an 
increasing acetonitrile gradient over 43 minutes at a flow rate of 250 nL/min. The mass 
spectrometer was operated in positive ion mode with a capillary temperature of 220 °C and 
with a potential of 2000 V applied to the frit. All data were acquired with the mass 
spectrometer operating in automatic data dependent switching mode. A high resolution 
(70,000) MS scan (300-2000 Dalton) was performed using the Q Exactive to select the 15 
most intense ions prior to MS/MS analysis using higher-energy collisional dissociation 
(HCD).  
 
2.3.6 LFQ analysis 
Protein identification and LFQ analysis was conducted using MaxQuant (version 1.3.0.5; 
http://maxquant.org/). The Andromeda database search engine was used to correlate MS/MS 
data against the IPI Human FASTA protein database provided by MaxQuant version 1.3.0.5.  
Protein identification was performed according to the search parameters specified in Table 
2.9. 
 
Table 2.9: Search parameters for protein identification on Andromeda protein database. 
Search Parameter Parameter used 
Precursor-ion mass tolerance 1.5 Da 
Fragment ion mass tolerance 6 parts per million   
Fixed modification Cysteine carbamidomethylation 
Variable modifications Protein N-acetylation                   
Methionine Oxidation  
Missed Cleavage Sites Max 2 missed cleavage sites  
False Discovery Rates  0.01 (peptides and proteins) 
Min. peptide length considered for 
identification 
6 aa 
Min. peptides for protein identification 2 peptides 
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Differentially expressed proteins among experimental groups were determined by LFQ using 
MaxQuant and Perseus (version 1.2.0.17). Peptides were matched across samples based on 
mass to charge ratio, elution time (within a 2 min boundary) and spectral features. Protein 
intensities were determined using unique and razor (those most likely to have originated from 
a protein based on the principle of parsimony) peptides. Protein intensities were normalised 
across runs to account for variation in sample loading and pair-wise ratios of all peptides of a 
particular protein group were calculated across all samples and the protein intensities were 
corrected in order to reflect the median peptide ratios. The final data matrix was generated 
containing the normalised intensities (presented as LFQ intensities) for each individual 
sample where imported into Perseus for quantitative analysis. LFQ intensities measured for 
individual runs were grouped based on their experimental treatment, log2 transformed and an 
analysis of variance (ANOVA) (p<0.05) was performed to identify variation. A qualitative 
assessment of differential expression was also conducted. This involved the identification of 
proteins that were completely lacking from a specific treatment. Proteins that were 
completely missing from all replicates of a particular group but present in other groups were 
determined manually from the data matrix. These proteins are not considered statistically 
significant as the values for absences are given as NaN (not a number) which is not a valid 
value for an ANOVA analysis. However the complete absence of a protein from a group may 
be biologically significant and these proteins were reported as qualitatively differentially 
expressed.  
 
2.4 Statistical analysis 
Statistical analysis was carried out using the unpaired Student’s t test. P-values of less than or 
equal to 0.05 were considered to indicate a statistically significant difference where * 
indicates p<0.05, ** indicates p<0.005 and *** indicates p<0.001.  
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Chapter 3 
 
 
The TIR-adaptor TRAM is required for maximal 
TLR7 mediated RANTES and type-I IFN 
production 
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3.1: Introduction 
 
3.1.1 TRAM Structure 
In contrast with TRIF, TRAM is both the smallest adaptor protein (235 aa) and the least 
functionally diverse, mediating TLR4 and IL-18R signalling only (Figure 3.1) [12, 23]. 
 
 
Figure 3.1: Schematic illustrating domain segmentation of TRAM. TRAM can be divide 
into three separate regions: an N-terminal region containing a myriostoylation site; a central 
domain containing a phosphorylation site and the C-terminal TIR-domain. Adapted from [26]. 
 
 
Amino acids 1-7 at the N-terminus contain a myristoylation site which is believed to allow 
TRAM to target to the plasma membrane [82]. Serine 16 can be phosphorylated by protein 
kinase CΣ (PKCΣ) and this may serve to release TRAM from the plasma membrane upon 
activation, allowing it to transduce further signals downstream (Figure 3.1). Impairment of 
this phosphorylation inhibits TRAM signalling [83]. 
 
3.1.2 TLR7/8 and TLR9 evolution and structure 
The endosomal TLRs, TLR3, TLR7, TLR8 and TLR9 are part of an evolutionary cluster 
believed to have arisen via an X-linked duplication event approximately 150 million years 
ago [10, 185]. TLR7/8 and TLR9 are considered a subfamily within the TLRs for a number 
of reasons. Each contains an extracellular domain greater than 800 aa compared to the TLR1 
subfamily for example, which is less than 600 aa [10]. Unlike other TLRs, they each 
recognise pathogen derived nucleic acids [186] and also share structural similarities that 
classes them as phylogenetic neighbours [185]. Within the subfamily, crystal structures are 
currently available for TLR3, bound to its cognate ligand double-stranded RNA (dsRNA) 
[187] and also for TLR8, bound to its synthetic activators, CL097, CL075 and R848 [188] 
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(Figure 3.2). Under basal conditions, TLR8 exists as a homodimer [188]. Ligand binding 
causes a structural rearrangement in which the LRR-LRR interactions, which normally ensure 
monomer-monomer binding, are rearranged to cause an ‘opening-up’ of the TLR8 structure 
by 15Å on its upper face to allow efficient ligand recognition. The resulting rearrangements 
also cause the two C-termini to come into close proximity from approximately 53 to 30Å 
(Figure 3.2). Critically, this leads to binding of the cytoplasmic TIR domains which are 
essential in transducing a downstream signal to the nucleus [188].  
 
Figure 3.2: Conformational change adopted by TLR8 upon agonist binding. (A) TLR8 
exists in dimeric form basally with the C-termini directionally opposed to each other (B) 
Agonist binding causes a hinge-like conformational change in which the C-termini are 
brought closer together. This in turn brings the opposing TIR-domains into contact thus 
transmitting the activation signal. Adapted from [188]. 
 
Although the crystal structure for TLR9 has not been determined, its structure has been 
inferred from various biochemical studies [189, 190] and it would appear that the mechanism 
of activation is similar to that of TLR8. Like TLR8, TLR9 also exists basally in an inactive 
dimeric form [190]. In this form, TLR9 is capable of binding both stimulatory and inhibitory 
DNA but critically, only stimulatory DNA causes conformational changes in the TLR9 
homodimers which results in the association of the cytoplasmic TIR-domains [190].  Subtle 
differences within the nucleotide ligand appear to dictate vastly different responses from 
A B 
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TLR9 possibly indicating an evolutionary strategy to recognise non-host derived nucleotides 
preferentially.  
3.1.3 TLR9 signalling 
TLR9 was originally shown to recognise DNA of bacterial origin, specifically unmethylated 
CpG motifs, a distinction which is much rarer in mammalian DNA than in bacterial or viral 
DNA [38]. TLR9 can also recognise double stranded DNA containing viruses such as herpes 
simplex virus 1 and 2 [191, 192]. Synthetically produced CpG containing oligonucelotides 
are commonly used to specifically activate TLR9 and indeed specific sequence modifications 
are believed to tailor the cytokine response [193]. However, more recently it has been shown 
that the endosomal targeting of DNA is the determining factor in TLR9 activation rather than 
the particular sequence or even the origin of the DNA [194]. This would agree with 
observations that TLR9 in some cases can recognise self-nucleic acids as well as non-self 
[195]. TLR9 localises within intracellular compartments particularly the endoplasmic 
reticulum, endosome and lysosomes [196]. This strategy helps to isolate TLR9 from self-
nucleotides which are usually, but not always, excluded from these compartments. For TLR9 
to become activated however, it must traffic to the endolysosome where essential 
acidification occurs [197]. Trafficking is itself a highly regulated process with chaperones 
including gp96 and UNC93B1 being essential for TLR7/8 and TLR9 to traffic from the ER to 
the endolysosome. Once in the endolysosome, TLR9’s ectodomain is cleaved by cathepsins 
and this has been shown to increase its affinity for CpG DNA - however it is not essential 
[186]. Cleavage is however required for TLR9 to bind its downstream adaptor molecule 
MyD88 and to transmit a signal [198, 199].  
Recruitment of MyD88 to TLR9 can lead to both NFκB mediated pro-inflammatory and 
IRF7 mediated type-I IFN production [200]. N-terminal death domains (DD) on MyD88 
interact with and recruit IL-1R associated kinase-4 (IRAK4) via its own DDs [45]. This 
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causes downstream phosphorylation and activation of kinases IRAK1 (which is dispensible 
for TLR9 mediated NFκB but not IRF7 activation [201]) and IRAK2 which in turn 
phosphorylate and activate TNF receptor-associated factor 6 (TRAF6) [202]. TRAF6 utilises 
its E3 ubiquitin ligase activity to ubquitinate a scaffolding protein, NFκB essential modulator 
(NEMO) [47]. The combination of TRAF6 mediated ubiquitin chain formation and NEMO 
functions to recruit TGF-β activated kinase 1 (TAK1) which itself recruits the TAK-1 binding 
proteins 1 (TAB1) and TAB2. TAK1 phosphorylates IKKβ as well as initiating a MAP 
kinase cascade leading to activation of the transcription factor CREB. IKKβ phosphorylates 
the inhibitors of κB (IκB) α and IκBβ leading to NFκB release and nuclear translocation to 
bind the promoter regions of pro-inflammatory cytokines such as TNFα and IL-12. Other 
members of the IRF transcription factor family are also believed to be involved such as IRF5 
and IRF8 with IRF5 associating with MyD88 and TRAF6 (Figure 3.3) [203, 204].  
While the above pathway holds true for many classes of cells including macrophages and 
conventional dendritic cells, an additional pathway exists in plasmacytoid dendritic cells 
(pDCs). The exact details of this pathway have not been elucidated to the same extent as the 
pro-inflammatory pathway above, however it involves initial MyD88, IRAK4, IRAK1 and 
TRAF6 recruitment, as per the NFκB pathway, followed by engagement of TRAF3, IKKα 
and IRF7. The kinases IRAK1 and IKKα are believed to phosphorylate IRF7 leading to the 
production of large quantities of type-I IFN [200, 205]. It has been suggested that 
engagement of TLR9 in the early endosome leads to preferential activation of the IRF7 signal 
cascade whereas binding of TLR9 in the late endosome favours the activation of the NFκB 
pathway (Figure 3.3) [206]. 
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3.1.4 TLR7/8 signalling 
Both TLR7 and TLR8 were originally shown to sense synthetic antimicrobial 
imidazoquinoline derivatives such as imiquimod, an approved treatment for external genital 
warts, and its more powerful derivative, resiquimod (R848) [40]. Sensitivity to these ligands 
was abolished in both TLR7 and MyD88 deficient mice indicating that MyD88 was also a 
critical adaptor molecule in TLR7 signalling. Expression of both human and mouse TLR7 but 
only human TLR8 in HEK293 cells dose dependently conferred responsiveness to R848. 
Expression of murine TLR8 did not confer responsiveness and this combined with the 
observation that TLR7 deficient mice did not respond to R848 despite the presence of TLR8 
has led to the suggestion that murine TLR8, unlike its human counterpart, is non-functional 
[40, 207]. A role for the endosome and lysosome in TLR7 and TLR8 signalling was 
suspected early on as inhibition of their maturation or acidification inhibited TLR7, TLR8 
(and TLR9) mediated signalling and abolished MyD88’s endosomal translocation [208, 
209].  Further studies confirmed or suggested roles for IRAK1, IRAK4, IRF5, IRF7 and 
TRAF6 in TLR7/8 signalling and that for the most part, the signalling process involved 
replicated that of TLR9 (Figure 3.3) [200, 201, 210-212]. Consistent with their endosomal 
location and signalling similarities with TLR9, the physiological ligand for TLR7/8 was also 
found to be nucleotide based [213]. Specifically, guanidine (G) and uradine (U) rich ssRNA 
derived from viruses such as human immunodeficiency virus-1 (HIV-1), VSV, influenza 
virus as well as non-viral RNA were found to mount a prolific innate response in a TLR7/8 
dependent manner [214-216]. TLR7/8 can also sense bacterially derived RNA [217]. TLR8 is 
expressed in many tissues including the placenta, lung, spleen, lymph node and peripheral 
blood with TLR7’s expression confined to the placenta, lung and spleen [218]. 
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Figure 3.3: Overview of TLR7/8 and TLR9 signalling. Both TLRs from active dimer 
complexes within the endolysosomal membrane and transmit their downstream signal into 
the cytosol via MyD88. The inflammatory response from both TLR7/8 and TLR9 is mediated 
by an MyD88-IRAK1-IRAK2-TRAF6-TAK1 signalosome complex. This can then activate 
the AP-1 and NFκB transcription factors which bind promoter regions of proinflammatory 
cytokines in the nucleus. Anti-viral or type-I IFN signalling from both TLRs is mediated by a 
MyD88-IRAK4-IRAK1-TRAF3/6-IKKα signalosome complex. This serves to recruit and 
activate IRF7 which binds to the  promoter regions of IFNα/β in the nucleus. Adapted from 
[210]. 
 
 
3.1.5 Chapter aim 
The aim of this chapter is to re-evaluate the role of the TIR-domain containing adaptor 
TRAM in mediating the downstream signalling of multiple TLRs.   
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3.2: Results 
 
3.2.1 Confirmation of TRAM deficiency in TRAM 
-/-
 immortalised bone marrow 
derived macrophages (iBMDMs). 
Prior to initiation of phenotype studies and characterisation of signalling abnormalities as a 
consequence of TRAM loss in macrophages, qRT-PCR was used to test for the expression of 
the tram gene in TRAM deficient cells compared to WT cells. As expected, expression of 
tram was completely abolished in TRAM 
-/-
 cells compared to WT cells (Figure 3.4). Based 
on this result, it was decided to characterise the phenotype of WT and TRAM deficient cells 
in response to various TLR ligands.  
It should be stated at this point that major difficulties were experienced during initial 
optimisation studies using WT and TRAM 
-/-
 iBMDMs. The different cell lines often grew at 
notably different rates, with TRAM deficient cells growing faster and more reliably than WT 
cells. Moreover, the ability to replicate previous findings that would serve to phenotypically 
confirm TRAM’s absence from TRAM -/- cells, such as loss of TLR4 mediated signalling, 
often proved difficult with many attempts required, often requiring different vials of cells to 
be brought up from cryogenic storage. This led to a situation where the generation of reliable 
figures, particularly those relating to cytokine induction, took an extraordinarily long period 
of time. This was because a higher level of confidence, beyond what would be  needed when 
using normal cells, had to be ensured before moving on to the next experiement. 
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Figure 3.4: Confirmation of the absence of tram gene expression in TRAM deficient 
iBMDMs. WT and TRAM deficient iBMDMs were plated at a density of 1.3x10
6
 cells/ml in 
a six-well plate and incubated for 24 hr at 37°C. Cells were then harvested, total RNA 
isolated and from this, cDNA was synthesised. The cDNA was then used as a template for 
qRT-PCR using forward and reverse primers specific to either murine tram. Fold changes 
were compared to the level of the housekeeping gene gapdh. Graph is representative of two 
independent experiments.  
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3.2.2 Comparison of TNFα production in WT and TRAM -/-  iBMDMs 
Studies to date indicate that TRAM and TRIF mediate ‘late-stage’ NFκB activation and 
TNFα secretion upon ligand binding to TLR4 [219]. However, the role of TRAM in TNFα 
secretion following activation of the other TLRs, namely TLR1/2, TLR2/6, TLR3, TLR7 and 
TLR9, has not been adequately addressed. To this end, WT and TRAM 
-/-
 iBMDMs were 
stimulated with various TLR ligands. After 24 hr, cell free supernatants were removed and 
analysed for the presence of TNFα. It was found that ligands corresponding to TLR1/2, 
TLR2/6 and TLR7 (Pam3CSK4, Pam2CSK4/MALP-2 and R848 respectively) strongly 
induced the expression of TNFα activated in both WT and TRAM deficient iBMDMs. 
Ligands corresponding to TLR3, TLR4 and TLR9 (poly(I:C), LPS and CpG respectively) 
drove a weaker response (Figure 3.5A). Comparable levels of TNFα secretion was observed 
in   TRAM 
-/-
 cells compared to WT cells upon stimulation with almost all ligands tested 
(Figure 3.5A). TRAM has been shown to be a critical adaptor in TLR4 signalling [24] and as 
expected, reduced TNFα secretion was observed following stimulation of TRAM -/- cells with 
LPS when compared to WT cells (Figure 3.5A). The LPS phenotype would be expected as 
TRAM has been shown to be a critical adaptor molecule in TLR4 signalling. These data 
suggest that TRAM is not required for TNFα production following stimulation of cells with 
TLR1/2, TLR2/6, TLR3, TLR7 and TLR9 ligands. TRAM’s role in TNFα prodcution appears 
to be limited to the TLR4 pathway which is in line with previous studies [24].  
3.2.3 Comparison of RANTES and type-I IFN production in WT and TRAM 
-/-
 
iBMDMs  
Next, TLR mediated production of the chemokine RANTES was examined in WT and 
TRAM deficient cells. Cells were again stimulated with various ligands and it was found that 
TLR1/2, TLR2/6, TLR4, TLR7 and TLR9 ligands all induced RANTES secretion (Figure 
3.5B). As expected, reduced RANTES secretion was observed upon stimulation of TRAM 
-/-
 
cells with LPS when compared to WT cells. Interestingly, the loss of TRAM caused a 
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significant reduction in TLR1/2, TLR2/6, TLR7 and TLR9 mediated RANTES secretion 
(Figure 3.5B). The loss of function was expected in response to TLR4 activation but not for 
TLR2, TLR7 or TLR9 responses. As a negative control, RANTES secretion upon TLR3 
activation was unchanged in TRAM deficient cells compared to WT cells (Figure 3.5B). As 
TRAM has not been shown to play a role in TLR3 signalling [24], this precludes the 
possibility that TRAM 
-/- 
cells are unable to produce RANTES at a global level when 
compared to WT cells.  These data support a hypothesis that TRAM may have a specific role 
to play in RANTES production through selected TLRs. While no role for TRAM has 
previously been shown in the context of TLR7 or TLR9 signalling, a previous study 
suggested it may play a role in the TLR2 mediated response to the gram negative pathogen 
Francisella tularensis [178]. Indeed, the study demonstrated that TRAM co-
immunoprecipitated with TLR2 following TLR2 activation in macrophages [178].  
Next, levels of secreted type-I IFN were determined in supernatants from WT and TRAM 
-/-
 
cells stimulated with various TLR ligands (Figure 3.5C). In all cases, the levels of secreted 
type-I IFN was minimal such that only Pam3CSK4, poly(I:C), R848 and CpG induced the 
production of type-I IFN when compared to unstimulated control cells (Figure 3.5C). As 
expected, levels of TLR3 mediated production of type-I IFN were comparable between 
TRAM deficient cells and WT cells. Interestingly, levels of type-I IFN were significantly 
impaired in TRAM 
-/- 
cells following stimulation with R848 and this correlates with previous 
date showing suppressed RANTES secretion in TRAM 
-/-
 compared to WT cells (Figure 3.5C, 
3.5B). Again, this data contrasts with the unchanged levels of TNFα secretion observed 
between WT and TRAM deficient cells when stimulated with the same TLR ligands (Figure 
3.5A). 
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Figure 3.5: TNFα, RANTES and type-I IFN production in WT and TRAM -/- iBMDMs 
in response to various TLR ligands. WT and TRAM deficient iBMDMs were plated at a 
density of 1.3x10
6
 cells/ml in a six-well plate and incubated for 24 hr at 37°C. Individual 
wells were then either left unstimulated or stimulated with ligands specific to various TLRs: 
Pam2CSK4, (TLR2:TLR6 heterodimer) – 1 μg/ml, Pam3CSK4 (TLR1:TLR2 heterodimer) – 1 
μg/ml, poly(I:C) (TLR3) – 25 μg/ml, LPS (TLR4) – 100 ng/ml, R848 (TLR7) – 1 μg/ml and 
CpG-C (TLR9) – 5 μg/ml for 4 hr. Cell free supernatants were removed and assayed for 
levels of murine TNFα (A) and RANTES (B) by ELISA. Type-I IFN levels (C) were detected 
using B16-Blue™ IFN-α/β cells. * p<0.05, ** p<0.01 and *** p<0.001. Graphs are 
representative of at least four independent experiments.  
A 
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3.2.4 Comparison of rantes, and tnfα and ifnα gene expression iBMDMs derived from 
WT and TRAM 
-/- 
mice 
Initial studies indicated that TRAM may be required for TLR2, TLR7 and TLR9 mediated 
RANTES production. TRAM also appears to have a role in TLR7 mediated type-I IFN 
production (Figure 3.5). However, the potential role of TRAM may be at either the 
transcriptional or translational level. To examine this further, the genetic expression of rantes, 
tnfα and ifnα was studied in WT and TRAM deficient cells upon stimulation with various 
TLR ligands for 4 hr. It was found that all TLR ligands tested caused upregulation of both 
tnfα and rantes gene expression (Figure 3.6A-F). As very little type-I IFN was detected in 
Figure 3.5C, it was decided not to check for ifn-α or ifn-β gene expression. 
Interestingly, Pam3CSK4, MALP-2, LPS, R848 and CpG mediated RANTES mRNA 
expression was significantly reduced in TRAM 
-/-
 cells when compared to WT cells (Figure 
3.7). In contrast, no significant differences in TNFα mRNA expression were observed in 
TRAM deficient cells upon TLR ligand stimulation (Figure 3.6). The pattern of TNFα mRNA 
expression replicated that of TNFα protein expression except in the case of LPS stimulation 
where no change in the expression of TNFα mRNA was observed between WT and TRAM -/- 
cells (Figure 3.6D). This finding correlates with a previous study by Wang et al., [220] where 
they showed that TRAM is required for TNFα translation but not transcription in BMDMs in 
a process dependent on the regulatory kinase MK2. However, the same study showed that in 
peritoneal macrophages, TRAM is required for both transcription and translation [220]. Thus 
TRAM’s exact role in TLR4 signalling therefore appears to be cell-type specific. That TRAM 
deficient macrophages are significantly attenuated in their response to TLRs 2, 7/8 and 9 at 
the transcriptional level indicates that TRAM may mediate its effects upstream of gene 
transcription and therefore agrees with the physiological roles of the other adaptor proteins in 
TLR signalling. 
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Figure 3.6: TNFα mRNA expression in WT and TRAM -/- iBMDMs in response to 
various TLR ligands. WT and TRAM deficient iBMDMs were plated at a density of 1.3x10
6
 
cells/ml in a six-well plate and incubated for 24 hr at 37°C. Individual wells were then either 
left unstimulated or stimulated with ligands specific to various TLRs: (A) Pam2CSK4, 
(TLR2:TLR6 heterodimer) – 1 μg/ml, (B) Pam3CSK4 (TLR1:TLR2 heterodimer) – 1 μg/ml, 
(C) poly(I:C) (TLR3) – 25 μg/ml, (D) LPS (TLR4) – 100 ng/ml, (E) R848 (TLR7) – 1 μg/ml 
and (F) CpG-C (TLR9) – 5 μg/ml for 4 hr. Cells were then harvested and total RNA was 
isolated and used as a template for first strand cDNA synthesis. The cDNA was then used as 
a template for qRT-PCR using forward and reverse primers specific to murine tnf-α and 
gapdh (housekeeping gene). * p<0.05, ** p<0.01 and *** p<0.001. Graphs are representative 
of at least four independent experiments.  
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Figure 3.7: RANTES mRNA expression in WT and TRAM 
-/-
 iBMDMs in response to 
various TLR ligands. WT and TRAM deficient iBMDMs were plated at a density of 1.3x10
6
 
cells/ml in a six-well plate and incubated for 24 hr at 37°C. Individual wells were then either 
left unstimulated or stimulated with ligands specific to various TLRs: (A) Pam2CSK4, 
(TLR2:TLR6 heterodimer) – 1 μg/ml, (B) Pam3CSK4 (TLR1:TLR2 heterodimer) – 1 μg/ml, 
(C) poly(I:C) (TLR3) – 25 μg/ml, (D) LPS (TLR4) – 100 ng/ml, (E) R848 (TLR7) – 1 μg/ml 
and (F) CpG-C (TLR9) – 5 μg/ml for 4 hr.  Cells were then harvested and total RNA was 
isolated and used as a template for first strand cDNA synthesis. The cDNA was then used as 
a template for qRT-PCR using forward and reverse primers specific to murine rantes and 
gapdh (housekeeping gene). * p<0.05, ** p<0.01 and *** p<0.001. Graphs are representative 
of at least four independent experiments.  
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3.2.5 Expression levels of tram in response to TLR7 and TLR9 activation  
Levels of TRAM mRNA expression have previously been examined in response to LPS 
simulation with the finding that TRAM’s mRNA levels remained stable over multiple time 
points in HEK293-TLR4 cells despite its known role in TLR4 signalling [86]. Currently, it is 
not possible to measure the levels of endogenous TRAM protein expression despite the 
testing of over thirteen commercially available and self-raised antibodies towards the 
detection of endogenous TRAM expression [86]. Therefore, whilst the levels of TRAM gene 
expression remain unchanged, the possibilities that TRAM protein levels flux upon TLR4 
activation cannot be precluded. With this in mind, it was decided to measure TRAM mRNA 
expression in iBMDMs in response to TLR7, TLR9 and TLR4 activation over multiple time 
points.  
Results showed that levels of TRAM mRNA were decreased within 15 min of stimulation 
with TLR4 and TLR7 ligands, reaching their lowest levels upon TLR4 activation at 1.5 hr 
and at 2 hr upon TLR7 activation (Figure 3.8). Levels of TRAM mRNA had decreased 
approximately 40 % and 20 % respectively at these times. Levels of TRAM mRNA were 
largely unaffected by TLR9 activation over similar time points (Figure 3.8). The finding that 
decreased TRAM mRNA expression is evident upon both TLR4 and TLR7 activation is 
novel. In contrast, a previous study showed that levels of TRAM mRNA remained stable 
following LPS stimulation of HEK293-TLR4 cells. The disparity may be due to the different 
cell lines used – iBMDMs in the current study vs. HEK292-TLR4 cells in [86]. Levels of 
TRAM mRNA were consistently lower in response to both LPS and R848 stimuli and may 
indicate the presence of a TRAM dependent negative feedback loop in both TLR4 and TLR7 
signalling whereby activation of either pathway may cause suppression of TRAM mRNA so 
as to prevent an overactive immune response. Such intracellular feedback loops are indeed 
common in cell signalling [221]. The rebounding of TRAM’s expression at 4 hr consequently 
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might indicate to the cell that a PAMP is still present and that the immune response must be 
sustained (Figure 3.8). However, confirmation of this hypotheis would need to be undertaken 
by analysing TRAM protein levels. 
That TRAM’s mRNA undergoes dynamic patterns of expression in response to TLR 
activation provides further support for the hypothesis that TRAM plays a role within this 
pathway. The lack of an apparent change in TRAM mRNA in response to stimulation with 
the TLR9 ligand CpG may be due to CpG being a weaker driver of signalling compared to 
R848 and LPS as could be observed in Figure 3.5. This may in turn affect activation of 
downstream pathways including any changes in adaptor expression.  
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Figure 3.8: Expression of TRAM mRNA in response to TLR7, TLR9 and TLR4 ligand 
activation. WT iBMDMs were plated at a density of 1.3x10
6
 cells/ml in a six-well plate and 
incubated for 24 hr at 37°C. Individual wells were then either left unstimulated or stimulated 
with LPS (100ng/ml), R848 (1 μg/ml) and CpG-C (5 μg/ml) for various time points as 
indicated. Cells were then harvested and total RNA was isolated and used as a template for 
first strand cDNA synthesis. The cDNA was then used as a template for qRT-PCR using 
forward and reverse primers specific to murine tram with murine gapdh acting as a 
housekeeping gene for fold-change comparison. Graph is representative of two independent 
experiments.  
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3.2.6 R848 and CpG stimulation of iBMDMs causes TRAM dependent activation of 
IRF3  
Previous results indicated that RANTES and type-I IFN secretion were impaired in TRAM 
-/-
 
cells compared to WT cells when following stimulation with TLR7 and TLR9 ligands (Figure 
3.5). Further studies indicated that TRAM exerts its effects at the transcriptional level (Figure 
3.7). It was therefore hypothesised that TRAM may be required for transcriptional activation 
of TLR7 and TLR9 signalling. NFκB and the IRFs are key transcription factors involved in 
the TLR7 and TLR9 response [15]. In unstimulated cells, NFκB is sequestered in the 
cytoplasm by a group of inhibitory proteins called inhibitor of κBs (IκBs), the best studied of 
which is IκBα. IκBα binds to the NFκB subunits and masks its nuclear localisation sequences 
[222]. Activation of the cell, for example via TLRs, causes activation of the IKK complex 
which phosphorylates serine residues on IκB proteins causing their ubquitination and 
subsequent proteosomal degradation. Loss of IκB frees NFκB thus permitting it’s 
translocation into the nucleus where it can bind to the promoter regions of target genes [223]. 
Monitoring of IκBα degradation is therefore a model of NFκB activation. IRF5 and IRF7 
have been shown to be involved in both TLR7 and TLR9 pathways [205, 212] however, 
commercial phospho-IRF5 antibodies are not available and endogenous levels of IRF7 are 
generally low in macrophages [224] thus making the detection of activated IRF5 and IRF7 
technically difficult. It was therefore decided to measure IRF3 activity by immunoblot 
analysis using phospho-specific IRF3 antibodies following stimulation of WT and TRAM 
deficient iBMDMs with R848 and CpG.  
WT and TRAM 
-/-
 iBMDMs were stimulated with R848, CpG, poly(I:C) and LPS for 30, 60 
and 120 min after which whole cell lysates were collected and subjected to immunoblot 
analysis to detect endogenous levels of phospho-IRF3 (p-IRF3) and IκBα with total IRF3 and 
β-actin as loading controls respectively.  
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Stimulation of cells with R848, CpG, poly(I:C) and LPS resulted in activation of IRF3 in WT 
cells as evidenced by its increased phosphorylation in comparison to unstimulated controls 
(Figure 3.9). There appeared to be a pattern of slightly increased levels of basal IRF3 
phosphorylation in WT cells compared to TRAM deficient cells (Figure 3.9 A,B). R848 
appeared to drive maximal activation in WT cells at 30 min and 60 min with activation 
beginning to decrease at 120 min (Figure 3.9A). LPS strongly activated IRF3 at 30 min and 
60 min when compared to the other ligands tested (Figure 3.9A). Both poly(I:C) and CpG 
stimulation induced maximal IRF3 phosphorylation at 120 min of stimulation with activation 
steadily increasing at time points prior to that (Figure 3.9B,C).  When comparing IRF3 
phosphorylation in WT and TRAM deficient cells, poly(I:C) served as a negative control. As 
expected, poly(I:C) mediated levels of IRF3 activation in TRAM 
-/-
 cells were comparable to 
that detected in WT cells (Figure 3.9C). As a positive control, levels of IRF3 phosphorylation 
were abolished in TRAM deficient cells compared to WT following treatment of cells with 
LPS (Figure 3.9A). These results further confirm that TRAM is involved in TLR4 signalling 
but not TLR3.    
Next, IRF3 phosphorylation was determined in TRAM 
-/-
 cells following stimulation with 
TLR7 and TLR9 ligands. It was found the phosphorylation of IRF3 was abolished in TRAM 
deficient cells following stimulation with R848 when compared to WT cells (Figure 3.9A). 
Similarly, phosphorylation of IRF3 was abolished in TRAM 
-/-
 cells in response to CpG 
stimulation when compared to WT cells (Figure 3.9B). That reduced levels of activation were 
apparent across all time points tested indicates that IRF3 activation upon TLR7 and TLR9 
activation in completely dependent on TRAM at both early and late time points. Equitable 
levels of total IRF3 confirmed equal loading of protein across all lanes (Figure 3.9A-C). As a 
control to confirm that the phenotype observed was adaptor specific, it was examined 
whether the adaptor MAL also played a role in the TLR7 pathway using WT and MAL 
-/-
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iBMDMs. It was found that comparable IRF3 activation were detected in MAL deficient cells 
and WT cells (Figure 3.9D). Together, these data suggest that TRAM is required for TLR7 
and TLR9 mediated IRF3 activation. 
 
 
 
 
Figure 3.9: R848 and CpG stimulation activates IRF3 in a TRAM dependent manner. 
WT and TRAM 
-/- 
(A-C)
 
and MAL 
-/- 
(D)
 
iBMDMs were seeded in a 6-well plate at a density 
of 1.3x10
6
 cells/ml and incubated for 24 hr at 37°C. Thereafter, cells were stimulated with 
either R848 (1 μg/ml), CpG-C, (5 μg/ml) or poly(I:C) (25 μg/ml) for 30, 60 and 120 min. 
Cells were then harvested and each sample lysed in 100 μl H.S. buffer for 20 min on ice. Cell 
debris was removed by centrifugation with the remaining whole cell lysates mixed with 30 μl 
5x Laemmli loading buffer and boiled for 10 min. Proteins were separated by SDS-PAGE 
and subjected to immunoblot analysis using anti-p-IRF3 and anti-IRF3 antibodies. Results 
represent a minimum of three (WT vs TRAM 
-/-
) and two (WT vs MAL
-/-
) independent 
experiments.  
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3.2.7 R848 stimulation of iBMDMs causes TRAM dependent nuclear translocation of 
IRF3  
Like NFκB, unactivated IRF3 exists within the cytosol. However, serine phosphorylation by 
the upstream kinases TBK-1 and IKKε leads to conformational changes that cause 
homodimerisation and binding to nuclear trafficking proteins such as CREB-binding protein 
(CBP) and p300. This leads to nuclear translocation and accumulation of IRF3 and upon 
which it binds to DNA targets [225-227]. Therefore, an alternative approach to monitor the 
activation of IRF3 is to examine its accumulation in the nucleus following TLR activation.  
To this end, WT and TRAM 
-/-
 iBMDMs were stimulated with R848, CpG and poly(I:C) for 
30, 60 and 120 min upon which, cells were lysed and the nuclear fraction purified and 
subjected to immunoblot analysis using an anti-IRF3 antibody. Nuclear translocation of IRF3 
was observed following stimulation with R848, CpG and poly(I:C), correlating with the IRF3 
phosphorylation (Figure 3.9A, 3.10A).  Regarding CpG, the overall response appears to be 
weak compared to the other TLR ligands tested (Figure 3.10C). Whilst poly(I:C) mediated 
nuclear accumulation of IRF3 was unchanged between WT and TRAM 
-/-
 cells, R848 and 
CpG mediated accumulation of IRF3 appeared reduced or abolished in TRAM deficient cells 
compared to WT cells (Figure 3.9A-C). The nuclear pore protein Lamin A/C was used to 
confirm equal loading of protein across all lanes (Figure 3.9A-C).  
The observation that R848 induced the activation and nuclear translocation of IRF3 in 
iBMDMs may be cell type specific as a previous study conducted using HEK293 cells 
showed that overexpressed IRF3 did not translocate to the nucleus upon R848 stimulation 
[212]. In the same study, endogenous phosphorylation of IRF3 in RAW264.7 macrophages 
was not detected following stimulation with R848 [212]. Indeed, discrepancies in the 
modulation of the IRFs between macrophage cell lines have been noted previously [224] 
Herein, it is clearly demonstrated that IRF3 is both phosphorylated and translocated into the 
nucleus following stimulation of iBMDMs with R848 and CpG. Moreover, it is shown that 
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this process is dependent upon the presence of the TLR adaptor protein, TRAM. The role for 
TRAM in TLR7 and TLR9 signalling is strikingly similar to that of TRAM’s role in TLR4 
signalling post LPS stimulation whereby TRAM is also required for the activation of IRF3 
[228].  
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Figure 3.10: R848 and CpG mediated IRF3 nuclear translocation is TRAM dependent.                  
WT and TRAM 
-/- 
iBMDMs (A-C) were seeded in a 6-well plate at a density of 1.3x10
6
 
cells/ml and incubated for 24 hr at 37°C. Thereafter, cells were stimulated with either (A) 
R848 (1 μg/ml), (B) poly(I:C) (25 μg/ml) or (C) CpG (5 μg/ml) for 30, 60 and 120 min. Cells 
were then harvested and each sample subjected to nuclear extraction using a Nuclear 
Extraction Kit (Cayman Chemical). Nuclear Extracts were mixed with 30 μl 5x Laemmli 
loading buffer and boiled for 10 min. Proteins were separated by SDS-PAGE and subjected 
to immunoblot analysis using anti-IRF3 and anti-Lamin A/C antibodies. Results represent a 
minimum of two independent experiments.  
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3.2.8 IκBα degradation is unaffected in TRAM -/- cells in response to R848 and CpG 
Despite the loss of IRF3 activation following stimulation of TRAM 
-/-
 cells with R848 and 
CpG compared to WT cells, concurrent RANTES and type-I IFN secretion is evident, albeit 
at reduced levels compared to WT cells (Figure 3.5 C,D). It is plausible to speculate that 
while TRAM dependent IRF3 activation is required for maximal TLR7 and TLR9 dependent 
cytokine production, TLR7 and TLR9 dependent activation of alternative transcription 
factors such as NFκB may be TRAM independent.  
With this in mind, the degradation of IκBα in response to R848 and CpG was monitored by 
Western blot. In WT iBMDMs, IκBα was degraded in response to R848 stimulation at 15 min 
and was almost completely degraded at 30 min before rebounding fully by 60 min (Figure 
3.11A). Interestingly, in contrast to IRF3 phosphorylation, degradation of IκBα was 
comparable in WT and TRAM deficient cells (Figure 3.11A). It would therefore appear that 
TRAM’S role in TLR7 signalling is IRF3 dependent and NFκB independent. The kinetics of 
CpG mediated IκBα degradation difficult to detect as degradation of IκBα was not evident at 
any of the timepoints selected (Figure 3.11B).  
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Figure 3.11: R848 and CpG mediated IκBα degradation in WT and TRAM -/- cells.                  
WT and TRAM 
-/-
 iBMDMs were seeded in a 6-well plate at a density of 1.3x10
6
 cells/ml and 
incubated for 24 hr at 37°C. Thereafter, cells were stimulated with either (A) R848 (1 μg/ml) 
or (B) CpG (5 μg/ml) for 30, 60 and 120 min. Cells were then harvested and each sample 
lysed in 100 μl H.S. buffer for 20 min on ice. Cell debris was removed by centrifugation with 
the remaining whole cell lysates mixed with 30 μl 5x Laemmli loading buffer and boiled for 
10 min. Proteins were separated by SDS-PAGE and subjected to immunoblot analysis using 
anti-IκBα and anti-β-Actin antibodies. Results represent a minimum of three independent 
experiments.  
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3.2.9 TLR7/8 and TLR9 ligand preparations are incapable of activating TLR4 
It is well documented that endotoxin in the form of LPS is known to drive IRF3 
phosphorylation in a TLR4 dependent manner [229-231]. Unfortunately, endotoxin 
contamination of immune cell activator preparations has also been a problem for immune 
researchers [232, 233]. All TLR ligands used in the current study were commercially sourced 
from respected suppliers (see Materials and Methods) and preparations were resuspended 
with supplied endotoxin free water as verified by limulous amoebocyte lysate (LAL) testing. 
However, it is still conceivable that despite these stringent precautions, endotoxin may still be 
present in our preparations [233, 234]. Therefore, ligand preparations were additionally tested 
for endotoxin contamination by examining whether they were capable of specifically 
activating TLR4. To this end, HEK-293 cells stably transfected with human TLR4, the MD-
2/CD14 coreceptors and a secreted embryonic alkaline phosphatase (SEAP) reporter gene 
were used (HEK-Blue™ TLR4 cells). The SEAP gene is under the control of an IL-12p40 
promoter fused to five NFκB and AP-1 transcription factor binding sites. Contaminating LPS 
in the ligand preparations would bind TLR4 and thus activate NFκB and AP-1 which in turn 
drive production and secretion of SEAP into the culture medium. The presence of SEAP in 
medium therefore indicates the original presence of LPS and can itself be detected using a 
colourimetric alkaline phosphatase detection medium, commercially known as QUANTI-
Blue™.   Therefore, to account for possible endotoxin contamination of the TLR7/8 ligands 
(R848 and CLO97) and the TLR9 ligand (CpG) preparations,  HEK-Blue™ TLR4 cells were 
stimulated with increasing concentrations of R848, CLO97, CpG and LPS and TLR4 
activation with the presence of SEAP in the culture medium monitored. Addition of 50ng/ml 
of LPS induced detectable SEAP secretion and this dose-dependently increased with 
increasing concentration (Figure 3.12). Critically, neither R848, CLO97 or CpG induced 
detectable SEAP production despite addition of ligand corresponding to ten times the original 
concentrations used in our previous iBMDM assays (Figure 3.12). It was therefore concluded 
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that the TLR7/8 and TLR9 ligand preparations were incapable of activating TLR4 and that 
the results observed in assay’s involving these ligands were specifically due to their ability to 
activate their corresponding TLR and not due to non-specific TLR4 activation.  
Post submission script: It has been noted that as iBMDMs can respond to LPS concentrations 
as low as 0.1 ng/ml, the observed LPS sensitivity of the HEK-TLR4 Blue cells 
(approximately 50 ng/ml) is not sensitive enough to reliably detect LPS contamination in 
ligand preparations. A more suitable assay in this case would be a LAL test. 
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Figure 3.12: R848, CLO97 and CpG ligand preparations are incapable of activating 
TLR4. HEK-Blue™ hTLR4 cells were plated at a density of 1.4x105 cells/ml in a 96 well 
plate and incubated for 24 hr at 37 °C. Cells were then stimulated with either endotoxin free 
H2O or increasing amounts of LPS (50ng/ml, 100ng/ml and 500ng/ml), R848 (1 μg/ml, 5 
μg/ml and 10 μg/ml), CLO97 (1 μg/ml, 5 μg/ml and 10 μg/ml) and CpG-C (5 μg/ml, 10 
μg/ml and 50 μg/ml) for a further 24 hr. 20 μl of cell supernatants were then transferred to a 
separate 96 well plate containing 180 μl/well of pre-warmed QUANTI-Blue™ detection 
medium and incubated at 37 °C for approximately 2 hr. Induced colour changes in the 
detection medium were then detected and quantified by spectrophotometry at 630 nm. 
Results are representative of three independent experiments.   
 
 
 
 
 
 
121 
  
3.2.10 Screening human cell lines for broad TLR responsiveness: PMA differentiated, 
THP1 macrophages respond to ligand binding to TLR7/8, TLR3, TLR4, TLR9 and to 
HRV16 infection 
Data collected thus far indicate a role for TRAM in the transcriptional control of TLR7 and 
TLR9 mediated RANTES production in an IRF3 dependent, NFκB independent manner. 
However, these experiments were conducted exclusively in murine iBMDMs and are 
therefore relevant only to murine TRAM and the murine TLR7 and TLR9 pathways. Whilst 
the use of murine models has long been an acceptable method of elucidating signalling 
pathways and in assigning function to many proteins, murine protein functionality does not 
always correlate with that of human protein function [235]. It was therefore decided to extend 
the previous observations on the role of murine TRAM to that of human TRAM. Also, in 
order to focus more directly on a single signalling pathway and reduce lengthy optimisation 
procedures, it was decided to concentrate on the role of TRAM in TLR7/8 signalling only in 
future experiments.  
In order to replicate the previous experimental model in a human setting, a human cell line 
capable of responding efficiently to TLR3, TLR4 and TLR7/8 stimulation was required. The 
response of multiple available cell lines, namely BEAS-2B lung epithelial cells, HeLa cells, 
A549s, CD14-U373s, THP1 monocytes and THP1 macrophages was assayed to monitor their 
ability to drive cytokine gene expression in response to activation of the above TLRs. BEAS-
2B cells responded well to poly(I:C) with rantes, cxcl10 and ifnβ expression all upregulated 
(Figure 3.13A). LPS stimulation also drove expression of rantes and cxcl10 but not ifnβ. 
R848 and CpG on the other hand, drove comparatively little rantes expression and almost no 
cxcl10 and ifnβ expression (Figure 3.13A). As weak responders to TLR7/8 and TLR9 
simulation, BEAS-2B cells were therefore considered unsuitable. HeLa cells responded 
relatively well to poly(I:C) stimulation causing an approximately 30-fold increase in rantes 
production but successively less cxcl10 and ifnβ (Figure 3.13B). LPS was a poorer activator 
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inducing an increase only in ifnβ expression. R848 and CpG did not any increase in cytokine 
production (Figure 3.13B). HeLa cells were therefore also considered unsuitable. A549 cells 
were extremely poor and responded only weakly to LPS and CpG causing a respective 2 and 
1.5 fold increase in ifnβ expression. No other ligand was capable of driving a response to any 
of the cytokines tested (Figure 3.13C). CD14-U373 cells likewise responded only to LPS 
which drove expression of large amounts of all cytokines tested (Fig 3.13D). CD-14 U373s 
were therefore also considered unsuitable.  
THP1 monocytes can be differentiated into highly sensitive macrophages by the addition to 
the culture media of nanomolar quantities of PMA. PMA has an analogous structure to 
diacylglycerol which can activate protein kinase C to drive intracellular calcium release and 
multiple downstream signalling cascades. These cascades, in THP1 monocytes, ultimately 
result in various cellular morphological changes including adherence and spreading, as well 
as physiological changes such as increased CD14 expression and increased cytokine 
expression [236]. PMA differentiated THP1 macrophages (PMA-THP1s) were therefore also 
tested with the aforementioned ligand panel. PMA-THP1s responded to all ligands tested 
(Figure 3.13A). Poly(I:C), LPS and R848 all drove rantes, ifnβ and cxcl10 expression. Fold 
changes compared to unstimulated cells were typically in the 5-fold range although LPS 
mediated a 150-fold increase in rantes expression (Figure 3.13A). As PMA-THP1s appeared 
to be broadly responsive to a broad panel of ligands, they were subsequently tested for their 
ability to respond to infection with the ssRNA virus, and physiological TLR7/8 ligand human 
HRV16.  
PMA differentiated THP1 cells were stimulated with HRV16 for 72-80 hr at 37 °C. Again, 
rantes, cxcl10, type-I IFN genes and tnfα were all upregulated in response to HRV16 
predominantly around 70-96 hr post-infection (Figure 3.13B). HRV16 transcripts were also 
analysed which showed that intracellular levels of the virus were increasing at similar time 
123 
  
points (Figure 3.13 left panel). Based on these results, it was concluded that PMA-
differentiated THP1 cells were suitable for the study of TLR3, TLR4, TLR7/8 and TLR9 
activated pathways.  
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Figure 3.13: BEAS-2B, HeLa, A549 and U373-CD14 cell lines are unsuitable for 
simultaneous study of TLR3, TLR4, TLR7/8 and TLR9 signalling. (A) BEAS-2B, (B) 
HeLa, (C) A549 and (D) U373-CD14 cells were plated at densities ranging from 0.7x10
5
-
1x10
6
 cells/ml in six well plates and incubated for 24 hr at 37°C. Each cell line was then 
either left unstimulated or simulated with poly(I:C) (25 μg/ml), LPS (100 ng/ml), R848 (1 
μg/ml) or CpG (5 μg/ml) for 5 hr. Cells were then harvested and total RNA was isolated and 
used as a template for first strand cDNA synthesis. The cDNA was then used as a template 
for qRT-PCR using forward and reverse primers specific to murine rantes, cxcl10, ifn-β and 
gapdh (housekeeping gene). Graphs are representative of two independent experiments.  
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Figure 3.14: PMA differentiated THP1 macrophages are suitable for studying TLR3, 
TLR4 and TLR7/8 activation. THP1 monocytes were plated in a 12 well plate at a density 
of 1.4x10
6
 cells/ml and stimulated with 20 nM PMA for 48 hr at 37°C. Cells were then either 
left unstimulated, stimulated with (A) TLR ligands: poly(I:C) (25 μg/ml), LPS (100 ng/ml), 
R848 (1 μg/ml and 5 μg/ml), and CLO97 (1 μg/ml and 5 μg/ml) for 6 hr at 37°C or (B) 
infected with HRV16 for 48, 80 and 96 hr at 33°C. Cells were then harvested and total RNA 
was isolated and used as a template for first strand cDNA synthesis. The cDNA was then 
used as a template for qRT-PCR using forward and reverse primers specific to human rantes, 
cxcl10, ifn-β, ifn-α, tnf-α, hrv16 and gapdh (housekeeping gene). Graphs are representative of 
two independent experiments. 
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3.2.11 Knockdown of endogenous human TRAM using siRNA 
To investigate the role played by TRAM in TLR7/8 signalling, knockdown of endogenous 
TRAM in PMA-differentiated THP1 cells was performed using small interfering RNA 
(siRNA). SiRNA sequences are RNA nucleotide sequences approximately 21 nucleotides in 
length with a 2-nucleotide overhang on the 3’ end. Introduction of this sequence into the cell 
results in their integration into the RNA-induced silencing complex (RISC) resulting in 
complementary base-pairing with its target sequence to initiate its degradation thus impeding 
translation [237]. This process was harnessed to impede translation of TRAM and thus 
knockdown its expression. SiRNA corresponding to the unique N-terminal region of TRAM 
was transfected into PMA differentiated THP1s for 48 hr and knockdown of TRAM’s mRNA 
expression was assessed by qRT-PCR of the tram gene relative to cells transfected with a 
scrambled control siRNA sequence. It was found that TRAM specific siRNA significantly 
reduced the expression of TRAM mRNA as assessed by qRT-PCR. Estimated knockdown 
was 50% when compared to transfection with the scrambled control sequence (Figure 3.15A). 
It was not possible to observe a decrease of endogenous TRAM at the protein level as reliable 
anti-TRAM antibodies are not currently available [86].  
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Figure 3.15: Suppression of human TRAM mRNA using RNA interference in PMA 
differentiated THP1 macrophages. THP1 monocytes were plated in a 12 well plate at a 
density of 1.4x10
6
 cells/ml and stimulated with 20 nM PMA for 48 hr at 37°C. Cells were 
then transfected with either 200 nM TRAM specific siRNA or scrambled control siRNA for a 
further 48 hr. Cells were then harvested and total RNA was isolated and used as a template 
for first strand cDNA synthesis. The cDNA was then used as a template for qRT-PCR using 
forward and reverse primers specific to human tram and gapdh (housekeeping gene). Graph 
is representative of two independent experiments. 
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3.2.12 Suppression of TRAM impairs R848 and HRV16 mediated rantes, ifnβ and 
cxcl10 gene expression 
To investigate whether the role of human TRAM in TLR7/8 signalling correlated with the 
role of TRAM in murine cells, levels of rantes, ifnβ, cxcl10 and tnfα gene expression were 
monitored in PMA-differentiated THP1 macrophages transfected with either TRAM specific 
or scrambled siRNA nucleotides. After 48 hr, cells were then stimulated with R848, LPS, 
poly(I:C) for 6 hr or with HRV16 for 72-80 hr. Suppression of human TRAM significantly 
decreased R848, LPS and HRV16 mediated rantes and ifnβ gene expression compared to 
control cells (Figure 3.16A,B). Levels of cxcl10 were also significantly reduced in response 
to R848 and LPS. However, HRV16 infection induced minimal levels of cxcl10 and this may 
explain why no difference was observed between the control and TRAM-specific siRNA 
treatments (Figure 3.16C). R848, LPS and HRV16 all induced the expression of tnfα mRNA 
(Figure 3.16D). In contrast, suppression of TRAM expression failed to inhibit tnfα mRNA 
induction in response to R848 and HRV16. However, TRAM suppression significantly 
reduced LPS mediated tnfα expression compared to control cells (Figure 3.16D). Suppression 
of TRAM did not affect poly(I:C) mediated induction of rantes, ifnβ, tnfα and cxcl10 when 
compared to the control cells. The poly(I:C) control was particularly important in this 
experiment as HRV16, despite being a ssRNA virus known to signal through TLR7/8, also 
produces dsRNA during its replication which has been shown to signal through the dsRNA 
sensing PRRs, TLR3 and retinoic acid-inducible 1 (RIG-I) [238]. It could therefore be argued 
that HRV16 is signalling via these PRRs and not TLR7/8 and this would eliminate the 
specificity of the conclusions that could be drawn. However, as poly(I:C) is itself, synthetic 
dsRNA that can activate both TLR3 and RIG-I and stimulation using it indicated no 
difference in cells in which levels of TRAM were reduced, it can logically be suggested that 
the cytokine phenotype observed upon HRV16 infection of TRAM-suppressed cells is 
specific to TLR7/8 signalling and not to TLR3/RIG-I.  
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Attempts were also made to compare cytokine secretion between TRAM supredded and 
control cells by ELISA. However, it was found that PMA was causing major basal cytokine 
secretion such that stimulation with LPS, R848, poly(I:C) or HRV16 resulted in little or no 
increase in cytokine production compared to unstimulated controls.  Further time would be 
required to optimise PMA mediated basal cytokines activity in the THP1 cells.  
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Figure 3.16: Suppression of endogenous levels of human TRAM reduces TLR7/8 and 
RV16 mediated rantes, ifn-β, cxcl10 but not tnf-α gene expression. THP1 monocytes were 
plated in a 12 well plate at a density of 1.4x10
6
 cells/ml and stimulated with 20 nM PMA for 
48 hr at 37°C. Cells were then transfected with either 200nM TRAM specific siRNA or 
scrambled control siRNA for a further 48 hr. At this point, cells were either left unstimulated, 
stimulated with poly(I:C) (25 μg/ml), LPS (100ng/ml) and R848 (1 μg/ml), for 6 hr at 37°C, 
or infected with HRV16 for 80 hr at 33°C. Cells were then harvested and total RNA was 
isolated and used as a template for first strand cDNA synthesis. The cDNA was then used as 
a template for qRT-PCR using forward and reverse primers specific to human (A) rantes, (B) 
ifn-β, (C) cxcl10, (D) tnf-α and gapdh (housekeeping gene). * p<0.05, ** p<0.01 and *** 
p<0.001. Graphs are representative of three independent experiments. 
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3.2.13 A TRAM mutant inhibits TLR7 mediated gene reporter activation 
TLR7 and TLR8 have been shown to localise to the endoplasmic reticulum (ER), endosome 
and lysosomes. In resting cells, they reside in the ER lumen but transverse to the 
endolysosome via the golgi apparatus in order to detect nucleic acids released into the 
endolysosome by acidification [210, 239]. TRAM has previously been shown to localise to 
the plasma membrane and golgi apparatus in resting cells but can also traffic independently 
of TLR4 to endosome membranes via a bipartite sorting motif [84]. Myriostoylation of 
TRAM has been shown to be required for both plasma and endosomal membrane localisation 
as mutation of the myriostoylation sequence causes mislocalisation and in fact negates the 
functionality of TRAM’s role in TLR4 signalling leading to reduced cytokine production in 
response to LPS [82, 84].  
With this in mind, it was decided to examine whether overexpression of a dominant-negative 
TRAM mutant (TRAM G2A) [82], which is unable to undergo myriostoylation, could inhibit 
TLR7 mediated responses. To this end, HEK293 cells stably expressing TLR7, and therefore 
responsive to the TLR7 activator CLO97, were transiently transfected with the IFN-α, IFN-β, 
NF-κB and RANTES reporter gene constructs as well as increasing amounts of the TRAM 
G2A plasmid. As previously reported [82], overexpression of TRAM G2A did not drive 
promoter activation in all cases examined (Figure 3.17A-D). In agreement with our data in 
murine TRAM 
-/-
 iBMDMs and siRNA interference of human TRAM in THP1 cells, 
increasing amounts of dominant negative TRAM inhibited TLR7 mediated RANTES, IFN-β, 
IFN-α. It was also observed that NFκB promoter activation was similarily reduced upon 
overexpression of TRAMG2A suggesting that TRAM’s role in HEK293 cells may not be 
restricted to IRF3 mediated signalling (Figure 3.17A-D). To confirm that the phenotype 
exhibited by TRAM G2A was attributable to a defect in the ability of TRAM to signal and 
not a non-specific consequence of overexpression, we repeated the same experiment using a 
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dominant-negative form of the adaptor MAL which has no known role in TLR7 signalling.  
Indeed, overexpression of dominant-negative MAL had no significant effect on TLR7 
mediated RANTES, IFN-β, IFN-α or NFκB promoter activation (Figure 3.18A-D). From 
these data, it would appear that myriostoylation of TRAM, and therefore the ability of TRAM 
to membrane localise, is required for its ability to mediate TLR7 induced RANTES, IFN-α 
and IFN-β promoter activation. 
 
3.2.14 TRAM and MyD88 physically interact upon activation of TLR7 
The data obtained thus far definitively indicates a role for TRAM in TLR7/8 signalling. 
However, whilst perturbations to TRAM resulting in its genetic loss, genetic reduction or 
protein modification all indicate a specific role for TRAM in TLR7 signalling, evidence for 
the physical presence of TRAM in the TLR7 pathway is still lacking. A recent study 
demonstrated that TRAM can act as a linker molecule between MyD88 and the IL-18 
receptor (IL-18R), allowing IL-18 signalling to be transduced in a manner resembling the role 
of TRAM linking TRIF to TLR4 signalling [23, 179]. The study in question used 
overexpression to demonstrate an interaction between TRAM and MyD88 which surprisingly 
dissociated upon activation of the IL-18R with exogenous IL-18 [179]. Herein, to extend this 
study towards establishing a physical association between TRAM and the TLR7 signalling 
pathway, Flag-tagged TRAM and myc-tagged MyD88 were overexpressed in HEK-TLR7 
cells followed by stimulation of cells for 15, 30 and 60 min with the TLR7 ligand CLO97.  
Flag-TRAM was immunoprecipitated with the resulting complex subjected to SDS-PAGE 
followed by immunobloting for myc-MyD88. The finding that TRAM and MyD88 interacted 
in resting cells could not be replicated despite many attempts (Figure 3.19).  This could be 
due to the aforementioned study introducing higher concentrations of Flag-TRAM and myc-
MyD88 (4 μg per plasmid vs 3 μg of plasmid in the current study).  Interestingly, co-
expression of TRAM and MyD88 followed by TLR7 stimulation with CLO97 induced the 
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physical interaction between the two proteins at 15, 30 and 60 min with distinct myc-MyD88 
specific bands appearing directly underneath the heavy chain band (Figure 3.19). It should be 
noted that myc-MyD88 band (~ 38 kDa) and the anti-flag antibody heavy chain band (~ 50 
kDa) appear so close due to the high percentage (18 %) acrylamide gel used in this 
experiement which combined with the lack of allowed seperation time meant that protein 
bands within this region did not sepearte well. A previous study indicated that TRAM did not 
interact with TLR7 or TLR8 in resting cells but did interact with TLR4 [240]. Other studies 
have shown that TRAM is present at the plasma membrane and cytoplasm in resting cells and 
traffics to the endosome upon TLR4 activation [84, 86]. This would suggest that TRAM 
preferentially localises to endosomes upon pathogen challenge. Here it may encounter the 
‘TLR7 signalosome’, binding to MyD88 to direct IRF3 activation. It is known that MyD88, 
whilst present in the cytoplasm of resting cells, also traffics to endosomal compartments upon 
TLR7 and TLR9 activation [196, 209]. This could explain the observation that TRAM did not 
interact with MyD88 in unstimulated cells, but did interact upon TLR7 stimulation, as both 
TRAM and MyD88 had by now trafficked to the endosome to mediate TLR7’s signalling 
requirements. Endosomal acidification and maturation has also been shown to be critical for 
TLR7 activation as treatment of cells with the inhibitor of the vacuolar H(+)-ATPase, 
bafilomycin A1, which inhibits maturation, prevents TLR7 signalling. TRAM has been 
shown to be present in both early and late (mature) endosomes during TLR4 signalling [86] 
which again suggests that TRAM is capable of localising to TLR7 containing structures. The 
downstream implications of the TRAM-MyD88 interaction are unclear at present. TRAM is 
required for IRF3 activation so further experiments ascertain whether TRAM binds to IRF3 
or any of the several proteins involved in the downstream signalling of TLR7. MyD88 has 
also been shown to interact with TLR7 but it would be interesting to know if this requires an 
additional ‘linker’ adaptor, such as TRAM to facilitate this interaction as is the case with 
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MAL and MyD88 in TLR2 and TLR4 signalling [12] as well as with TRAM and MyD88 in 
IL-18 signalling [179]. 
 
 
 
 
 
 
 
 
 
 
 
135 
  
 
Figure 3.17: A dominant negative mutant of TRAM (TRAM G2A), negatively regulates 
TLR7 induced RANTES, IFN-β, IFN-α, but not NF-κB reporter gene activity. A–D, 
HEK293-TLR7 cells were cotransfected with vectors encoding either a reporter gene for the 
RANTES (A), NF-κB (B) IFN-α (C) or IFN-β (D) promoters and either empty vector 
(pcDNA3; 40 ng) or increasing amounts of an expression vector encoding TRAM G2A (10, 
20, 40 ng) as indicated. After 24 h, cells were stimulated with CLO97 (5 μg/ml) for a further 
24 hr followed by harvesting and lysis. Cell lysates were frozen at -80°C overnight prior to 
assessment of luciferase reporter gene activity. * p<0.05, ** p<0.01 and *** p<0.001. Results 
are representative of at least three independent experiments.  
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Figure 3.18: A dominant negative mutant of MAL (MAL P126H) has no effect on TLR7 
induced RANTES, IFN-β, IFN-α, or NF-κB reporter gene activity. A–D, HEK293-TLR7 
cells were cotransfected with vectors encoding either a reporter gene for the RANTES (A), 
NF-κB (B) IFN-α (C) or IFN-β (D) promoters and either empty vector (pcDNA3; 40 ng) or 
increasing amounts of an expression vector encoding MAL P126H (10, 20, 40 ng) as 
indicated. After 24 h, cells were stimulated with CLO97 (5 μg/ml) for a further 24 hr 
followed by harvesting and lysis. Cell lysates were frozen at -80°C overnight prior to 
assessment of luciferase reporter gene activity. * p<0.05, ** p<0.01 and *** p<0.001. Results 
are representative of at least three independent experiments.  
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Figure 3.19: TRAM interacts with MyD88 upon TLR7 activation. HEK293-TLR7 cells 
were seeded into 6-well plates at a density of 1.4x10
6
 and incubated for approximately 24 hr 
at 37°C. At 70% confluency, cells were co-transfected with 3 μg Flag-TRAM and 3 μg EV or 
3 μg Flag-TRAM and 3 μg Myc-MyD88. Approximately 24 hr after transfection, cells were 
either left unstimulated or stimulated with CLO97 (5 μg/ml) for 15, 30 and 60 min as 
indicated. Thereafter, cells were lysed in 200 μl low stringency buffer (LSB) (50 mM HEPES, 
pH 7.5, 150 mM NaCl, 2 mM EDTA pH 7.6, 1 % NP-40, 0.5 % sodium deoxycholate 
supplemented with 1 mM PMSF, 1 mM DTT, 1 mM NaVO3, 5 mM EGTA and protease 
inhibitor cocktail). Cellular debris was removed by centrifugation upon which 20 μl of the 
remaining whole cell lysate (WCL) was removed, mixed with an equal volume of 5x Lamelli 
loading buffer, boiled for 10 min and frozen for later WCL analysis. Remaining cell lysates 
were incubated with 1 μg of anti-Flag monoclonal antibody overnight with gentle shaking 
followed by addition of 25 μl Protein A/G beads for a second night with gentle shaking. 
Samples were then washed 4 times with unsupplemented LSB and released from the beads by 
addition of 50 μl of 5x Laemmli loading buffer, followed by boiling for 10 min. Both these 
immunoprecipitated samples and the WCL samples were separated by SDS-PAGE gel 
electrophoresis and subjected to immunoblot analysis using anti-Flag and anti-Myc and anti 
β-Actin antibodies. 
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3.3 Discussion 
 
The TIR-domain containing adaptor protein TRAM has until recently, been associated with 
TLR4 signalling only, acting a linker molecule bridging TLR4 and TRIF to facilitate MyD88 
independent, predominantly anti-viral signalling [15].  Recent studies however, have 
suggested additional roles for TRAM. A novel role has been proposed in IL-18 signalling 
whereby TRAM acts as a linker molecule between MyD88 and IL-18R to enable downstream 
inflammatory cytokine production [179]. There is also evidence to indicate a role for TRAM 
in TLR2 signalling in response to the gram negative, TLR2 specific bacteria Francisella 
tularensis [178]. The current data provides evidence for an additional role for TRAM in 
TLR7 signalling whereby it mediates production of RANTES, IFNβ, CXCL10 but not TNFα. 
A significant reduction in secretion of the cytokine RANTES but not TNFα was observed in 
TRAM deficient iBMDMs compared to WT cells when stimulated with the TLR7 ligand 
R848. The role of TRAM appears to be at the transcriptional level as levels of the rantes gene 
transcript were also significantly reduced. This phenotype was replicated in PMA-
differentiated THP1 macrophages using siRNA specific to the unique N-terminal region of 
TRAM with levels of rantes, ifnβ and cxcl10 significantly reduced. It was planned to also 
monitor modulation of cytokine secretion upon suppression of TRAM. However, due to time 
constraints, it was not possible to optimise basal levels of secretion from PMA differentiated 
THP1 cells. Results would be expected to mirror those obtained by monitoring cytokine 
mRNA induction.  
To date, MyD88 is the only TIR-domain containing adaptor known to be involved in TLR7 
and TLR8 signalling. Evidence for the lack of involvement of other adaptors in this pathway 
derives mainly from studies where the adaptors are used as negative controls and have 
examined only at their role in mediating inflammatory cytokines such as TNFα, IL-6 and IL-
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12p40 [23, 24]. Therefore, to our knowledge, this is the first study to examine TRAM’s role 
in anti-viral cytokine induction mediated by the TLR7 pathway.  
Co-immunoprecipitation experiments in HEK-293 cells stably expressing TLR7 indicated 
that TRAM and MyD88 do not interact basally but do co-localise upon stimulation with the 
TLR7 ligand, CLO97 at 15, 30 and 60 minutes. TRAM and MyD88 have previously been 
shown to co-immunoprecipitate to mediate IL-18R signalling but in that case, the complex 
dissociated upon stimulation with IL-18 [179]. Although presenting a different mode of 
localisation, this study does agree, first with our ability to co-immunoprecipitate TRAM and 
MyD88 and second, with the observed dynamism exhibited by TRAM upon ligand-receptor 
binding. TRAM has also been shown to be phosphorylated on serine-16 upon TLR4 
activation and this phosphorylation event is required for its ability to transmit the TLR4 
signal [83].  In this respect, it would be interesting to examine whether phosphorylation of 
TRAM is required for its ability to mediate TLR7 signalling or whether there are other 
important residues involved.  
Overexpression of a TRAM myriostoylation mutant, TRAM G2A, which is unable to 
membrane localise within cells, dose dependently inhibited RANTES, IFNβ, IFN-α but not 
NFκB promoter activation in HEK-TLR7 cells. In contrast, overexpression of a dominant 
negative version of MAL had no significant effect on the same pathway. Myriostoylation of 
TRAM has been shown to be important for its ability to transmit TLR4 dependent signals in 
that it is required for TRAM’s localisation to the plasma membrane and by extension, for it to 
interact with TLR4. Indeed, overexpression of the TRAM G2A mutant is unable to drive 
NFκB or RANTES reporter gene activation in human cells and in fact dose-dependently 
repressed LPS mediated activation of the same reporter genes [82]. Basally, TRAM has been 
shown to be expressed on the plasma membrane, golgi apparatus and on endosomal structures 
in resting cells [84, 86, 87]. Its presence on endosomal structures remains even when 
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dynamin dependent TLR4 endocytosis is inhibited [84] suggesting that TRAM targets 
independently to the endosomal membrane and that its endosomal presence may be non-
exclusive regarding TLR4. Based on the data presented here, it is proposed that the presence 
of TRAM on endosomal structures is myriostoylation dependent and serves to aid signalling 
from both TLR4 and TLR7. 
An additional finding was that TLR7 mediated, TRAM dependent phosphorylation of the 
transcription factor IRF3. IRF3 was phosphorylated in WT iBMDMs by the TLR7 ligand 
R848 in a time dependent manner from 15 minutes to two hours. Confirmation of its 
activation was the observance of IRF3 nuclear translocation, again mediated by TLR7, in a 
TRAM dependent manner. It is suspected that the observed activation of IRF3 is cell type, or 
even cell line specific as a previous study conducted in HEK293 cells indicated that 
overexpressed IRF3 did not translocate to the nucleus upon R848 stimulation. The same 
study was unable to detect endogenous phosphorylation of IRF3 in RAW264.7 macrophages 
in response to R848 [212]. It is well documented that endotoxin in the form of LPS is known 
to drive IRF3 phosphorylation in a TLR4 dependent manner and so to account for possible 
endotoxin contamination of the R848 preparation, HEK-TLR4 cells were stimulated with 
increasing concentrations of R848 with no activation of TLR4 apparent.  
 
The majority of our current knowledge on TLR7’s role in anti-viral signalling comes from 
studies conducted in pDCs owing to their ability to secrete higher levels of type-I IFN than 
macrophages and conventional dendritic cells [241]. Both type-I IFN and inflammatory 
cytokines are produced in a MyD88 dependent manner however type-1 IFN secretion utilises 
IRAK-1 recruited IRF7 whereas inflammatory cytokines are induced via TRAF6, IRAK-4 
and the IKK complex to drive NFκB activation [12]. Comparatively little work has been 
undertaken regarding TLR7 mediated IFN signalling in macrophages however and there is a 
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dearth of information regarding the role of the adaptors in mediating this pathway. It is 
notable that loss of TRAM did not abolish TLR7 signalling as has been previously reported 
with MyD88 [40] and that while it is required for TLR4 mediated anti-viral signalling, 
TLR4’s MyD88 dependent pathway remains intact in TRAM deficient cells [28]. IL-18 
signalling can still occur in TRAM deficient cells, albeit to a limited extent [179]. 
Therapeutic targeting of TRAM could therefore provide a significant but not detrimental 
suppression of innate derived, predominantly anti-viral cytokines.  
As mentioned in section 3.2.1, the iBMDM cell lines were problematic in a number of ways. 
Growth rates differed between the WT and TRAM 
-/-
 iBMDMs  and at times they failed to 
consistently replicate previously published phenotypes such as reduced signalling in TRAM 
deficient cells compared to WT in response to LPS [24]. Therefore, relatively simple 
experiments often became extremely drawn-out affairs. It was originally intended to attempt 
a proteomic comparision of WT versus TRAM 
-/- 
iBMDMs for the following two results 
chapters however in light of the problems experienced during completion of Chapter 3, and 
due to the implicit time constraints inherent to the current work, it was decided to modify 
future experiements to avoid investing excess time conducting experiments involving 
iBMDMs. Therefore, a proteomic study using a single cell line, it was hoped, would generate 
useful publication quality data without the complications experienced in the current chapter. 
The following two results chapters therefore attempt to characterise proteomic changes 
induced in a single respiratory cell line in response to two respiratory pathogens: B. pertussis 
and HRV16.   
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Chapter 4 
 
 
Investigations into respiratory cell proteome 
changes in response to infection with the 
respiratory pathogen Bordetella pertussis 
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4.1 Chapter Aim 
 
The aim of this chaper was to analyse proteome modulation of a lung epithelial cell line in 
response to infection with the gram negative bacterium B. pertussis. This would be 
accomplished using 2D-DIGE combined with LC-MS and also using LFQ-MS. Protein hits 
obtained from both techniques would be compared to see if the techniques are 
complementary. A selection of hits would then be validated and an analysis of their role in 
immune signalling undertaken by supresssion their expression priot to infection with B. 
pertussis. 
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4.2 Results 
 
4.2.1 B. pertussis activation of BEAS-2B cells 
In order to identify an optimal timepoint for B. pertussis to activate the immune response, a 
timecourse experiment was carried out in which B. pertussis was allowed to infect BEAS-2B 
cells for 6, 12, 24, 32 and 48 hr. Inflammatory cytokine gene expression was then monitored 
at each timepoint in order to identify the point at which the immune response was maximally 
activated (Figure 4.1).  
Upon infection of BEAS-2B cells with B. pertussis, levels of IL-6 mRNA were upregulated 
at both 6 and 24 hr with maximal activation occurring at 12 hr (Figure 4.1A). A significant, 
but much smaller upregulation of TNFα gene expression was also observed at 12 hr but not at 
6 hr or 24 hr (Figure 4.1B).Based on these observations, it was decided to infect BEAS-2B 
cells with B. pertussis for 12 hr prior to protein solubilisation and preparation for 2D-DIGE 
and LFQ analysis. 
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Figure 4.1: B. pertussis infection of BEAS-2B cells activates the immune response. 
BEAS-2B cells were plated at a density of 0.7x10
6
 cells/ml in a six-well plate and incubated 
for 24 hr at 37°C. Individual wells were then either left unstimulated or stimulated with B. 
pertussis (200 bacteria/cell) for the timepoints indicated. Cells were then harvested, total 
RNA isolated and from this, cDNA was synthesised. The cDNA was then used as a template 
for qRT-PCR using forward and reverse primers specific to human il-6 and gapdh 
(housekeeping gene). * p<0.05, ** p<0.01 and *** p<0.001. Graphs are representative of two 
independent experiments.  
 
 
 
 
 
 
 
 
 
A B 
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4.2.2 Proteomic response to B. pertussis infection – common trends and functional 
annotation of protein hits obtained by 2D-DIGE / MS 
Protein hits that were significantly up or down regulated in response to B. pertussis infection 
of BEAS-2B cells, as identified by 2D-DIGE with MS were categorised first based on a 
broad generalisation of their biological role (Figure 4.2A). A protein was considered to be a 
true hit when it fulfilled a number of statistical criteria. First was that the protein in question, 
derived from whole cell lysates from B. pertussis stimulated cells, must have exhibited a fold 
change equal to or greater than plus or minus 1.3 fold compared to unstimulated cells. This 
fold change also must have been detected across N=4 independent experiments. From this 
then the statistical significance was based on a P value below 0.05. At this point the 
equivalent protein spot on the 2D-DIGE gel was extracted for MS analysis. Using software 
analysis, recognised peptides were then matched to proteins. A peptide was considered 
matched upon recognition of extensive homology with a P value below 0.05 which typically 
equated to a ‘Mascot Score’ of ≥50 (Appendix Table A1.1) [242].  
 
A total of 47 protein hits were found to be significantly up or down regulated in response to B. 
pertussis infection (Table 4.1). The observed protein fold changes averaged approximately 
1.4 fold indicating that although many proteins underwent modulation of expression, the level 
of modulation was quite small. This could be a limitation of the 2D-DIGE technique however 
firther experimentation would be required to confirm this. Of the 47 proteins hits identified, 
42 proteins, or 87 % of the total, were found to be upregulated and five proteins, or 13% of 
the total, were downregulated (Figure 4.2B, Table 4.1). The protein hits were found to fall 
into seven general functional categories namely the redox response, the immune response, 
transcription and DNA editing, structural proteins, cancer related proteins, protein synthesis 
and modification and trafficking (Figure 4.2A). Proteins with previously documented roles in 
the immune response represented 29 % of the total observed hits, the largest category 
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observed and indicating that lung epithelial cells are equipped with many defence 
mechanisms to deal with such as pathogen, perhaps unsurprising as they would be one of the 
first exposed to a respiratory pathogen such as B. pertussis [140]. Structural proteins were the 
next best represented functional subset with accounting for 15 % of total hits identified 
(Figure 4.2A).  Many of these proteins were found to have known functions in regulating 
tubulin and actin formation within the cell (Table 4.1). B. pertussis is known to actively enter 
ciliated lung epithelial cells and inhibit intracellular immune responses whist simultaneously 
evading the extracellular immune response [138, 243-245]. Although it is well documented 
that intracellular bacteria can modify the host actin network for their own means [246-248], 
recently, some light has been shed on the mechanism of B. pertussis entry into cells and the 
involvement of the host microtubule network. It has been shown that entry is dependent upon 
microtubule assembly, lipid raft integrity and activation of tyrosine-kinase mediated 
signalling [249]. Indeed, treatment of cells with a microtubule depolymerisation agent 
significantly reduced the number of internalised bacteria [249]. Relating to this, 5 % of 
proteins identified were involved in trafficking (Figure 4.2A) which likely utilise the cell’s 
structural network to enable the bacteria to internalise. Proteins involved in protein synthesis 
and modification as well as transcription and DNA editing exhibited large changes in 
expression accounting for 15 % and 10 % respectively of the observed global changes (Figure 
4.2A). Given the immediate threat to the cell’s integrity, the accommodation of a new, 
foreign organism and the mobilisation of defence mechanisms against the pathogen, this 
observation, was unsurprising. An interesting observation was that 12 % of dynamically 
regulated proteins in response to B. pertussis infection harboured known links to cancer either 
as known biomarkers or as mediators of cancer signalling (Figure 4.2A, Table 4.1). Many 
parallels have been drawn between cancer progression and the immune response and it is 
becoming increasingly clear that the two are intertwined [250-252].  An example of this from 
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the current study is the protein hit stathmin (Table 4.1). Stathmin has long been known as a 
marker for cancer progression had recently been shown to be an endogenous activator of 
TLR3 [253-255]. Finally, proteins involved in the redox response accounted for 9 % of 
observed protein hits (4.2A). Redox signalling has many roles in cell physiology particularly 
in defence with reactive oxygen and nitrogen species playing key roles in the innate defence. 
However, as these reactive species are consequently damaging to both the invading pathogen 
and the host a large number of proteins are involved in tailoring redox signalling to best 
benefit the host [256].  
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Figure 4.2: Pie chart representations of proteins identified by 2D-DIGE in response to B. 
pertussis infection. (A) Identified proteins were manually researched for functional 
properties and assigned functions(s) to form the basis of categorisation. Total numbers of 
proteins assigned to each function were inputted into a pie chart for appropriate visualisation. 
(B) Protein hits that were adjudged to be up or down regulated via Progenesis software, were 
inputted into a pie chart in order to visualise the divide.  
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Fold Ch. Protein Name Function 
↑1.5 Thioredoxin Redox Signalling. Regulates NFκB DNA binding [257] 
DNA repair, recombination and replication. Inhibits viral DNA replication [258] 
Important in glycolytic pathway [259] 
Tubulin folding [260] 
Endogenous TLR3 agonist [255]. Cancer marker. Microtubule regulation [261]. 
Microtubule regulation. Associated with Alzheimer’s [262] 
Catalyses protein folding. MHC loading [263]. Required for HIV infection [264].  
Intracellular trafficking [265] 
Protein chaperone. Aids protein folding [266]. TLR2/4 activator [267]. 
MHC class I peptide loading [268]. 
Redox signalling. Indirect NFκB modulator [269]. 
Metabolism. Levels increased in colorectal cancer [270]. 
Required for MAP Kinase activation [271]. Role in TRAF6 mediated signalling [272].  
Actin modulator. Role in cell migration [273]. 
Redox signalling [274]. Prostate cancer marker [275]. 
Chloride Channel. Aids macrophage phagosome acidification [276]. 
↑1.5 Replication protein A 14 kDa subunit  
↑4.4 Triose phosphotate Isomerase 
↑1.4 Tubulin-specific chaperone A 
↑1.5 Stathmin 
↑1.5 Stathmin-2 
↓1.3 Protein disulfide-isomerase 
↓1.5 Transitional endoplasmic reticulum ATPase  
↓1.4 heat shock 70kDa protein 9B  
↓1.4 Tapasin ERP57  
↑1.3 Superoxide dismutase [Cu-Zn] 
↑1.3 GSTP1-1 
↑1.3 Ubiquitin-conjugating enzyme E2 N (Ubc13) 
↓1.7 Cofilin-1 
↑1.3 PRDX3  
↑1.4 Clic1 
↑1.3 EB1    Microtubule regulator [277]. 
↑1.4 Glutathione S-transferase omega-1 
NLRP12 
 
 
 
  Suspected inflammasome modulator. Binds to ASC [278, 279]. 
  Cytosolic PRR. Senses Yersinia pestis. Supresses inflammation [280]. 
 
 
 
Overview of protein hits obtained by 2D-DIGE with LC-MS 
Table 4.1: Proteins identified by 2D-DIGE combined with LC-MS showing changes in expression in response to B. pertussis 
infection. Protein function is also indicated. Full annotation of protein hits can be found in appendix table A1.1. 
 
↑1.4 
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Fold Ch. Protein Name Function 
↑1.5 
↑1.5 
↑1.5 
↑1.5 
↑1.4 
↑1.3 
↑1.3 
↑1.3 
↑1.4 
↑1.3 
↑1.4 
↓1.3 
↑1.3 
↑1.4 
↑1.3 
↑1.3 
↑1.4 
↑1.4 
Proteasome subunit beta type-4 
Annexin A2 
Thioredoxin domain-containing protein 12 
Mitotic spindle-associated MMXD complex  
Nucleoside diphosphate kinase A (NME1) 
Peroxiredoxin-6 
Dj-1  
Acyl-protein thioesterase 1 
Phosphoglycerate mutase 1  
Transaldolase 
Serine/threonine-protein phosphatase PPP1Cα 
ER-60 protease 
Human Galectin-1  
40S ribosomal protein S12 
IL-25 
Caspase 3 
PSMB10 
Platelet-activating factor acetylhydrolase  
 
Protein degradation [281]. 
Vascular homeostasis [282]. Post transcriptional regulation [283] 
Part of thioredoxin superfamily. Redox signalling [284]. 
Iron/sulphur incorporation. Involvement in mitosis [285]. 
Transfers phosphate groups between kinases [286]. 
Redox signalling. Phospholipase activity [287]. 
Associated with Parkinson’s Disease. Protective against oxidative stress [288]. 
Fatty acid hydrolysis. Involved in Ras signalling [289]. 
Phosphate transfer in glycolysis [290]. 
Role in pentose phosphate pathway [291].  
Phosphotase. Required for RIG-I and MDA5 signalling [292]. 
ER resident protein-cysteine protease activity. Degrades misfolded proteins [293] 
Inhibits macrophage migration and pathogen killing. Increased in tumours [294] 
Ribosome subunit. Site of protein synthesis [295].    
TH2 cytokine-induces secretion of IL-4 [296]. Anti-inflammatory [297] 
Protease. Central apoptosis mediator [298].  
Proteasome subunit. MHC class I peptide cleavage [299]. 
Suggested anti-inflammatory. Produced by lymphocytes in atherosclerosis [300]. 
 
 
 
 
  
Overview of protein hits obtained by 2D-DIGE with LC-MS 
Table 4.1 (contd): Proteins identified by 2D-DIGE combined with LC-MS showing changes in expression in response to B. pertussis 
Infection. Protein function is also indicated. Full annotation of protein hits can be found in appendix table A1.1. 
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Fold Ch. Protein Name Protein Name Function 
↑1.3 
↑1.3 
↑1.4 
↑1.3 
↑1.4 
↑1.4 
↑1.4 
↑1.4 
↑1.4 
Replication Protein A (Rpa14 And Rpa32) 
Eukaryotic translation initiation factor 4E 
Heat shock protein beta-1 
DNA replication complex GINS protein PSF2 
ATP synthase subunit d, mitochondrial 
Calpain small subunit 1  
14-3-3 protein epsilon  
Complement component 1 Q  
Putative hydrolase RBBP9 
 
 
 
 
 
Binds DNA to ensure efficient replication and repair [301]. 
Directs ribosomes to mRNA for translation. Viral target to aid replication [302]. 
Cell stress resistance and actin organization [303]. 
Role in DNA replication. Preferentially binds single stranded DNA [304]. 
Produces ATP from ADP [305]. 
Calcium dependent cysteine protease. Active in cell migration [306]. 
Signal transduction. Inhibits multiple TLR signalling pathways [307].  
Regulator of DC differentiation [308] . Inhibitor of RIG-I and MDA5 [309] 
Serine hydrolase. Role in TGF-β signalling. Implicated in pancreatic cancer [310] 
Overview of protein hits obtained by 2D-DIGE with LC-MS 
Table 4.1 (contd): Proteins identified by 2D-DIGE combined with LC-MS showing changes in expression in response to B. pertussis 
Infection. Protein function is also indicated. Full annotation of protein hits can be found in appendix table A1.1. 
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4.2.3 Verification of protein hits from B. pertussis infection. 
As can be seen from Table 4.1, over 40 proteins whose expression were significantly up or 
down regulated in response to B. pertussis infection were identified by 2D-DIGE with LC-
MS. These proteins have documented functions in diverse cellular processes ranging from 
structural integrity and metabolism to immune function and redox signalling (Table 4.1 and 
Figure 4.2A). However, immunoblotting using antibodies specific to selected proteins of 
interest must also be undertaken in both unstimulated and B. pertussis stimulated whole cell 
lysates in order to confirm the stimulation dependent changes in expression. With this in 
mind, it was decided to confirm the expression of proteins that were considered interesting 
with respect to B. pertussis infection and which represented a range of the different cellular 
processes affected by B. pertussis infection. Proteins selected for verification include DJ-1 – 
a protein whose exact function is unknown but is linked to redox prcocesses, Parkinson’s 
disease and pancreatic cancer progression (Table 4.1). The proteins glutathione S-transferase 
omega 1 (GSTO1) and NLRP12 both have demonstrated roles in immune function but 
neither have been linked to B. pertussis pathogenesis (Table 4.1). Stathmin 1 is known 
primarily for its role in structural processes within the cell. PPP1Cα is a phosphatase capable 
of protein modifications and finally, triosephosphate isomerase whose role in is the 
glycolytic pathway and thus is important in cellular metabolism. Further insight on each 
protein is provided in the following sections. 
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4.2.4 2D DIGE Protein Hit Verification: DJ-1 
DJ-1, otherwise known as PARK7, is an evolutionarily conserved protein found in all 
aerobic species including humans, Drosophila melanogaster, Caenorhabditis elegans and 
Escherichia coli [288].  
Its exact function within the cell is to date, unclear. However it has been shown that a lack of 
DJ-1 causes increased sensitivity to oxidative stress, leading to cell death. Similarly, 
overexpression of DJ-1 is protective under the same conditions [311]. This function is 
dependent upon the modification of cysteine residues on DJ-1 to cysteine-sulfonic residues 
[312-314]. The observed phenotype was specific to oxidative stress as no correlation was 
found between DJ-1 and non-oxidative stress [315]. Exactly how DJ-1 mediates these effects 
is unknown with suggestions ranging from transcriptional coactivaor to molecular chaperone 
[311]. DJ-1 localises to the cytoplasm and nucleus and is omnipresent throughout human 
tissue, including the brain [316]. Interestingly, DJ-1 null mice have been shown to release 
less dopamine which is turn linked to a severe reduction in function of the D2 receptor, a key 
molecule in the regulation of the dopaminergic system [317]. This study added credence to 
an earlier publication which showed that a mutation in the DJ-1 gene was associated with 
early-onset Parkinson’s Disease (Figure 4.3) [316]. 
In recent years, a role for DJ-1 in innate immunity has been suggested. DJ-1 
-/- 
mice have 
been shown to produce higher levels of nitric oxide in response to stimulation with the TLR4 
agnoist LPS compared to WT mice [318]. Furthermore, DJ-1 deficient  Caenorhabditis 
elegans (C. elegans) showed increased activation of MAP-kinase controlled genes related to 
the innate immune response compared to WT in response to pathogenic Pseudomonas 
aeruginosa [319]. 
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The current work has shown that when analysed by 2D-DIGE, levels of the DJ-1 protein are 
elevated 1.3 fold in human lung epithelial cells infected with B. pertussis compared to 
uninfected controls (Figure 4.4A, Table 4.1). This result was verified by western blot (Figure 
4.4B). Levels of the DJ-1 gene were also significantly upregulated 2.2 fold compared to 
unstimulated controls (Figure 4.4C) indicating that upon response to B. pertussis infection, 
DJ-1 levels are regulated at the transcriptional level. 
As mentioned previously, DJ-1 has been suggested to be a redox responsive protein in that it 
undergoes cysteine modifications to mediate a protective effect upon cells [313]. B. pertussis 
PTx has been shown to induce NO production in spleen cells. 
 
 
Figure 4.3: Overview of suspected roles for Dj-1. Mutations in DJ-1 can cause misfolding 
which overloades protein degradation systems causing cytotoxicity that could contribute to 
PD pathogenesis. Mutations in DJ-1 have also been linked to increased sensitivity to 
oxidative stress leading to increased cell death. Adapted from [320] 
  
 
 
156 
  
 
 
 
 
 
 
Figure 4.4: Verification of DJ-1 upregulation in response to B. pertussis. (A) Screen grab 
of Progenesis analysis showing DJ-1 presence on 2D-DIGE gel from control (Ctrl) and B. 
pertussis infected (BP) lysates. (B)  BEAS-2B cells were seeded in a 6-well plate at a density 
of 0.7x10
6
 cells/ml and incubated for 24 hr at 37 °C. Thereafter, cells were either left 
uninfected or infected with B. pertussis (MOI of 200) for 15 min, 30 min, 60 min, 2 hr, 4 hr, 
6 hr and 12 hr. Cells were then harvested and each sample lysed in 100 μl H.S. buffer for 20 
min on ice. Cell debris was removed by centrifugation with the remaining whole cell lysates 
mixed with 30 μl 5x Laemmli loading buffer and boiled for 10 min. Proteins were separated 
by SDS-PAGE and subjected to immunoblot analysis using anti-DJ-1 and anti-β-Actin 
antibodies. Results represent two independent experiments. (C) BEAS-2B cells were plated 
at a density of 0.7x10
6
 cells/ml in a six-well plate and incubated for 24 hr at 37 °C. 
Individual wells were then either left unstimulated or stimulated with B. pertussis (MOI of 
200) for the timepoints indicated. Cells were then harvested, total RNA isolated and from 
this, cDNA was synthesised. The cDNA was then used as a template for qRT-PCR using 
forward and reverse primers specific to human dj-1 and gapdh (housekeeping gene). * 
p<0.05, ** p<0.01 and *** p<0.001. Graph is representative of four independent 
experiments.  
 
 
A 
B 
C 
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4.2.5 2D-DIGE Protein Hit Verification: GSTO1 
Glutathione S-transferases are a family of enzymes that catalyse the conjugation of 
glutathione, via a sulfhydryl group, to electrophilic centres on a wide range of substrates 
including carcinogens, oxidative products and synthetic drugs [321]. Based on sequence 
similarities and immune cross reactivity, there are seven classes of cytosolic GST in humans: 
Alpha, Mu, Sigma, Pi, Theta, Zeta and a more recently identified class, Omega [322, 323]. 
They are highly conserved with more classes present across species [324].   A number of 
features set the omega class apart from the other GST family members. It contains a unique 
N-terminal, proline rich extension of 19 aa which forms a distinct structural unit in 
conjunction with the C-terminus. The function of this unit however, is currently unknown 
[323]. Other GST family members contain a tyrosine or serine residue within hydrogen 
bonding distance of a sulphur atom of the bound glutathione and mutation of either of these 
residues results in complete or severe inactivation [325]. The Omega class does not contain 
equivalent residues but does contain an active site cysteine suggesting the GSTO1 does not 
have the glutathione conjugation abilities common to other GSTs and instead have another 
as yet undescribed function [323]. A mouse orthologue of GSTO1, termed p28, also lacks 
GST activity but changes its subcellular location in response to heat suggesting a role in 
cellular stress response mechanisms [326].  
 
GSTO1 has been implicated in a number of studies as playing a role in IL-1β processing 
through its association with cytokine release inhibitory drugs (CRIDs) [278, 279]. Affinity 
labelling and affinity binding chromatography identified GSTO1 as a target of CRID and 
this interaction was dependent on the aforementioned active cysteine site, Cys
32
 [278].  The 
concentration of [
14
C]CRID required to label cell-associated GSTO1 was also directly 
proportional to the extent of inhibition of IL-1β posttranslational processing. 
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A second study examined this finding further by showing the GSTO1 interacts with adapter 
molecule apoptosis-associated speck-like protein containing a CARD (ASC), a pivotal 
protein in the assembly of NACHT, LRR and pyrin domain (PYD) domains-containing 
protein (NLRP) 1, NLRP3 and absent in melanoma 2 (AIM2) inflammasome formation 
[279]. This study showed that CRID3 inhibited ASC oligomerization in the NLRP3 and 
AIM2 inflammasome and speculated that glutathionylation of ASC by GSTO1 could be 
required for ASC function [279]. 
 
The current study identified GSTO1 as being upregulated 1.4 fold in BEAS-2B cells in 
response to infection with B. pertussis (Figure 4.5A, Table 4.1). Immunoblotting using an 
anti-GSTO1 antibody confirmed this result and indeed indicated that GSTO1’s expression 
was upregulated in response to B. pertussis after only 30 min of infection with expression 
being maintained at multiple further timepoints up to and including 12 hr of infection (Figure 
4.5B). GSTO1 gene expression was also significantly upregulated at both 6 and 12 hr post 
infection suggesting its regulation in transcriptionally regulated (Figure 4.5C).  
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Figure 4.5: Verification of GSTO1 upregulation in response to B. pertussis. (A) Screen 
grab of Progenesis analysis showing GSTO1 presence on 2D-DIGE gel from control (Ctrl) 
and B. pertussis infected (BP) lysates. (B)  BEAS-2B cells were seeded in a 6-well plate at a 
density of 0.7x10
6
 cells/ml and incubated for 24 hr at 37 °C. Thereafter, cells were either left 
uninfected or infected with B. pertussis (MOI of 200) for 15 min, 30 min, 60 min, 2 hr, 4 hr, 
6 hr and 12 hr. Cells were then harvested and each sample lysed in 100 μl H.S. buffer for 20 
min on ice. Cell debris was removed by centrifugation with the remaining whole cell lysates 
mixed with 30 μl 5x Laemmli loading buffer and boiled for 10 min. Proteins were separated 
by SDS-PAGE and subjected to immunoblot analysis using anti-GSTO1 and anti-β-Actin 
antibodies. Results represent two independent experiments. (C) BEAS-2B cells were plated 
at a density of 0.7x10
6
 cells/ml in a six-well plate and incubated for 24 hr at 37 °C. 
Individual wells were then either left unstimulated or stimulated with B. pertussis (MOI of 
200) for the timepoints indicated. Cells were then harvested, total RNA isolated and from 
this, cDNA was synthesised. The cDNA was then used as a template for qRT-PCR using 
forward and reverse primers specific to human gsto1 and gapdh (housekeeping gene). * 
p<0.05, ** p<0.01 and *** p<0.001. Graph is representative of four independent 
experiments.  
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4.2.6 2D-DIGE Protein Hit Verification: Stathmin 1 
Stathmin is a ubiquitous phosphorprotein, highly conserved among vertebrates, which was 
originally discovered from analysis of lysates derived from cells perturbed with hormones 
such as thyrotropin-releasing hormone and corticotropin-releasing hormone [327, 328].  It 
was also recognised as a protein that was highly expressed in acute leukaemias [329]. 
Indeed, stathmin has been shown to be highly expressed in multiple human malignancies and 
interestingly, a high level of stathmin expression correlates with poor prognosis [253, 254]. 
Stathmin’s main role is in the regulation of microtubule dynamics by promoting 
depolymerisation of microtubules or preventing polymerisation of tubulin heterodimers 
[261]. Because of this, stathmin plays a particularly important role in mitotic spindle 
formation during the cell cycle in both early and late stages of mitosis. Because microtubule 
formation effects diverse cellular functions, stathmin has also been found to play a role in 
activated T cell polarization. Polarisation of the microtubule organising center of activated T 
cells was defective in stathmin null mice causing reduced secretion of cytolysic granules and 
target cell lysis [330]. 
 
In keeping with immune related functions of stathmin, a startling observation was that 
stathmin acts as an endogenous protein agonist for TLR3 [255]. TLR3 and stathmin were 
shown to colocalise under neuroinflammatory conditions replicating multiple sclerosis in 
astrocytes, neurons and microglia. Monocyte derived dendritic cells were also activated by 
stimulation with stathmin. Cytokine expression profiles of stathmin and poly(I:C) stimulated 
WT and TLR3 deficient cells were almost identical. The authors hypothesised that as both 
TLR3 and stathmin can inhibit axon and dendrite formation, the interaction between the two 
may underlie, or even be required for, their functional similarities [255]. 
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Stathmin was observed by 2D-DIGE with LC-MS to be upregulated 1.5 fold in B. pertussis 
infected cells compared to controls (Figure 4.6A, Table 4.1). This finding was verified by 
western blot over multiple timepoints up to and including 12 hr (Figure 4.6B). Analysis of 
stathmin mRNA levels did not indicate any significant increase in transcription of stathmin 
mRNA indicating that its dynamic regulation is determined by post-transcriptional events 
(Figure 4.6C).  
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Figure 4.6: Verification of STMN1 upregulation in response to B. pertussis. (A) Screen 
grab of Progenesis analysis showing STMN1 presence on 2D-DIGE gel from control (Ctrl) 
and B. pertussis infected (BP) lysates. (B)  BEAS-2B cells were seeded in a 6-well plate at a 
density of 0.7x10
6
 cells/ml and incubated for 24 hr at 37 °C. Thereafter, cells were either left 
uninfected or infected with B. pertussis (200 bacteria/cell) for 15 min, 30 min, 60 min, 2 hr, 
4 hr, 6 hr and 12 hr. Cells were then harvested and each sample lysed in 100 μl H.S. buffer 
for 20 min on ice. Cell debris was removed by centrifugation with the remaining whole cell 
lysates mixed with 30 μl 5x Laemmli loading buffer and boiled for 10 min. Proteins were 
separated by SDS-PAGE and subjected to immunoblot analysis using anti-STMN1 and anti-
β-Actin antibodies. Results represent two independent experiments. (C) BEAS-2B cells were 
plated at a density of 0.7x10
6
 cells/ml in a six-well plate and incubated for 24 hr at 37 °C. 
Individual wells were then either left unstimulated or stimulated with B. pertussis (200 
bacteria/cell) for the timepoints indicated. Cells were then harvested, total RNA isolated and 
from this, cDNA was synthesised. The cDNA was then used as a template for qRT-PCR 
using forward and reverse primers specific to human stmn1 and gapdh (housekeeping gene). 
* p<0.05, ** p<0.01 and *** p<0.001. Graph is representative of four independent 
experiments.  
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4.2.7 2D-DIGE Protein Hit Verification: PPP1Cα 
Protein phosphatase PP1 alpha catalytic subunit (PPP1Cα), also known as PP1α, is one of 
three catalytic subunits of protein phosphatase 1, the other two subunits being PPP1β and γ. 
They form a small but vitally important part of the phosphoprotein phosphatase (PPP) 
superfamily which comprises serine/threonine phosphatases 1-7 [331]. Together, PPP1-7 
catalyse over 90% of dephosphorylating reactions in eukaryotic cells [332]. The most 
important of these seven, in terms of substrate diversity, is PPP1 as it is predicted to 
hydrolyse the majority of serine and threonine-linked phosphate ester bonds in eukaryotic 
cells [333]. Further evidence of PPP1’s importance is the fact that it is extremely highly 
conserved between yeast and humans with greater than 80% sequence similarity between the 
two. Indeed, human PPP1 can rescue the lethal loss of PPP1 in yeast [334]. PPP1 affects 
such a large proportion of dephosphorylation events by its ability to interact with over 200 
known targeting proteins that serve to localise PPP1 to distinct cellular regions whilst also 
modifying its substrate specificity. The use of these targeting proteins is therefore believed to 
allow PPP1 to be converted into 100s of highly specific holoenzymes  [335]. The 
phosphatase activity of PPP1 is regulated by endogenous inhibitory proteins such as the 
aptly named inhibitor-1 and inhibitor-2, as well as CPI-17 and DARPP-32 [336]. As PPP1 
interactors are the main determinant of PPP1 function, they too are studied in detail. Their 
role is predominantly in signalling processes with known involvements in metabolism, the 
cell cycle and stress responses [337].  The importance of PPP1α in the immune response can 
be demonstrated by the encoding by herpes simplex virus of a PPP1α interactor termed 
ICP34.5. This protein interacts with PPP1α directing it to dephosphorylate and thus activate 
eIF2α which in turn inhibits PKR, a key mediator of the antiviral immune response [338, 
339]. A further interactor, nuclear inhibitor of protein phosphatase 1, in combination with 
PP1 can act as a molecular compass to direct cancer cell migration by affecting guanosine 
164 
  
triphosphate (GTP)ase signalling, with an implied role in cancer cell metastasis [340]. While 
the current work on PPP1α was proceeding, a striking observation was made regarding its 
role in innate immune signalling. It has been shown that dephosphorylation of the viral RNA 
sensors retinoic acid-inducible gene 1 (RIG-I) and melanoma differentiation-associated 
protein 5 (MDA5) by PPP1α and its isoform PPP1γ is essential for their ability to drive type-
I IFN production [292]. Both PPP1α and PPP1γ were shown to interact with RIG-I and 
MDA5 upon viral infection to inhibit phosphorylation of specific serine residues on CARD 
domains pertaining to both receptors. Furthermore, mutation of the PPP1 binding motif on 
both RIG-I and MDA5, led to an almost complete abolishment of their ability to signal 
[292]. 
The current study identified PPP1α as being upregulated 1.4 fold in a 2D-DIGE comparison 
between uninfected and B. pertussis infected lung epithelial cells (Figure 4.8A, Table 4.1). 
This result was verified by western blot at multiple timepoints from 15 min up to 12 hr. Gene 
expression of PPP1α was also shown to be significantly upregulated 15-fold upon 
stimulation with B. pertussis for 12 hr (Figure 4.8B). PPP1α mRNA was also upregulated 
approximately 3 fold after 6 hr of infection with B. pertussis (Figure 4.8C). This would 
suggest that PPP1α is somehow induced by B. pertussis at the transcriptional level. This 
result also hints at an increasing role for PPP1α as the infection increase in severity over 
time. 
 
Figure 4.7: General functions of PP1/PPP1. Roles for PPP1 include recovery from 
starvation, protein synthesis regulation, calcium signalling, immune function and mitosis. 
Adapted from [341]. 
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Figure 4.8: Verification of PPP1Cα upregulation in response to B. pertussis. (A) Screen 
grab of Progenesis analysis showing PPP1Cα presence on 2D-DIGE gel from control (Ctrl) 
and B. pertussis infected (BP) lysates. (B)  BEAS-2B cells were seeded in a 6-well plate at a 
density of 0.7x10
6
 cells/ml and incubated for 24 hr at 37 °C. Thereafter, cells were either left 
uninfected or infected with B. pertussis (MOI of 200) and each sample lysed in 100 μl H.S. 
buffer for 20 min on ice. Cell debris was removed by centrifugation with the remaining 
whole cell lysates mixed with 30 μl 5x Laemmli loading buffer and boiled for 10 min. 
Proteins were separated by SDS-PAGE and subjected to immunoblot analysis using anti-
PPP1Cα and anti-β-Actin antibodies. Results represent two independent experiments. (C) 
BEAS-2B cells were plated at a density of 0.7x10
6
 cells/ml in a six-well plate and incubated 
for 24 hr at 37 °C. Individual wells were then either left unstimulated or stimulated with B. 
pertussis (MOI of 200) for the timepoints indicated. Cells were then harvested, total RNA 
isolated and from this, cDNA was synthesised. The cDNA was then used as a template for 
qRT-PCR using forward and reverse primers specific to human ppp1cα and gapdh 
(housekeeping gene). * p<0.05, ** p<0.01 and *** p<0.001. Graph is representative of four 
independent experiments.  
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4.2.8 2D-DIGE Protein Hit Verification: Triosephosphate Isomerase 
Triose phosphate isomerase (TPI) is a dimeric enzyme consisting of two identical subunits of 
critical importance to the glycolytic pathway. Its specific role is in the interconversion of two 
triose phosphate isomers, dihydroxyacetone phosphate and D-glyceraldehyde-3-phosphate, 
which are intermediates in both the glycolytic and pentose phosphate pathways [259]. 
Humans born with mutations in TPI suffer from multiple pathologies including anaemia, 
cardiomyopathy, neuromuscular impairment, increased susceptibility to infection and is in 
most cases fatal by early childhood [342]. With its role exclusively related to metabolism, 
TPI has no direct documented role in the immune response however absence of evidence is 
not evidence of absence. Indeed the role of metabolism and metabolites in the inflammatory 
conditions is fast becoming vogue [343]. The initiation and maintenance of an inflammatory 
response requires intensive energy usage by the cells involved and similarities have been 
observed  between the increased metabolism exhibited by tumour cells to that of activated T 
cells [344]. Moreover, it has recently been shown that succinate, an intermediate in the citric 
acid cycle (which itself requires pyruvate derived from glycolysis) has been shown to be an 
inflammatory signal which drives LPS mediates IL-1β production in macrophages [345]. 
 
TPI was found to by 2D-DIGE to be upregulated 4.4 fold in response to B. pertussis 
infection (Figure 4.9A, Table 4.1). This result was verified by western blot using an anti-
triosephosphate isomerase antibody. TPI levels were increased at 15 min post infection, 
peaking at 2 hr before decreasing slightly by 12 hr (Figure 4.9B). Comparison of TPI mRNA 
in uninfected and infected cells indicated no significant increase between the two states 
(Figure 4.9C). This suggests that TPI’s levels are being modified post-transcriptionally. The 
exceptionally high fold change in TPI upon B. pertussis infection indicates that metabolism 
within the cell is increases upon infection. 
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Figure 4.9: Verification of TPI upregulation in response to B. pertussis. (A) Screen grab 
of Progenesis analysis showing TPI presence on 2D-DIGE gel from control (Ctrl) and B. 
pertussis infected (BP) lysates. (B)  BEAS-2B cells were seeded in a 6-well plate at a density 
of 0.7x10
6
 cells/ml and incubated for 24 hr at 37 °C. Thereafter, cells were either left 
uninfected or infected with B. pertussis (MOI of 200) for 15 min, 30 min, 60 min, 2 hr, 4 hr, 
6 hr and 12 hr. Cells were then harvested and each sample lysed in 100 μl H.S. buffer for 20 
min on ice. Cell debris was removed by centrifugation with the remaining whole cell lysates 
mixed with 30 μl 5x Laemmli loading buffer and boiled for 10 min. Proteins were separated 
by SDS-PAGE and subjected to immunoblot analysis using anti-TPI and anti-β-Actin 
antibodies. Results represent two independent experiments. (C) BEAS-2B cells were plated 
at a density of 0.7x10
6
 cells/ml in a six-well plate and incubated for 24 hr at 37 °C. 
Individual wells were then either left unstimulated or stimulated with B. pertussis (MOI of 
200) for the timepoints indicated. Cells were then harvested, total RNA isolated and from 
this, cDNA was synthesised. The cDNA was then used as a template for qRT-PCR using 
forward and reverse primers specific to human tpi and gapdh (housekeeping gene). * p<0.05, 
** p<0.01 and *** p<0.001. NS, not significant. Graph is representative of four independent 
experiments.  
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4.2.9 2D-DIGE Protein Hit Verification: NLRP12 
NACHT, LRR and PYD domains-containing protein 12 (NLRP12), is a member of the 
nucleotide oligomerisation and binding domain (NOD)-like receptor (NLR) family of 
proteins. This family contains more than 20 members and are a relatively recent addition to 
the cadre of innate PRRs, playing critical roles in the recognition of many infectious 
pathogens including fungi, bacteria, viruses, protists and helminthes [346-351]. During an 
infection, NLRs oligomerise into multiprotein complexes termed inflammasomes that cleave 
pro-caspase-1 into its active form. Active caspase-1 in turn cleaves pro-IL1-β, pro-IL-18 and 
pro-IL-33 to generate mature proteins which are then secreted to mediate their downstream 
inflammatory effects (Figure 4.12) [352].   
 
Figure 4.10:  Overview of non-NLRP3 inflammasome signalling. NLRP4, 6, 7 and 12 
share a C-terminal leucine rich repeat (LRR) region an internal nucleotide-binding-domain 
(NBD) and an N-terminal PYD. AIM2 has a HIN200 DNA binding domain and a PYD but 
no NBD. The NLR recruits the adaptor ASC, a PYD domain containing protein and a 
caspase recruitment and activation domain (CARD) which bridges the NLR with caspase-1. 
Caspase-1 cleaves pro-IL-1β and pro-IL-18 into their mature, secretory forms. Adapted from 
[352]. 
 
In general, inflammosome forming NLRs exhibit the same structural features. NLRP12, 
along with NLRP3, NLRP6 and NLRP7 all share a C-terminal LRR region, an internal 
nucleotide-binding-domain (NBD) and an N-terminal Pyrin domain (PYD). The NLR 
recruits the adaptor ASC, a PYD domain containing protein and a caspase recruitment and 
activation domain (CARD) which links the NLR to caspase-1 (Figure 4.10) [352].  
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NLRP12 was originally shown to play a pro-inflammatory role by driving NFκB induction 
as well as caspase-1 mediated cleavage and secretion of IL-1β in vitro [353]. A later in vivo 
study largely agreed with this showing that NLRP12 was required to drive IL-1β and IL-18 
production following murine infection with the gram negative bacterium Yersina pestis, the 
causative agent of plague. However, the authors detected minimal NLRP12 mediated NFκB 
activity [280]. On the other hand, two recent studies presented in-vivo evidence that 
NLRP12 negatively regulates inflammatory processes relating to colon inflammation and 
tumorigenesis by specifically inhibiting activation of NFκB [354, 355]. It is worth noting 
that similar conflicting reports have emerged regarding NLRP6 [356, 357] such that it has 
been proposed that individual NLRs can play different roles in different infections, the 
phenotype perhaps depending upon their levels of expression and functionality in the tissues 
and cells that undergo pathology relating to a particular disease [352]. 
 
NLRP12 was identified as being upregulated 1.3 fold in BEAS-2B cells in response to B. 
pertussis infection (Figure 4.11A) (Table 4.1). This result was verified by immunobloting for 
endogenous NLRP12 where its levels were again found to be increased at multiple 
timepoints in repose to B. pertussis infection (Figure 4.11B). A slight increase was found in 
levels of NLRP12 mRNA at 12 hr post infection however this increase was not found to be 
significant (Figure 4.11C). 
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Figure 4.11: Verification of NLRP12 upregulation in response to B. pertussis. (A) 
Screen grab of Progenesis analysis showing NLRP12 presence on 2D-DIGE gel from control 
(Ctrl) and B. pertussis infected (BP) lysates. (B)  BEAS-2B cells were seeded in a 6-well 
plate at a density of 0.7x10
6
 cells/ml and incubated for 24 hr at 37 °C. Thereafter, cells were 
either left uninfected or infected with B. pertussis (MOI of 200) for 15 min, 30 min, 60 min, 
2 hr, 4 hr, 6 hr and 12 hr. Cells were then harvested and each sample lysed in 100 μl H.S. 
buffer for 20 min on ice. Cell debris was removed by centrifugation with the remaining 
whole cell lysates mixed with 30 μl 5x Laemmli loading buffer and boiled for 10 min. 
Proteins were separated by SDS-PAGE and subjected to immunoblot analysis using anti-
NLRP12 and anti-β-Actin antibodies. Results represent two independent experiments. (C) 
BEAS-2B cells were plated at a density of 0.7x10
6
 cells/ml in a six-well plate and incubated 
for 24 hr at 37 °C. Individual wells were then either left unstimulated or stimulated with B. 
pertussis (MOI of 200) for the timepoints indicated. Cells were then harvested, total RNA 
isolated and from this, cDNA was synthesised. The cDNA was then used as a template for 
qRT-PCR using forward and reverse primers specific to human nlrp12 and gapdh 
(housekeeping gene). * p<0.05, ** p<0.01 and *** p<0.001. NS, not significant. Graph is 
representative of four independent experiments.  
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4.2.10 Proteomic response to B. pertussis infection – common trends and functional 
annotation of protein hits obtained by LFQ MS 
2D-DIGE is based upon the quantitative labelling of proteins within a gel matrix, followed 
by protein excision, digestion and MS identification. As previously discussed however, this 
method has drawbacks such as the masking of low abundance proteins by high abundant 
ones and a low throughput. LFQ MS, as previously discussed, does not suffer from either of 
these drawbacks and may therefore be capable of identifying expression changes in low 
abundant proteins that were missed by 2D-DIGE analysis. Thus the same whole cell lysates 
from uninfected and B. pertussis infected BEAS-2B cells that were used for 2D-DIGE 
analysis were also used for LFQ MS.  
As with the 2D-DIGE study, protein hits that were significantly up or down regulated in 
response to B. pertussis infection, as identified LFQ MS were categorised first based on a 
broad generalisation of their biological role (Figure 4.12). Again, a protein was considered to 
be a true hit when it fulfilled certain statistical criteria. Protein intensities were normalized 
across all runs (N=4 for control and infected) and the resulting ‘LFQ intensities’ were 
grouped based on treatment and an ANOVA test performed to identify statistically 
significant variation in protein intensity between all control and infected samples. Proteins 
that were completely lacking from one treatment but present in the other were determined 
manually. Statistics could not be performed on these proteins as one treatment set had no 
intensity values. Therefore, LFQ intensities and ANOVA values for these proteins are 
presented as NaN (Section 2.4.6 and Appendix Table A1.2). 
Proteome analysis by LFQ MS found a total of 60 protein hits that were significantly up or 
down regulated in response to B. pertussis infection. Of these, 29 proteins, or 48 % of the 
total were found to be upregulated and 31 proteins, or 52 % of the total were downregulated 
(Figure 4.13A,B), Table 4.2). The protein hits were grouped into the same seven general 
functional categories as the proteins identified by 2D-DIGE (Figure 4.12A,B). There were 
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some protein functionalities differentially represented with LFQ MS than with 2D DIGE. 
LFQ MS identified more proteins involved in transcription/DNA synthesis and trafficking 
than 2D DIGE. LFQ MS also identified fewer proteins involved in maintaining structural 
integrity and those involved in protein synthesis and redox reactions compared to 2D-DIGE 
(Figure 4.12A,B). Furthermore, there was a notable difference in the number of proteins 
identified as being significantly up or down regulated with an almost even split in the LFQ  
analysis compared to 2D-DIGE where the vast majority were upregulated (Figure 4.13A,B). 
Differences between the two methods were expected to a certain extent and indeed have 
been demonstrated previously in a similar study which compared 2D gel electrophoresis with 
an LFQ analysis [358]. Surprisingly, there was very little overlap between the two 
techniques in terms of actual proteins identified with only two proteins identified using both 
techniques despite samples for both coming from the same whole cell lysates (4.13A,B) 
(Table 4.2).  
 
Figure 4.12: Pie chart representation and comparison of proteins identified by LFQ 
and 2D-DIGE in response to B. pertussis infection. (A) LFQ identified proteins were 
manually researched for functional properties and assigned functions(s) to form the basis of 
categorisation. Total numbers of proteins assigned to each function were inputted into a pie 
chart for appropriate visualisation. (B) 2D-DIGE identified proteins from Figure 2 for 
comparative purposes 
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Figure 4.13: Pie chart representation and comparison of proteins identified by LFQ in 
response to B. pertussis infection. (A) Total number of LFQ derived protein hits that were 
adjudged to be up or down regulated via MaxQuant was inputted into a pie chart in order to 
visualise the divide. (B) Total number of 2D-DIGE derived up and downregulated proteins 
adapted from Figure 2 for comparative purposes. (C) Venn diagram illustrating the total 
number of protein hits identified by LFQ (red circle) and 2D-DIGE (blue circle) with the 
number of identical hits detected by both methods in the centre. Identical hits are annotated.  
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Fold Ch. Protein Name Function 
BP+ Elongation Factor gamma  Delivers tRNA’s to ribosome. Aids replication of VSV [359].  
Ion transporter across plasma membrane [360]. 
Regulation of actin cytoskeleton, cell adhesion and motility [361]. 
Transports proteins out of nucleus into cytoplasm [362]. 
Involved in DNA damage response and cell cycle [363]. 
Ribosomal subunit. Involved in protein synthesis [364]. 
Inhibits transcriptional activity of NFκB [365]. 
Metabolism. Involved in pentose phosphate pathway. Maintains levels of NADPH [366]. 
Critical role in apoptosis [298]. 
Possible role in caspase 8 mediated apoptosis [367]. Protein transporter [368]. 
Mitosis. Essential component of mitotic spindle [369]. 
Serine/Threonine protein kinases. Important in DNA recombination [370]. 
Major functional component of basement membranes [371]. 
Ribosomal subunit. Involved in protein synthesis [295] 
Ribosomal subunit. Involved in protein synthesis [295] 
Contains leucine rich repeat domain. Localises to endosome [372]. 
Protein transporter and anchor. Interacts with 14-3-3ζ a known TLR mediator [373]. 
Mediates RNA functions such as alternative splicing and translation regulation [374]. 
Exports certain proteins with no signal peptide for example IL-1α [375].  
 
 
 
BP+ Sodium/potassium-transporting ATPase  
BP+ Adenylyl cyclase-associated protein 1 
BP+ Exportin-2 
BP+ Pre mRNA slicing factor SYF2 
BP+ 60S ribosomal protein L9 
BP+ Pre-rRNA-processing protein TSR2  
BP+ Glucose-6-phosphate 1-dehydrogenase 
BP+ Caspase-7 
BP+ B-cell receptor-associated protein 31 
BP+ Small kinetochore-associated protein 
BP+ DNA-dependent protein kinase  
BP+ Laminin subunit gamma-1 
BP+ 60S ribosomal protein L7a 
BP+ 60S ribosomal protein L17 
BP+ Ribosome-binding protein p34 (p34) 
BP+ RACK1 
BP- RNA-binding protein 4 
BP- Protein S100-A13 
  
 
 
Protein hits obtained by LFQ MS 
Table 4.2: Proteins identified by LFQ MS showing changes in expression in response to B. pertussis Infection. Protein function is also 
indicated. BP+ indicates proteins detected in B. pertussis infected samples but not in uninfected samples. BP- indicated proteins detected in 
uninfected samples but not in B. pertussis infected samples. Full annotation of protein hits can be found in appendix table A1.2.  
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Fold Ch. Protein Name Function 
BP- NUDT15 Helps to prevent mutations in DNA, possibly by degrading oxygen radicals [376]. 
Transcription factor. Binding site on HLA locus [377, 378]. 
Adaptor protein. Regulates activation of downstream mediators [379]. 
Aid formation of intraluminal vesicle formation. Also required for virus budding [380]. 
Targets proteins for proteosomal degradation. Inhibits ERK/MAPK pathway [381]. 
Anti-apoptotic via caspase 3, 9 and 10 [382]. 
Involved in transcription [383]. 
Function unknown. Human form localized predominantly to nucleus [384]. 
Localises to mitochondria [385]. 
Component of exon splicing junction complex [386]. 
Pre mRNA splicing [387]. 
Function unknown. May bind to RNA (Uniprot). 
Negatively regulates RIG-I and MDA5 by ubquitination [388].  
Induced by B. pertussis [136]. Receptor for leukocytes to migrate into tissue [389]. 
Involved in pre-mRNA splicing and RNA metabolism [390]. 
Inactivated by Wnt signalling [391]. Regulates macrophage phagocytosis [392]. 
Function unknown 
Links clathrin vesicles to early endosomes [393] 
BP- Upstream stimulatory factor 2 
BP- Nck-1 
BP- BRO1 domain-containing protein BROX 
BP- E3 ubiquitin-protein ligase RNF181 
BP- Caspase activity and apoptosis inhibitor 1 
BP- RNA polymerase-associated protein RTF1  
BP- Kanadaptin 
BP- Cx9C motif-containing protein 4 
↓0.64 RNA-binding protein 8A 
↓0.75 Serine/arginine-rich splicing factor 2 
↑0.85 Putative RNA-binding protein Luc7-like 2 
↓1.23 UV excision repair protein RAD23 
↑3.87 Intercellular adhesion molecule 1 
↓0.88 Serine/arginine-rich splicing factor 6 
↓0.59 Calponin-2 
↑1.53 Uncharacterized protein C14orf119 
↓0.64 SNX15 
↓1.21 U4/U6.U5 Nuclear ribonucleoprotein Pre mRNA splicing [394]. 
 
 
Protein hits obtained by LFQ MS 
Table 4.2 (contd): Proteins identified by LFQ MS showing changes in expression in response to B. pertussis Infection. Protein function 
is also indicated. BP+ indicates proteins detected in B. pertussis infected samples but not in uninfected samples. BP- indicated proteins 
detected in uninfected samples but not in B. pertussis infected samples. Full annotation of protein hits can be found in appendix table A1.2.  
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Fold Ch. Protein Name Function 
↓2.38 SH3-containing Grb-2-like 1 protein Function unknown. May be similar to GRB2 [395]. 
Pro-phagocytic signal on cancer cell surface [396]. Found in NK & T cell granules [397] 
Redox Signalling. Indirect NFκB modulator [398].  
Role in alternative splicing [399]. 
Associated with tissue injury and inflammation. Endogenous TLR4 activator [400].  
Pre mRNA splicing [401]. 
Pre mRNA splicing [402]. 
Function unknown 
Component of 40S ribosome subunit. Involved in protein synthesis [295]. 
Inhibits macrophage migration and pathogen killing. Overexpressed in tumours [294]. 
Spliceosome component (Uniprot). 
Involved in maintenance of actin cytoskeleton [403]. 
Transcriptional repressor activity [404]. Implicated in tumourgenesis [405]. 
Function unknown. 
Involved in pre-mRNA processing [406]. 
Critical in iron storage. Upregulated during inflammatory processes [407]. 
Suspected role in Parkinson’s Disease [408]. Involved in cell cycle progression [409]. 
May be involved in transcription (Uniprot). 
Component of ferritin. Upregulated during inflammatory processes [407].  
 
 
 
↓1.19 Calreticulin  / ER resident protein 60 
↑4.13 Superoxide dismutase 
↓0.77 Zinc finger Ran-binding domain protein 2 
↑1.73 Tenascin  
↑1.23 U6 snRNA-associated Sm-like protein  
↓1.73 RNA-binding protein - serine rich domain 
↓0.84 Coiled-coil domain-containing protein 97 
↑0.87 40S ribosomal protein S29 
↑0.67 Galectin-1 
↓0.97 N-alpha-acetyltransferase 38 
↓1.14 Cdc42 effector protein 3  
↑1.00 TSC22 domain family protein 1 
↓0.64 Protein TSSC4  
↓2.11 Serine/arginine repetitive matrix protein 1 
↑3.02 Ferritin 
↑1.06 Periphilin-1 
↓0.89 Transcription elongation factor A  
↑3.64 Ferritin heavy chain   
Protein hits obtained by LFQ MS 
Table 4.2 (contd): Proteins identified by LFQ MS showing changes in expression in response to B. pertussis Infection. Protein function 
is also indicated. BP+ indicates proteins detected in B. pertussis infected samples but not in uninfected samples. BP- indicated proteins 
detected in uninfected samples but not in B. pertussis infected samples. Full annotation of protein hits can be found in appendix table A1.2.  
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Fold Ch. Protein Name Function 
↓0.91 Transcription elongation factor A  Necessary for efficient RNA polymerase II transcription [410]. 
Involved in pre-mRNA splicing [411]. 
May have role in ubquitination [412]. Nuclear translocation upon heat shock [413]. 
↓2.01 
 
Serine/arginine repetitive matrix protein 2 
Suppressor of G2 allele of SKP1 homolog 
  
  
         
         
↓0.68 
Protein hits obtained by LFQ MS 
Table 4.2 (contd): Proteins identified by LFQ MS showing changes in expression in response to B. pertussis Infection. Protein function 
is also indicated. BP+ indicates proteins detected in B. pertussis infected samples but not in uninfected samples. BP- indicated proteins 
detected in uninfected samples but not in B. pertussis infected samples. Full annotation of protein hits can be found in appendix table A1.2.  
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4.2.11 Verification of LFQ MS derived protein hits from B. pertussis infection. 
Two hits were selected for verification by immunoblotting. These were superoxide dismutase 
(SOD) and ferritin. SOD was selected because it was one of two proteins that appeared in 
both the 2D-DIGE with MS and the LFQ MS studies and also because SODs play important 
roles in innate immunity (Table 4.2). Ferritin was selected due to its critical role in iron 
storage which is important for host metabolism. It is also known to be upregulated during 
inflammatory processes (Table 4.2). 
4.2.12 Verification of LFQ MS protein hit: Superoxide Dismutase  
SODs play a key role in metabolising O2 radicals thus pre-empting the formation of 
damaging reactive oxygen reactive species (ROS) such as hypochlorite, peroxynitrate and 
hydrogen peroxide [398]. High levels of these ROS lead to oxidative stress which is 
implicated in may cardiovascular diseases. However, low levels are important in innate 
immune defences as well as general cell signalling [414]. Although the term superoxide 
dismutase denotes three independent enzymes (SOD1, SOD2 and SOD3), at the core of each 
is the ability to convert two molecules of superoxide into dioxegen (O2) and hydrogen 
peroxide. The difference between the three SODs resides both in their fold and in the 
different metal ion(s) in their active site. SOD1 can bind copper and zinc ions, SOD2 
contains an manganese ion while SOD3 also binds copper and zinc ions [269]. SOD1 is the 
major intracellular SOD. It exists as a 32kDa homodimer mainly in the cytosol, with smaller 
fractions residing within the nucleus, lysosomes, peroxisomes and intermembrane space of 
mitochondria [398].  
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Fig 4.14: Role of SOD1 in NFκB activation. During redox signalling, SOD1 is recruited to 
the endosomal surface where it indirectly regulates Nox2 mediated O2 radical formation. O2 
radicals exit via chloride channels (CIC3) whereupon they are dismutated by SOD1to 
produce hydrogen peroxide and promoting redox activation of NFκB. Adapted from [398]. 
 
SOD1’s role in redox signalling is well documented with the dismutation of O2 radicals 
produced following IL-1 signalling, producing hydrogen peroxide which goes on to activate 
and modulate the NFκB pathway [398, 415]. SOD2 is an exclusively mitochondrial enzyme 
utilising a manganese ion. Its function is identical to that of SOD1 (and SOD3) in that it too 
facilitates the dismutation of O2 radicals to oxygen and hydrogen peroxide [398].  
SOD1 was found to be upregulated in response to B. pertussis infection, as detected by LFQ 
MS (Figure 4.15A). This was verified by immunoblotting for SOD1 in whole cell lysates 
infected with B. pertussis for various timepoints.  SOD1’s expression was increased at one 
hour post infection and remained so up to 12 hr (Figure 4.15B). Expression of SOD1 mRNA 
was not found to be significantly upregulated at 6 or 12 hr post infection (Figure 4.15C) 
indicating that its expression in response to B. pertussis is governed by post-transcriptional 
processes.  
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Figure 4.15: Verification of SOD1 upregulation in response to B. pertussis. (A)  BEAS-
2B cells were seeded in a 6-well plate at a density of 0.7x10
6
 cells/ml and incubated for 24 hr 
at 37 °C. Thereafter, cells were either left uninfected or infected with B. pertussis (MOI of 
200) for 15 min, 30 min, 60 min, 2 hr, 4 hr, 6 hr and 12 hr. Cells were then harvested and 
each sample lysed in 100 μl H.S. buffer for 20 min on ice. Cell debris was removed by 
centrifugation with the remaining whole cell lysates mixed with 30 μl 5x Laemmli loading 
buffer and boiled for 10 min. Proteins were separated by SDS-PAGE and subjected to 
immunoblot analysis using anti-SOD1 and anti-β-Actin antibodies. Results represent two 
independent experiments. (B) BEAS-2B cells were plated at a density of 0.7x10
6
 cells/ml in a 
six-well plate and incubated for 24 hr at 37 °C. Individual wells were then either left 
unstimulated or stimulated with B. pertussis (MOI of 200) for the timepoints indicated. Cells 
were then harvested, total RNA isolated and from this, cDNA was synthesised. The cDNA 
was then used as a template for qRT-PCR using forward and reverse primers specific to 
human nlrp12 and gapdh (housekeeping gene). * p<0.05, ** p<0.01 and *** p<0.001. NS, 
not significant. Graph is representative of four independent experiments.  
 
A 
B 
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4.2.13 Verification of LFQ MS protein hit: Ferritin 
Ferritin is a hollow, spherical and mainly cytosolic protein consisting of 24 subunits whose 
main function is the periodic sequesterisation and release of intracellular iron (Fe). Ferritin 
can store up to 4,500 iron atoms within its core with multiple mechanisms regulating its 
storage and release – mainly determined by the current status of the iron labile pool (free iron 
available within the cell) at any given time [416].  In addition to iron storage and release, 
ferritin has enzymatic properties converting Fe(II) to Fe(III) [417].  Iron in the cell has many 
critical roles. For example, iron in heme is essential for oxygen transport around – essential 
for survival. It is also an essential component of many enzymes involved in the cell cycle and 
electron transport. Fe (III) is involved in the generation of the potentially toxic superoxide 
radical which can damage DNA, lipids and proteins [407]. For these reasons, iron levels are 
highly regulated with ferritin playing a key role in the buffering of intracellular 
concentrations. Evidence of its innate importance is that the knocking out of the ferritin gene 
is embryonic lethal in mice [418]. Ferritin is known to be upregulated during inflammatory 
processes with the cytokines IL-1α and TNFα playing noted roles in this regard, by 
transcriptionally upregulating the H-chain of ferritin via NFκB binding sites on the ferritin h-
chain gene (Figure 4.16) [407]. 
 
Figure 4.16: Ferritin gene promoter region. Binding sites for NFκB, AP-1 and creb 
binding protein (CBP) are indicated thus indicating its regulation by inflammatory processes. 
Adapted from [407]. 
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The current study identified ferritin as being upregulated by LFQ MS in response to B. 
pertussis at 12 hr post infection (Table 4.2). This result was verified by western blot using 
antibodies specific to both the ferritin heavy chain and the ferritin light chain which indicated 
that the heavy chain was strongly induced at 6 hr post infection with the light chain 
upregulated much later at approximately 12 hr (Figure 4.17A,B). Analysis of both Ferritin LC 
and HC mRNA showed no such increases at either 6 or 12 hr (Figure 4.17C,D). Ferritin HC 
mRNA showed a slight increase at 12 hr but this approximated to 1.4 fold and was not 
significant (Figure 4.17C). As Ferritin HC has been shown to be upregulated transcriptionally 
by both TNF and IL-1 signalling, this would suggest that there are other factors at play in 
upregulating its expression. LPS for example, when administered endotracheally to rats, had 
been shown to induce ferritin protein but not mRNA [419]. With B. pertussis being a gram 
negative, LPS containing bacterium, this is one possible mechanism by which ferritin is being 
induced.  
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Figure 4.17: Verification of Ferritin upregulation in response to B. pertussis. (A and B)  
BEAS-2B cells were seeded in a 6-well plate at a density of 0.7x10
6
 cells/ml and incubated 
for 24 hr at 37 °C. Thereafter, cells were either left uninfected or infected with B. pertussis 
(MOI of 200) for 15 min, 30 min, 60 min, 2 hr, 4 hr, 6 hr and 12 hr. Cells were then harvested 
and each sample lysed in 100 μl H.S. buffer for 20 min on ice. Cell debris was removed by 
centrifugation with the remaining whole cell lysates mixed with 30 μl 5x Laemmli loading 
buffer and boiled for 10 min. Proteins were separated by SDS-PAGE and subjected to 
immunoblot analysis using anti-Ferritin HC, Ferritin LC and anti-β-Actin antibodies. Results 
represent two independent experiments. (C and D) BEAS-2B cells were plated at a density of 
0.7x10
6
 cells/ml in a six-well plate and incubated for 24 hr at 37 °C. Individual wells were 
then either left unstimulated or stimulated with B. pertussis (MOI of 200) for the timepoints 
indicated. Cells were then harvested, total RNA isolated and from this, cDNA was 
synthesised. The cDNA was then used as a template for qRT-PCR using forward and reverse 
primers specific to human ferritin-lc, ferritin-hc and gapdh (housekeeping gene). * p<0.05, 
** p<0.01 and *** p<0.001. NS, not significant. Graph is representative of four independent 
experiments.  
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4.2.14 Selection and expression knockdown of selected protein hits 
Although the identification of proteins whose expression is significantly changed due to 
system perturbation is often cited as implying function , a deeper analysis of these protein’s 
physiological role is required in order to assign function with better understanding and 
confidence [112, 420]. With this in mind, it was decided to select a number of verified 
protein hits for further analysis by utilising RNA interference to knockdown their endogenous 
expression levels and from this, to examine if, or how, their reduced expression affected the 
immune response to B. pertussis infection.  Proteins were selected for further analysis by 
thoroughly researching their known functionality and from here, inferring potentially 
unknown roles in the immune response. The proteins selected for further analysis were 
stathmin 1, PPP1Cα, NLRP12, GSTO1 and DJ-1. All of these proteins shared in common, 
functions that indicate their capability of playing roles in the innate immune response to B. 
pertussis infection.   
To investigate the role played by these proteins in the response to B. pertussis, knockdown of 
their expression was performed in BEAS-2B cells using endoribonuclease-prepared siRNA 
(esiRNA). EsiRNA’s were purchased commercially and are prepared by amplifying cDNA 
specific to the gene of interest followed by generation of dsRNA from the cDNA, using RNA 
polymerase. This dsRNA is then chopped by RNase III into a heterogeneous mixture of short, 
overlapping siRNA fragments all specific to the target gene that triggers highly specific and 
effective gene silencing [421]. To confirm knockdown of target genes, BEAS-2B cells were 
transfected with either an esiRNA control sequence against green fluorescent protein (eGFP) 
or esiRNA specific to one each of the above proteins for 24 hr after which gene expression 
specific to each protein was monitored by real time PCR (Figure 4.20). Sufficient knockdown 
of gene expression was found to occur in each of the proteins targeted by esiRNA with 
approximately 50 % reduction in PPP1Cα mRNA, a 40 % reduction in NLRP12 mRNA, 95 % 
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reduction in levels of stathmin 1 mRNA levels and a 60 % reduction DJ-1 gene expression 
(Figure 4.18A-D). 
 
 
Figure 4.18: Suppression of human PPP1Cα, stathmin 1, NLRP12 and Dj-1 mRNA 
using RNA interference. BEAS-2B cells were seeded in a 6-well plate at a density of 
0.4x10
6
 cells/ml and incubated for 24 hr at 37 °C. Cells were then transfected with either 200 
ng target gene specific esiRNA or a control esiRNA (eGFP) for a further 24 hr. Cells were 
then harvested, total RNA isolated and from this, cDNA was synthesised. The cDNA was 
then used as a template for  qRT-PCR using forward and reverse primers specific to human 
ppp1cα (A), stmn1 (B), nlrp12 (C), dj-1(D) and gapdh (housekeeping gene). * p<0.05, ** 
p<0.01 and *** p<0.001. Graphs are representative of two independent experiments. 
 
 
 
 
 
 
A B 
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4.2.15 Cytokine production after gene knockdown in response to B. pertussis and TLR4 
activation 
In order to ascertain if the selected protein hits could somehow affect the innate immune 
response of BEAS-2B cells during B. pertussis infection, their expression was individually 
supressed using esiRNA and the cells immediately infected with the bacteria as normal for 12 
hr. Cell supernatants derived from infected cells were then analysed for inflammatory 
cytokine expression by ELISA in order to evaluate whether or not suppression of each 
particular protein could affect the inflammatory response. In unstimulated cells, transfection 
of the various esiRNAs did not drive any major production of IL-6 (Figure 4.19) thus 
ensuring that any effects observed upon B. pertussis stimulation were specific to esiRNA 
mediated protein supression and not to the presence of the esiRNA nucleotides themselves. 
Cells transfected with the negative control esiRNA, eGFP, and stimulated with B. pertussis 
for 12 hr produced large quantities of IL-6 with approximately 5000 pg/ml secreted (Figure 
4.19A). However, knockdown of expression of NLRP12, PPP1Cα, DJ-1 or stathmin 1 did not 
significantly modulate IL-6 protein production (Figure 4.19A). B. pertussis, like any 
pathogenic organism, likely activates multiple signalling pathways during an infection 
process. As well as this, B. pertussis is known to encode multiple virulence factors some of 
which can modulate various immune response signalling pathways in order to preserve its 
presence within the host. For example, one virulence factor, adenylate cyclase toxin, can 
supress superoxide production and inflammatory cytokine production [422]. Another 
virulence factor, FHA , can inhibit IL-12 production while inducing IL-6 and IL-10 [423]. 
Moreover, LPS can induce IL-6, TNFα, IL-1β, IL-12 and IL-8 secretion whilst inhibiting NO 
production [424]. B. pertussis therefore employs multiple strategies to modulate the immune 
response and thus the lack of an observed phenotype upon suppression of multiple protein 
hits may be due to a lack of specificity on the part of B. pertussis and how it interacts with the 
host immune system and not necessarily due to a lack of involvement of the protein hits. 
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As B. pertussis in known to activate TLR4 amongst other PRRs [143, 425], it was next 
examined whether knowndown of the selected proteins could affect the immune response 
specific to TLR4. To this end, BEAS-2B cells were again transfected with either control 
esiRNA or esiRNA specific to each protein 24 hr prior to stimulation with LPS. After 24 hr 
stimulation, supernatants were removed and examined for secreted levels of proinflammatory 
cytokines IL-6 and TNFα (Figure 4.19B,C).  
Transfection of cells with the various esiRNAs again had little effect on basal levels of IL-6 
and TNFα (Figure 4.19B,C). Transfection with the negative control esiRNA, eGFP, and 
stimulation with LPS caused detectable secretion of IL-6 but not TNFα from BEAS-2B cells 
(Figure 4.21B,C). LPS induced IL-6 production was significantly increased upon suppression 
of NLRP12 thus agreeing with previous studies showing that it could exert a negative 
influence on inflammatory cytokine production (Figure 4.19B) [354, 355]. Suppression of 
DJ-1 gave rise to a slight increase in IL-6 production but this was determined to be non-
significant (Figure 4.19B). Interestingly, knockdown of statmin-1 and PPP1Cα both led to a 
significant reduction in TLR4 mediated IL-6 production (Figure 4.19B).  
Apart from the previously discussed role for stathmin 1 as an endogenous activator of TLR3 
signalling [255], no other role for stathmin in mediating the innate immune response has 
previously been identified. Stathmin has been shown to colocalise with TLR3 in MS lesions 
on both the surface of astrocytes and neurons and also in intracellular vesicular structures of 
astrocytes and microglia [255]. This observation would suggest that stathmin is capable of 
localising to areas of the cell where TLRs are expressed and with TLR4 known to localise to 
the cell surface as well as vesicular structures within the cell, this leaves open the possibility 
that stathmin 1 can localise to the TLR4 signalling pathway. Stathmin 1 is also a key 
regulator of microtubule dynamics within the cell during lymphocyte activation [330] and as 
the ‘TLR4 signalosome’ is known to traffic between the plasma membrane and endosomal 
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compartments in a process dependent upon microtubule transport, it is conceivable that 
suppression of stathmin 1 is inhibiting the ability of TLR4 and/or its adaptors and interactors 
to localise to the signalling complex thereby reducing downstream cytokine production [84, 
86].  
PPP1Cα has a known role in innate signalling in that it dephosphorylates RIG-I and MDA5 to 
allow them to signal recognition of RNA viruses such as influenza virus, paramyxovirus, 
dengue virus, and picornavirus [292]. As a negative control, the authors of this study 
examined the role of PPP1Cα in TLR3 signalling (where it had no effect) but did not examine 
its role in other TLRs including TLR4.  Many proteins within the TLR4 pathway are 
phosphorylated on either serine or threonine residues including MAL, TRAM, IRAK4, 
STAT1, IRF3, IRF7 and IκB kinase β (IKKβ) [15, 57, 83, 426-428]. However, as PPP1Cα is 
a phosphatase, it would be expected that suppression on PPP1Cα would lead to increased 
phosphorylation. Knockdown of PPP1Cα led to a decrease in inflammatory cytokine 
production (Figure 4.19B) and so it would also be expected that PPP1Cα is acting on a 
protein which requires dephosphorylation for its activity, similar to RIG-I and MDA5. 
Proteins that are dephosphorylated to aid relay of TLR4 signal include eukaryotic initiation 
factor 2B and heat shock protein 27 (Hsp27) [429, 430]. It is possible that PPP1Cα acts on 
these molecules in order to drive TLR4 signalling. 
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Figure 4.19: B. pertussis and LPS meditated inflammatory response upon suppression of 
human PPP1Cα, stathmin 1, NLRP12 and Dj-1. BEAS-2B cells were seeded in a 6-well 
plate at a density of 0.4x10
6
cells/ml and incubated for 24 hr at 37 °C. Cells were then 
transfected with either 200ng target gene specific esiRNA or a control esiRNA (eGFP) for 24 
hr. At this point, medium was removed and fresh medium added. After 2 hr, cells were either 
left unstimulated or stimulated with either B. pertussis (400 bacteria/cell) or LPS (500ng/ml) 
for a further 12 and 24 hr respectively. Cell free supernatants were then harvested and 
analysed for the presence of (A) B. pertussis mediated IL-6 (N=5) and (B, C) LPS mediated 
IL-6 and TNFα by ELISA (N=3). * p<0.05, ** p<0.01 and *** p<0.001. NS, not significant. 
A 
B 
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4.2.16 Examination of stathmin 1’s and PPP1Cα’s ability to drive NFκB/AP-1 activation 
Due to the observed reduction of TLR4 mediated IL-6 production upon suppression of 
stathmin 1 and PPP1Cα, it was hypothesised that their signalling could in some way drive 
activation of the transcription factors NFκB and AP-1, both of which have binding sites on 
the IL-6 promoter sequence [431]. To investigate whether either of these proteins are capable 
of driving activation of these transcription factors in a TLR4 dependent manner, increasing 
amounts of plasmid DNA corresponding to either stathmin or PPP1Cα were expressed in 
HEK-Blue™-hTLR4 cells. After 24 hr, cells were stimulated with LPS for a further 24 hr 
after which signal activation was assayed. 
Although stimulation of the cells with LPS drove activation, expression of increasing 
amounts of plasmid DNA corresponding to 10-80 ng of either stathmin 1 or PPP1Cα failed to 
increase the intensity of the LPS generated signal (Figure 4.20A,B). This could mean that 
additional cofactors are required for both proteins to activated TLR4 signalling that are not 
present in the parental HEK cell line used. Recently, stathmin was shown to be an 
endogenous ligand for TLR3 and this was proven using a number of methods including the 
use of TLR3 deficient mice and RNA interference [255]. Interestingly, TLR3 transfected 
HEK293 cells were unable to respond to stathmin despite responding normally to poly(I:C) 
leading the authors to conclude that HEK 293 cells are missing cofactors that are required for 
the stathmin mediated activation of TLR3 [255]. Therefore, the observed results obtained in 
the current study are not without precedent. 
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Figure 4.20: Investigation of ability of stathmin 1 and PPP1Cα to independently drive 
NFκB and AP-1 signalling. A, HEK-Blue™-hTLR4 cells were plated at a density of 25,000 
cells/well in a 96-well plates and incubated at 37 °C for 24 hr. Cells were then transfected 
with either empty vector (EV) or increasing amounts of either stathmin 1 or PPP1Cα plasmid 
DNA as indicated and incubated for 24 hr. Cells were then stimulated with LPS (100 ng/ml) 
for a further 24 hr followed addition of 20 μl of supernatant from each well to 180 μl/well of 
prewarmed Quanti-Blue detection medium. Colour changes were measured by spectrometry 
reading at a wavelength of 630 nm. Results are representative of two independent 
experiments. NS, not significant. 
 
 
 
 
 
 
 
 
 
A B 
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4.3 Discussion 
 
The current study was conceived around the need to better characterise the physiological 
response to B. pertussis - a human pathogen that despite a widely available vaccine with high 
uptake has seen the recent doubling of reported cases in western countries. Taking Ireland as 
an example, in 2012, 444 cases were reported. This was double the number of cases reported 
in 2011 which itself was double the number of cases reported in 2010 [432]. Of the reported 
2012 cases, 30 % required hospitilisation and two were fatal [432]. Similar figures have been 
noted in the UK also [433]. The ability to improve the B. pertussis vaccine in order to 
increase the longevity and strength of its protection from the earliest point in life is the 
ultimate aim but to do this, a better understanding of both vaccine development and also B. 
pertussis infection is required [139].    
To this end, it was decided to characterise changes induced in the proteome of a human lung 
epithelial cell line upon infection with B. pertussis with the aim of cataloguing the proteins 
induced or repressed during infection which may ultimately play a role in its pathogenesis. 
Two separate proteomic techniques were used in this regard namely 2D-DIGE with LC-MS 
and LFQ MS. One of the most striking initial observations from the two studies was the lack 
of overlap in identified propteins between 2D-DIGE and LFQ MS. Proteins identified by 
LFQ MS but 2D-DIGE could be due to the higher sensitivity of LFQ MS compared to the 
more restrictive 2D-DIGE. However, the inability of LFQ MS to identify almost any proteins 
identified by 2D-DIGE is puzzling. One factor could be that during the preparation of protein 
lysates for LFQ MS, difficulties were experienced when trying to resuspend required 
quantities of protein in the resuspension buffer (Section 2.3). It could be possible that only 
proteins exhibiting particular characteristics regarding solubility were reuspended which 
could have led to exclusion of others that happened not be as solubule.   
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Another observation was that approximately one quarter of all proteins identified by both 
techniques as being significantly up or down regulated in response to infection were proteins 
with previously known roles in the immune response but of which, critically few have been 
shown to play a role in the response to B. pertussis (Figure 4.12 and Tables 4.1, 4.2). This 
result in itself would suggest that there is still a large amount of work still to be done in the 
characterisation of the immune response to B. pertussis and similarily to any bacterium. 
Other functional areas that were well represented were transcription and DNA editing, 
structural proteins and those involved in protein synthesis. The involvement of transcription 
and translation processes would be expected as the cell gears up to respond to infection. 
However it is interesting to correlate this observation the real time-PCR and immunoassay 
vertifications of various protein hits. Of the eight hits selected for verification, four did not 
correlate increased protein expression with increased gene expression (Figures 4.9, 4.11, 4.15 
and 4.17). This would suggest that approximately half of all protein regulation in response to 
B. pertussis is occurring at the post-transcriptional level. Post transcriptional control plays an 
important role in the regulation of immune effector proteins. Transcript specific regulation 
requires individual factors that bind to particular mRNA targets. The functional fate of a 
particular transcript is often defined by a myriad of RNA-binding proteins (RBPs) can 
stabilise mRNA transcripts and stimulate their translation or vice-versa [434].  Indeed, four 
separate RBPs were identified from the LFQ MS study and these, along with many other 
RNA modifying proteins, comprised 31 % of all proteins identified as being dynamically 
regulated in response to B. pertussis infection (Figure 4.12, Table 4.2). This would suggest 
that targeting the post-transcriptional regulation of immune signalling is a field with 
therapeutic potential. Indeed, a relatively recently characterised subset of post-transcriptional 
regulators, the micro-RNAs, which typically supress translation by targeting mRNA 
194 
  
transcripts of degradation have been identified as one such contributor to immune modulatory 
therapy in the future [435, 436].  
Unfortunately, upon suppression of a number of selected protein hits, no striking 
inflammatory based phenotype was observed during B. pertussis infection (Figure 4.19A). As 
previously stated, this could be due to the myriad of documented immune modulatory 
mechanisms possessed by B. pertussis and the many concurrent detection and signalling 
pathways employed by humans to respond to B. pertussis [139]. Therefore, the suppression of 
one individual protein with a function in one pahtway may have no overall effect. 
Interestingly however, significant modulation of the inflammatory response was noted upon 
suppression of the selected protein’s expression prior to stimulation with a purified version of 
a known B. pertussis PAMP, LPS (Figure 4.19B). Specifically, suppression of NLRP12 led 
to significantly increased IL-6 secretion while suppression of both the protein phosphotase 
PPP1Cα and the microtubule regulator stathmin 1 led to significantly decreased IL-6 
production (Figure 4.19B). As LPS, through its membrane receptor TLR4, is a key sensor of 
gram negative bacteria and consequently a major driver of the symptoms of septic shock, a 
role for these two proteins in mediating this response is a tantalising possibility. They do not 
appear to be intrinsic activators of the transcription factors NFκB and AP-1 upon 
overexpression of their wild-type forms in a TLR4 dependent system however perhaps 
overexpression of mutant forms of the proteins could inhibit activation. Alternatively, their 
role in TLR4 signalling may be more abstract and require the presence of other cellular 
proteins not present in the HEK293 cells used.  
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Chapter 5 
 
 
Investigations into respiratpry cell proteome changes 
in response to infection with the respiratory pathogen 
human rhinovirus 16. 
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5.1 Chapter Aim 
 
The aim of this chaper was to analyse proteome modulation of a lung epithelial cell line in 
response to infection with the respiratory virus HRV16. This would be accomplished by 2D-
DIGE combined with LC-MS. Protein hits obtained would be compared to those obtained 
upon infection with the same cell line with B. pertussis. A selection of hits would then be 
validated and an analysis of their role in immune signalling undertaken by supresssion their 
expression priot to infection with HRV16. 
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5.2 Results 
5.2.1 Optimisation of HRV16 infection protocol 
As with B. pertussis in Chapter 4, an infection protocol had to be designed that would drive a 
sufficient immune response to HRV16 infection in BEAS-2B cells. It has been shown that 
HRV infects cells more efficiently at temperatures below 37 °C and this has been suggested 
as a reason why the human nasal cavity, which is exposed and therefore cooler, serves as the 
primary site of natural inoculation for HRVs [162, 437]. It has also been shown that infecting 
cells in vitro with HRV is more efficient when the cell monolayer is subconfluent [437]. For 
these reasons, BEAS-2B cells were infected with HRV16 (MOI of 3) at an estimated 50-60% 
confluency at 33 °C covering timpoints between 24 and 72 hr.    
Infection of BEAS-2B cells with HRV16 drove significant increases in RANTES, IL-6 and 
IFN-β mRNA expression however this only became apparent at 72 hr post infection (Figure 
5.1B,C). There was little or no change in gene expression at 6 or 24 hr with increases 
beginning at 48 hr. A possible explanation for the requirement of such a long timescale for an 
immune response to become apparent is simply the level of viral replication occurring. This 
was measured by quantitative PCR with primers specific to HRV16 (Figure 5.1D). This 
indicated that although there was an approximate 10-fold increase in HRV16 presence at 24 
hr post infection compared to 6 hr, it then took until 72 hr for this level be doubled (Figure 
5.1D). This would suggest that the HRV16’s replication was being impeded by the host’s 
immune response, activation of which was being detected at approximately 48 hr and at 
significant levels by 72 hr (Figure 5.1 A-C). In any case, HRV16 infection of BEAS-2B cells 
was confirmed along with the activation of an immune response. It was therefore decided to 
analyse the whole cell proteomic response to HRV16 at 72 hr post infection. 
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Figure 5.1: HRV16 infection of BEAS-2B cells activates the immune response. BEAS-2B 
cells were plated at a density of 0.4x10
6
 cells/ml in a six-well plate and incubated for 24 hr at 
37 °C. Individual wells were then either left unstimulated or stimulated with HRV16 (MOI of 
3) for the timepoints indicated. Cells were then harvested, total RNA isolated and from this, 
cDNA was synthesised. The cDNA was then used as a template for qRT-PCR using forward 
and reverse primers specific to human il-6, ifn-β, rantes and gapdh (housekeeping gene). * 
p<0.05, ** p<0.01 and *** p<0.001. Graphs are representative of three independent 
experiments.  
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5.2.2 Proteomic response to HRV16 infection – common trends and functional 
annotation of protein hits obtained by 2D-DIGE with MS 
Protein hits that were significantly up or down regulated in response to HRV16 infection of 
BEAS-2B cells, as identified by 2D-DIGE and MS were categorised as per Figure 4.2. 
Categorisation of each protein into the same broad functional roles applied to the B. pertussis 
study revealed broadly similar levels of contributions to processes such as immune function 
(24 % of proteins with HRV16 vs. 27 % with B. pertussis), cancer related (14 % of proteins 
with HRV16 vs. 12 % with B. pertussis), structural (15 % vs. 12 %) and redox (7 % vs. 9 %) 
(Figure 5.2A,B). However, notable differences were evidenced with a reduction of those 
involved in metabolism (7 % with HRV16 vs. 10 % with B. pertussis) and trafficng (12 % vs. 
5 %) (Figure 5.2A,B).    
It is possible that these differences in overall cellular function mobilisation represent at the 
broadest level, the contrasting cellular response to infection with a virus versus the response 
to a bacterium. Increased expression of proteins involved in protein synthesis for example, 
would align with dogma regarding viral hijacking of host transcription and translation 
machinery in order to replicate itself [162]. The 30 % reduction in proteins involved in 
metabolism is interesting but can be explained by the fact that unlike B. pertussis, HRV 
infection does not tend to drive pathology in lung epithelial cells [162, 437, 438]. As HRV 
infection is less lethal to the cell, it could be hypothesised that the cell in turn expends less 
energy in fighting it. Also, although both pathogens can reside within the cell [163, 249], the 
fact that B. pertussis is a much more complex organism compared to HRV (viruses are not 
considered a form of life according to modern taxonomy [439]) could mean that the levels of 
host metabolism subverted by an intracellular bacterial infection versus an intracellular viral 
infection are much higher.  
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The total number of upregulated proteins vs downregulated proteins was broadly similar 
between HRV16 and B. pertussis infection with an approximate 4:1 ratio of upregulated 
proteins against down regulated proteins observed in both studies (Figure 5.2C,D). 
 
 
 
Figure 5.2: Pie chart representation and comparison of protein function from hits 
identified by 2D-DIGE in response to HRV16 and B. pertussis infection. (A) 2D-DIGE 
identified proteins from HRV16 infected cells were researched for functional properties and 
grouped according to function(s) in one or more of eight general categories: protein synthesis, 
trafficking, redox, immune function, transcription/DNA editing, metabolism, structural and 
cancer. Total numbers of proteins assigned to each function were then displayed in pie chart 
format for visualisation. (B) 2D-DIGE identified protein hits from B. pertussis infected cells 
underwent a similar process and are displayed for comparative purposes. (C) Total numbers 
of 2D-DIGE MS – HRV16 derived protein hits that were up or down regulated according to 
Progenesis software were visualised in pie chart format (D) Total numbers of up and 
downregulated protein hits derived from the 2D-DIGE MS - B. pertussis study are shown for 
comparative purposes.  
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5.2.3 2D-DIGE protein hits common to both HRV16 and B. pertussis infection 
An average of 44 protein hits were identified as being significantly up or downregulated in 
response to either HRV16 or B. pertussis infection (Figure 5.3A). Of these, 11, or 
approximately 25 % of proteins were identified in both infection settings indicating that these 
play a role in the host response to both viral and bacterial challenge to cells of the respiratory 
system. These proteins were TPI, SOD1, DJ-1, stathmin 1, ubiquitin conjugating enzyme 13 
(Ubc13), peroxiredoxin 3 (PRDX3), nucleoside diphosphate kinase (NDK), gankryin (p28), 
IL-25, caspase 3 and partner of Sld five 2 (PSF2) (Figure 5.3A). Annotation and 
categorisation of these proteins according to their function revealed the processes that appear 
to be most important in the host response immune response to both bacterial and viral 
infections (Figure 5.3B, Table 5.1). 
Proteins with documented roles in immune function represent the majority (one-third) of 
those whose expression changed significantly in response to both viral and bacterial 
challenge. Proteins with roles in cancer processes represented slightly less than one quarter of 
the total with 22 %. Those involved in redox signalling and transcription/DNA editing 
accounted for 17 % and 11 % respectively. Metabolism, structural and trafficking proteins 
were each responsible for approximately 6 % (Figure 5.3B). It is interesting to note that when 
examining the proteome in response to bacterial or viral infection, by either 2D-DIGE MS or 
LFQ MS, between one quarter and one third of dynamically regulated proteins are known to 
have some function within the immune response. However, this in turn means that between 
three quarters and two thirds of identified proteins respectively, have no documented role in 
the immune response – a large proportion considering that they were identified upon 
pathogenic infection. While some of these undoubtedly have to date unknown links or roles 
in the immune response, it is unlikely that all do. Therefore, another avenue of research in 
terms of defining therapeutic targets could be in targeting proteins involved not in the 
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immune response, but involved in disregulated cancer signalling pathways for example or 
redox signalling pathways in response to infection.  
 
  
 
 
Figure 5.3: Quantification of unique and identical protein hits identified in response to 
HRV16 and B. pertussis infection by 2D-DIGE with LC/MS. (A) Venn diagram 
illustrating the total number (underlined) of protein hits identified by HRV16 (red circle) and 
B. pertussis (blue circle) infection of BEAS-2B cells. The number of identical protein hits 
detected in both infections is in the centre and the names of these proteins are annotated 
below. These identical protein hits were then researched for function and assigned to groups 
in the pie chart in (B). Functions were found to fall into seven general categories: trafficking, 
redox, immune function, transcription and DNA editing, metabolism, structural and cancer 
related.  
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Fold Ch. Protein Name Function 
↑1.6 
↑1.6 
↑1.5 
↑1.7 
↑1.6 
↑1.5 
↑1.5 
↑1.5 
↑1.6 
↑1.5 
↑1.6 
↓1.7 
↑1.5 
↑1.6 
↑1.5 
↓1.3 
↑1.4 
↑1.5 
↑1.3 
Stathmin 
Actin-related protein 2/3 complex subunit 5 
Prefoldin subunit 5 
Superoxide dismutase [Cu-Zn] 
Deoxyuridine 5'-triphosphate nucleotidohydrolase,  
Nucleoside diphosphate kinase A (NME1)  
Putative hydrolase RBBP9 
α/β hydrolase domain-containing protein 14B 
Dj-1 
PRDX3 
Lysozyme C  
Myosin regulatory light chain 12A 
60S acidic ribosomal protein P2 
Eukaryotic Translation Initiation Factor Eif5a 
Glia maturation factor beta 
Heme-binding protein 1 (p22HBP) 
Glutathione S-Transferase P1 
Gankryin or p28 or GANK 
Caspase 3 
Endogenous TLR3 agonist [255]. Cancer marker. Microtubule regulation [261]. 
Regulates general actin cytoskeleton [440].  
Promotes folding of nascent polypeptide chain [441].  
Redox signalling. Indirect NFκB modulator [269].   
Nucleotide metabolism [442]. 
Transfers phosphate groups.Cancer metastasis marker & link to endocytosis [443].  
Serine hydrolase.Increased in pancreatic cancer.Suppression of TGFβ signalling[444] 
Unknown  
Associated with Parkinson’s Disease. Protective against oxidative stress [288]. 
Redox signalling [274]. Prostate cancer marker [275]. 
Glycoside hydrolase. Damages peptidoglycan layer in bacterial cell walls [274].   
Critical in maintain cell structure and cellular integrity [445]. 
Component of ribosome 60S subunit. Protein synthesis elongation step [446]. 
Translation factor [447]. Regulates iNOS levels [448].  
Overexpression drives NFκB activation in astrocytes. Neuronal survival [449]. 
Binds heme [450]. 
Polymorphisms associated with multiple cancers[451]Inhibits JNK signalling[452]  
Inhibits NFκB by retaining in cytoplasm [453]. Noted oncoprotein [454]. 
Protease. Central apoptosis mediator [454]. 
 
 
Protein hits obtained by 2D-DIGE with MS 
Table 5.1: Proteins identified by 2D-DIGE combined with LC-MS showing changes in expression in response to HRV16 Infection. 
Protein function is also indicated. Full annotation of protein hits can be found in appendix table A1.3. 
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Fold Ch. Protein Name Function 
↑1.5 
↑1.5 
↓1.3 
↑1.5 
↑1.5 
↑1.5 
↑1.5 
↓1.5 
↓1.6 
↑1.5 
↓1.7 
↓1.7 
↓1.6 
↑1.4 
↑1.4 
↑1.4 
↑1.4 
↑1.4 
↑1.3 
DNA-directed RNA polymerases subunit RPABC1 
Phosphoglycerate mutase 1 
unnamed protein product  
40S ribosomal protein S12 
HINT1 
S-phase kinase-associated protein 1 
DNA replication complex GINS protein PSF2 
Lamin-B1  
Mitogen-activated protein kinase kinase kinase 5 
Splicing factor 3A subunit 1 
Menin 
Glycogen debranching enzyme  
Tetratricopeptide repeat protein 21B 
IL-25 
Histidine triad nucleotide-binding protein 2 
Cofilin-1 
Ubiquitin-conjugating enzyme E2 N (Ubc13) 
Triosephosphate isomerase 
coiled-coil domain containing 69 
Transcribes DNA into RNA [455].  
Phosphate transfer in glycolysis [290].  
Unknown 
Ribosome subunit. Site of protein synthesis [295].  
Tumour suppressor. Can inhibit NFκB activity [456]. Can trigger apoptosis [457].  
Component of SCF ubiquitin ligase. Targets proteins for degradation [458]. 
Essential in initiation of DNA replication. Preferentially binds to ssDNA [304]. 
Nuclear membrane protein. Structural integrity [459]. 
Serine/threonine kinase-mediates inflammatory and stress signals via AP-1[460]. 
Complex required for mRNA splicing [461]. 
Primarily nuclear. Inhibits AP-1 transcription factor jun-D [462]. 
Metabolism. Glycogen breakdown [463]. 
Component of IFT complex which maintains cilia (Uniprot). 
TH2 cytokine-induces secretion of IL-4 and others[296].Anti-inflammatory[297] 
Mitochondrial apoptotic sensitiser[464]. Regulates intracellular calcium levels [465] 
Actin modulator. Role in cell migration [273]. 
Required for MAP Kinase activation [271]. Role in TRAF6 mediated signalling [271] 
Important in glycolytic pathway [259]. 
Mitosis. Regulates spindle formation [466]. 
 
 
Protein hits obtained by 2D-DIGE with MS 
Table 5.1 (contd): Proteins identified by 2D-DIGE combined with LC-MS showing changes in expression in response to HRV16 
Infection. Protein function is also indicated. Full annotation of protein hits can be found in appendix table A1.3. 
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Fold Ch. Protein Name Function 
↑1.4 
↑1.4 
↑1.4 
Prefoldin subunit 3  
Acyl-protein thioesterase 1  
NME1-NME2 protein (Nucleoside diphosphate 
kinase A and B) 
Prefoldin promotes folding of nascent polypeptide chain [441]. 
T-cell activation . Depalmitoylation . Affects Ras signalling [467]. 
NME1 is a tumour suppressor. NME2 involved in activation of G proteins [468]. 
Protein hits obtained by 2D-DIGE with MS 
Table 5.1 (contd): Proteins identified by 2D-DIGE combined with LC-MS showing changes in expression in response to HRV16 
Infection. Protein function is also indicated. Full annotation of protein hits can be found in appendix table A1.3. 
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5.2.4 Verification of protein hits from HRV16 infection. 
As mentioned previously, approximately 25 % of proteins whose expression was significantly 
modulated in response to HRV16 infection were similarly modulated in response to B. 
pertussis infection (Figure 5.3A). Because expression of these proteins appeared modulated 
in response to two distinct pathogenic challenges, particular importance was assigned to them 
as they may play central roles host defence. With this in mind, it was decided to verify a 
selection of proteins which appeared in response to HRV16 that were also identified in B. 
pertussis infection. These proteins were further selected based on their contribution to each of 
the broad functional categories alluded to in Figure 5.3B. These were NDK (or NME) which 
has roles in cancer and trafficking, TPI which is involved in metabolism, SOD1 which has 
redox and immune functions, DJ-1 which is also involved in redox signalling and finally 
stathmin 1 which has demonstrated roles in immune function, cell structure and cancer (Table 
5.1). These proteins therefore play diverse roles within the cell and may play equally diverse 
roles in the response to pathogen challenge.  
 
5.2.5 Verification of HRV16 protein hit:  Nucleoside diphosphate kinase (NME1-NME2) 
 NDK A, also known as NME1 or nm23-H1 and NDK B, also known as NME2 or nm23-H2, 
are highly conserved and expressed enzymes with roles in many cellular processes. First, as 
its name suggests, it is a kinase that transfers phosphate groups between nucleoside tri- and 
diphosphates, for example, between adenosine triphosphate (ATP) and guanosine 
diphosphate (GDP) [443]. It can also bind to DNA to modulate transcription [469, 470]. 
Moreover, NDK has a granzyme-A dependent DNase activity during caspase independent 
apoptosis [471]. Somewhat controversially, NDK levels have been inversely associated with 
cancer metastasis in xenografts of human breast cancer and oral squamous cancer with 
reduced expression correlating with increased metastasis [472, 473]. However, other studies 
have doubted this [443, 474]. More recently, NDK has been shown to interact with the 
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Epstein-Barr virus (EBV) virulence factor  nuclease antigen 1 which inhibits NDK’s ability 
to supress cell migration in lymphoblastoid cell lines [475]. Finally, NDK has also been 
shown to play a role in dynamin dependent processes such as cytokinesis and endocytosis by 
way of its role in GTP production, which is required for dynamin activity [476, 477]. The 
exact mechanism for this role has not been ascertained. 
 
The current 2D-DIGE with MS study identified both NDK A and its isoform NDK B as being 
upregulated 1.5 fold in BEAS-2B cells infected with HRV16 for 72 hr compared to 
uninfected control cells (Figure 5.4A, Table 5.1). This result was verified by western blot 
using an anti-NME2 antibody. This showed that levels of both isoforms undergo major 
upregulation upon infection with HRV16 at 24 hr with this upregulation being maintained at 
112 hr (Figure 5.4B). Levels of NME2 mRNA were also analysed by real time PCR which 
did not indicate any significant upregulation at the gene level suggesting that NDK undergoes 
post-transcriptional or translational modifications to increase its expression (Figure 5.4C).  
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Figure 5.4: Verification of NME2 upregulation in response to HRV16. (A) Screen grab of 
Progenesis analysis showing NME2 presence on a reference 2D-DIGE gel image from 
control (Ctrl) and HRV16 infected (72 hr) lysates. Image represents four independent 
experiments (B) BEAS-2B cells were seeded in a 6-well plate at a density of 0.4x10
6
 cells/ml 
and incubated for 24 hr at 37 °C. Thereafter, cells were transferred to a 33 °C incubator and 
either left uninfected or infected with HRV16 (MOI of 3) for the timepoints indicated. Cells 
were then harvested and each sample lysed in 100 μl H.S. buffer for 20 min on ice. Cell 
debris was removed by centrifugation with the remaining whole cell lysates mixed with 30ul 
5x Laemmli loading buffer and boiled for 10 min. Proteins were separated by SDS-PAGE 
and subjected to immunoblot analysis using anti-NME2 and anti-β-Actin antibodies. Results 
represent two independent experiments. Image is representative of three independent 
experiments (C) BEAS-2B cells were plated, incubated and stimulated according to (B). Cells 
were then harvested, total RNA isolated and from this, cDNA was synthesised. The cDNA 
was then used as a template for qRT-PCR using forward and reverse primers specific to 
human nme2 and gapdh (housekeeping gene). * p<0.05, ** p<0.01 and *** p<0.001. NS, not 
significant. Graph is representative of two independent experiments. 
A 
B 
C
C 
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5.2.6 Verification of HRV16 protein hits:  DJ-1 and stathmin 1 
DJ-1 and stathmin 1 were both found to be upregulated 1.6 fold in HRV16 infected BEAS-2B 
cells compared to uninfected controls (Figure 5.5A, 5.6A). These results were verified by 
western blot which in the case of DJ-1, showed increased expression at 72 and 96 hr of 
HRV16 infection (Figure 5.5B). Stathmin 1 expression was found to be increased at 24 hr 
post infection and this was maintained until 96 hr (Figure 5.6B). DJ-1 mRNA was not found 
to be significantly changed across multiple timepoints indicating that its levels are being 
regulated post-transcriptionally (Figure 5.5C). This contrasts with its expression upon B. 
pertussis infection which indicated a small but significant increase in gene DJ-1 gene 
expression upon B. pertussis infection (Figure 4.4C). Expression of stathmin 1 mRNA was 
significantly upregulated upon HRV16 by approximately 4 fold compared to uninfected cells. 
This result correlates with stathmin 1’s gene expression upon B. pertussis infection which 
was also upregulated (Figure 5.6C and 4.6C). Further discussion of both DJ-1 and stathmin 1 
can be found in Section 4.2.1 and 4.2.6 respectively. 
5.2.7 Verification of HRV16  protein hits:  TPI and SOD 
TPI and SOD were both found by 2D-DIGE MS to be upregulated 1.4 and 1.7 fold 
respectively upon HRV16 infection at 72 hr (Figures 5.7A, 5.8A) (Table 5.1). Again, both 
results were verified by western blot with TPI undergoing upregulation between 48 hr and 96 
hr (Figure 5.7B). Levels of SOD were also increased at 48 hr and remained so at 112 hr of 
infection (Figure 5.8B). Analysis of mRNA corresponding to both proteins revealed no 
significant changes in expression across all timepoints analysed (Figure 5.7C and 5.8C). 
These results agreed with observations of the levels of the same mRNAs in response to B. 
pertussis infection which were also unchanged (Figure 4.16C and 4.15C). Further discussion 
of both TPI and SOD can be found in Section 4.2.8 and 4.2.12 respectively. 
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Figure 5.5: Verification of DJ-1 upregulation in response to HRV16. (A) Screen grab of 
Progenesis analysis showing DJ-1 presence on a reference 2D-DIGE gel image from control 
(Ctrl) and HRV16 infected (72 hr) lysates. Image represents four independent experiments (B) 
BEAS-2B cells were seeded in a 6-well plate at a density of 0.4x10
6
 cells/ml and incubated 
for 24 hr at 37 °C. Thereafter, cells were transferred to a 33 °C incubator and either left 
uninfected or infected with HRV16 (MOI of 3) for the timepoints indicated. Cells were then 
harvested and each sample lysed in 100 μl H.S. buffer for 20 min on ice. Cell debris was 
removed by centrifugation with the remaining whole cell lysates mixed with 30ul 5x 
Laemmli loading buffer and boiled for 10 min. Proteins were separated by SDS-PAGE and 
subjected to immunoblot analysis using anti-DJ-1 and anti-β-Actin antibodies. Results 
represent two independent experiments. Image is representative of three independent 
experiments (C) BEAS-2B cells were plated, incubated and stimulated according to (B). Cells 
were then harvested, total RNA isolated and from this, cDNA was synthesised. The cDNA 
was then used as a template for qRT-PCR using forward and reverse primers specific to 
human dj-1 and gapdh (housekeeping gene). * p<0.05, ** p<0.01 and *** p<0.001. NS, not 
significant. Graph is representative of two independent experiments. 
 
B 
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Figure 5.6: Verification of stathmin 1 upregulation in response to HRV16. (A) Screen 
grab of Progenesis analysis showing stathmin 1 presence on a reference 2D-DIGE gel image 
from control (Ctrl) and HRV16 infected (72 hr) lysates. Image represents four independent 
experiments (B) BEAS-2B cells were seeded in a 6-well plate at a density of 0.4x10
6
 cells/ml 
and incubated for 24 hr at 37 °C. Thereafter, cells were transferred to a 33 °C incubator and 
either left uninfected or infected with HRV16 (MOI of 3) for the timepoints indicated. Cells 
were then harvested and each sample lysed in 100 μl H.S. buffer for 20 min on ice. Cell 
debris was removed by centrifugation with the remaining whole cell lysates mixed with 30ul 
5x Laemmli loading buffer and boiled for 10 min. Proteins were separated by SDS-PAGE 
and subjected to immunoblot analysis using anti-stathmin 1 and anti-β-Actin antibodies. 
Results represent two independent experiments. Image is representative of three independent 
experiments (C) BEAS-2B cells were plated, incubated and stimulated according to (B). Cells 
were then harvested, total RNA isolated and from this, cDNA was synthesised. The cDNA 
was then used as a template for qRT-PCR using forward and reverse primers specific to 
human stmn1 and gapdh (housekeeping gene). * p<0.05, ** p<0.01 and *** p<0.001. NS, not 
significant. Graph is representative of two independent experiments. 
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Figure 5.7: Verification of triose phosphate isomerase upregulation in response to 
HRV16. (A) Screen grab of Progenesis analysis showing triose phosphate isomerase (TPI) 
presence on a reference 2D-DIGE gel image from control (Ctrl) and HRV16 infected (72 hr) 
lysates. Image represents four independent experiments (B) BEAS-2B cells were seeded in a 
6-well plate at a density of 0.4x10
6
 cells/ml and incubated for 24 hr at 37 °C. Thereafter, cells 
were transferred to a 33 °C incubator and either left uninfected or infected with HRV (MOI 
of 3) for the timepoints indicated. Cells were then harvested and each sample lysed in 100 μl 
H.S. buffer for 20 min on ice. Cell debris was removed by centrifugation with the remaining 
whole cell lysates mixed with 30ul 5x Laemmli loading buffer and boiled for 10 min. 
Proteins were separated by SDS-PAGE and subjected to immunoblot analysis using anti-TPI 
and anti-β-Actin antibodies. Results represent two independent experiments. Image is 
representative of three independent experiments (C) BEAS-2B cells were plated, incubated 
and stimulated according to (B). Cells were then harvested, total RNA isolated and from this, 
cDNA was synthesised. The cDNA was then used as a template for qRT-PCR using forward 
and reverse primers specific to human tpi and gapdh (housekeeping gene). * p<0.05, ** 
p<0.01 and *** p<0.001. NS, not significant. Graph is representative of two independent 
experiments. 
B 
A 
C 
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Figure 5.8: Verification of superoxide dismutase upregulation in response to HRV16. (A) 
Screen grab of Progenesis analysis showing superoxide dismutase (SOD) presence on a 
reference 2D-DIGE gel image from control (Ctrl) and HRV16 infected (72 hr) lysates. Image 
represents four independent experiments (B) BEAS-2B cells were seeded in a 6-well plate at 
a density of 0.4x10
6
 cells/ml and incubated for 24 hr at 37 °C. Thereafter, cells were 
transferred to a 33 °C incubator and either left uninfected or infected with HRV (MOI of 3) 
for the timepoints indicated. Cells were then harvested and each sample lysed in 100 μl H.S. 
buffer for 20 min on ice. Cell debris was removed by centrifugation with the remaining whole 
cell lysates mixed with 30ul 5x Laemmli loading buffer and boiled for 10 min. Proteins were 
separated by SDS-PAGE and subjected to immunoblot analysis using anti-SOD and anti-β-
Actin antibodies. Results represent two independent experiments. Image is representative of 
three independent experiments (C) BEAS-2B cells were plated, incubated and stimulated 
according to (B). Cells were then harvested, total RNA isolated and from this, cDNA was 
synthesised. The cDNA was then used as a template for qRT-PCR using forward and reverse 
primers specific to human sod and gapdh (housekeeping gene). * p<0.05, ** p<0.01 and *** 
p<0.001. NS, not significant. Graph is representative of two independent experiments. 
B 
A 
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5.2.8 HRV16 and poly(I:C) mediated cytokine production post knockdown of stathmin 
1 and DJ-1 expression in BEAS-2B cells 
As previously discussed, stathmin 1’s primary function in microtubule organisation implies 
possible roles in diverse cellular functions [253, 261, 330]. Indeed, previous data has 
indicated a role for stathmin 1 in TLR4 mediated IL-6 production (Figure 4.19). Moreover, 
stathmin 1 has been described as a candidate TLR3 agonist and TLR3 is also known to sense 
dsRNA produced by HRV16 in BEAS-2B cells [478].  DJ-1 is a known biological marker for 
Parkinson’s disease susceptibility and may play a role in its pathogenesis [313]. Furthermore, 
DJ-1 has been shown to play a conserved role in the regulation of NO production in response 
to gram-negative bacteria [318, 319]. However a role for either proteins in mediating the 
immune response to viral infection has not been shown.  
In order to attain a greater understanding of the role that stathmin 1 and DJ-1 play in the host 
innate immune response to HRV16 infection, their levels were endogenously supressed in 
BEAS-2B cells immediately prior in HRV16 infection. Resulting cytokine expression in 
infected cells with suppressed levels of either protein were therefore compared to control 
infected cells. 
Validation of esiRNA mediated suppression of mRNA expression corresponding to both 
stathmin 1 and DJ-1 was previously carried out (Figure 4.18). Estimated knockdown 
efficiency was 95 % and 60 % respectively compared to controls (Figure 4.18B,D).  
Transfection of esiRNA specific to either stathmin 1 or DJ-1 did not significantly alter basal 
IL-6, RANTES or type-I IFN cytokine production (Figure 5.9A-E). Infection with HRV16 
induced production of IL-6 with approximately 400 pg/ml secreted compared to uninfected 
controls (Figure 5.9A). However, minimal RANTES or type-I IFN was detected (Figure 
5.9B,E). In contrast, poly(I:C) stimulation mediated strong production of all three cytokines 
compared to unstimulated controls (Figure 5.9C-E). Knockdown of stathmin 1 expression did 
not significantly modulate secretion of IL-6, RANTES or type-I IFN in response to HRV16 
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infection or poly(I:C) stimulation compared to uninfected or unstimulated controls (Figure 
5.9A-E). The same result was obtained upon suppression of DJ-1 (Figure 5.9A-E). Levels of 
IL-6 increased slightly upon stathmin 1 and DJ-1 suppression during HRV16 infection but 
this was not significant (Figure 5.9A). It would therefore appear that stathmin 1 and DJ-1 do 
not play a role in both pro-inflammatory cytokine and type-I IFN production in response to 
TLR3 activation and infection with HRV16.     
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Figure 5.9: HRV16 and poly(I:C) mediated cytokine production upon suppression of 
stathmin 1 and Dj-1. For HRV16 mediated responses, BEAS-2B cells were seeded in a 6-
well plate at a density of 0.4x10
6
cells/ml and either left uninfected or infected with HRV16 
(MOI of 3) in an incubator at 33 °C for 24 hr. Cells were then transfected with either 200 ng 
of target gene specific esiRNA or a control esiRNA (eGFP) for a further 24 hr. At this point, 
medium was removed and fresh medium containing HRV16 (MOI of 3) was added for a 
further 24 hr. Cell free supernatants were then harvested and analysed for the presence of 
human IL-6 (A), RANTES (B) and type-I IFN (E). For poly(I:C) mediated responses, BEAS-
2B cells were seeded in a 6-well plate at a density of 0.4x10
6
cells/ml for 24 hr at 37 °C. Cells 
were then transfected with either 200 ng of target gene specific esiRNA or a control esiRNA 
(eGFP) for a further 24 hr. At this point, medium was removed and fresh medium was added 
for 2 hr upon which cells were either left unstimulated or stimulated with poly(I:C) (25 μg/ml) 
for 24 hr. Cell free supernatants were then harvested and analysed for the presence of human 
IL-6 (C), RANTES (D) and type-I IFN (E). Results are representative of 3 independent 
experiments. NS, not significant. 
A B 
C D 
E 
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5.3 Discussion 
 
Viral respiratory tract infections (VRTIs) are among the most common illnesses in humans 
[479]. Non-influenza related VRTIs, particularly the picnoraviruses place a significant 
economic burden on society in terms of missing direct medical costs and indirect losses in 
productivity including absences from work and school [480]. Annual losses to the US 
economy for example, have been estimated to total $40 billion annually, with  a close to 
50:50 split between direct and indirect expenditures [479]. Unlike influenza, for which there 
is a limited vaccine available that requires annual doses, there is no such prophylaxis 
currently available for protection against HRVs, despite the aforementioned economic toll. 
Antiviral therapies are therefore seen as a feasible method of control which serves to limit the 
virus’s ability hijack the host’s machinery and thus prevent replication, dissemination and the 
associated inflammatory symptoms. As previously mentioned, no analysis of the HRV 
induced changes to the host cell’s proteome have been conducted and a greater understanding 
of this area could aid the design of more effective antiviral drugs that target host response 
mechanisms, which the virus requires to survive, instead of targeting the virus itself.  
To this end, the whole cell proteome of a lung epithelial cell line, BEAS-2B, was assessed 
following infection with HRV16 using uninfected cells as a control. A total of 41 proteins 
were found to be significantly differentially regulated upon HRV16 viral infection (Figure 
5.3A, Table 5.1). Of these, 80% were upregulated and 20% were downregulated (Figure 
5.2C). Major cellular processes involved in the response to HRV16 appear to be immune 
function, protein synthesis, cancer related and structural processes (Figure 5.2A). 
Interestingly, approximately 25% of proteins identified as undergoing significant expression 
changes in response to HRV16 infection also underwent similar changes in response to B. 
pertussis infection (Figure 5.3A,B). As previously mentioned, these proteins in particular 
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may be of significant interest to future attempts at curbing the growth and pathogenesis of 
these two infections. It was interesting that the cytokine IL-25 was found to be significantly 
upregulated in response to both bacterial and viral challenge. IL-25 has only recently been 
discovered and is known to promote T helper cell 2 (TH2) associated pathology by 
augmenting production of TH2 cytokines such as IL-4, IL-5, IL-13 but not IL-17 (a TH1 
associated cytokine) despite IL-25 being a member of the IL-17 family [296]. A recent study 
has implicated IL-25 in enhancing herpes simplex virus 1 and VACV replication by 
inhibiting expression of an epithelial barrier protein, filaggrin as well as by synergistically 
acting with other TH2 cytokines to aid replication [481]. Moreover, HRV is known to induce 
higher clinical illness severity in asthmatic patients and this has been associated with 
significantly higher levels of TH2 cytokines and impaired TH1 immunity [482, 483]. As IL-25 
is a key driver of TH2 response it stands to reason that inhibiting its activity could lead to 
reduced viral replication and symptom severity. B. pertussis infection in infants and mice 
tends to drive a TH1 cytokine profile and it is difficult to speculate upon the effects of 
supressing IL-25 in this respect [484]. The number of proteins known to be cancer markers 
was surprising. Several of these have only transient if any known role in the host response to 
pathogens (Figure 5.2A and Table 5.1). NDK, RBBP9, PRDX3 and GSTP1 are examples of 
this trend and thus their identification as markers of host homeostatic disregulation, whether 
in a cancer or infection setting, signals their importance to host homeostasis. Either way, their 
dynamic regulation during the host response to HRV16 signifies a possible role in host 
defence against the virus or in viral subversion of the host response. Further experiments will 
need to be undertaken in order to identify the exact nature of their roles.  
Two proteins that were significantly upregulated in response to HRV16 infection, stathmin 1 
and Dj-1 were further assessed using RNA interference to examine if they were involved in 
mediating cytokine production in response to infection. Suppression of each protein 
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individually led to slight increases in IL-6 production during HRV16 however this was not 
significant. No change was similarly detected in the production of HRV16 or poly(I:C) 
mediated RANTES or type-I IFN upon suppression of either protein.  As no significant 
phenotype was observed, their exact role in the host innate immune response viral infection 
can only be speculated upon. Stathmin 1’s role in microtubule formation would suggest that it 
is involved in modulating intracellular structures or trafficking in response to viral entry 
within the cell.  DJ-1’s role in host protection against oxidative stress could serve to limit 
collateral damage to the host upon activation of ROS, a known human defence mechanism 
against viruses [485]. 
In conclusion, multiple proteins have been identified as being dynamically regulated in 
response to HRV16 infection. These proteins have documented roles in a wide variety of 
cellular processes and shed light on the host response to viral infection. Whilst no specific 
HRV16 infection related function could be found upon the suppression of expression of two 
of these proteins, more rigorous approaches are likely to yield dividends. These approaches 
would include the use of broad scale RNAi panels to supress many protein hits, both 
individually and simultaneously as well as a wider range of functional assays such as the 
monitoring of viral replication and ROS production in response to these protein knockdowns. 
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6.1 Discussion 
The overarching aim of the current work was to add new dimension(s) to our current 
knowledge regarding the host response to pathogen challenge. To this end, the aim of chapter 
3 was to examine the effects of the loss of a single, relatively understudied TLR adaptor 
molecule, TRAM, upon activation of multiple TLR signalling pathways. The central aim here 
was not to confirm previous findings regarding TRAM’s function but rather to re-evaluate its 
role in TLR signalling. Although it is generally accepted that TRAM functions solely as a 
linker molecule, bridging TLR4 with TRIF to primarily drive anti-viral cytokine production 
[15, 24], a careful reading of the primary papers that originally defined TRAM’s isolated role 
show that this hypothesis had not been stringently tested, particularly with regard to its 
possible role(s) in TLR4 independent IRF mediated cytokine production [23, 24]. Control 
experiments aiming to demonstrate that TRAM does not participate in TLR signalling 
pathways that are distinct from TLR4 have, to date, only examined NF-κB driven 
inflammatory cytokines such as TNFα and IL-6 upon perturbation of TRAM [23, 24]. This is 
surprising as the role of TRAM in TLR4 signalling has always been linked to the production 
of cytokines and chemokines associated with strong IRF3 and IRF7 regulation, such as type-I 
IFN [15].  Thus re-evaluating the role of TRAM in TLR signalling, whilst factoring in IRF3 
and IRF7 modulated cytokines, revealed a number of unanticipated roles for TRAM in TLR2, 
TLR7 and TLR9 signalling. Notably, these roles were not related to the production of the 
pro-inflammatory, primarily NF-κB controlled cytokine TNFα, but rather the IRF3 controlled 
chemokine RANTES and the type-I IFN (Figure 3.5). The observed phenotypes were 
unexpected for a number of reasons. Firstly, TLR2, TLR7 and TLR9 are primarily known as 
MyD88-dependent TLRs, which, upon recognition of their cognate PAMP, transduce their 
intracellular signal using only MyD88 (TLR2 also utilises the adaptor MAL at low PAMP 
concentrations) [15, 21]. TRAM, on the other hand is primarily known to mediate the MyD88 
independent signalling axis via TLR4 and thus it was surprising that it was found to play a 
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role in mediating MyD88-dependent TLR2, TLR7 and TLR9 signalling. However, the recent 
demonstration that TRAM physically interacts with MyD88 to mediate IL-18R signalling 
provides a precedent for a role for TRAM in mediating signalling via MyD88 dependent 
receptors. This result was verified in the current study, wherein an interaction between 
TRAM and MyD88 was demonstrated upon TLR7 stimulation and as elaborated upon earlier, 
suggests that TRAM is capable of localising to endosomal compartments upon TLR7 
signalling, just as it does during TLR4 signalling [84].    
Another reason for the unexpected phenotype was the observation that TRAM, at least in the 
case of TLR7 and TLR9 signalling, appears to mediate their signalling through a mechanism 
that involves IRF3 (Figure 3.9). The finding that IRF3 is activated in response to TLR7 or 
TLR9 signalling is novel and perhaps controversial, as it has previously been asserted that 
IRF3 is not involved in TLR7 signalling in Raw264.7 macrophages [212]. In contrast to the 
previous study that utilised the TLR7 ligand R848 at a concentration of 10 μM to activate the 
Raw264.7 macrophages, the current study demonstrated that 2.8 μM R848 (1 μg/ml) resulted 
in the activation of iBMDMs.  This suggests that iBMDMs may be more sensitive than 
Raw264.7 macrophages to TLR7 stimulation and that this may be due in part to their ability 
to utilise IRF3 to supplement their signalling. Thus, the observed TRAM-dependent IRF3 
activation may be cell type specific whereby iBMDMs display a lower TLR7 activation 
threshold due to their ability to activate IRF3 in a TRAM dependent  manner. From a 
(patho)physiological perspective, the reliance sole reliance on a MyD88-IRF5 or MyD88-
IRF7 for type-I IFN production by the endosomal TLRs seems a risky strategy for the cell. 
Although other cytosolic PRRs can also sense foreign nucleotides leading to the activation of 
Type-I IFN in an IRF3 and IRF7 dependent manner [486], the endosomsal TLRs nevertheless 
play an important role in pathogen response and the potential to utilise IRF3, via a TLR7-
MyD88-TRAM-IRF3 axis, would at least expand their ability to successfully transmit a 
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danger signal to the nucleus if IRF7 and in the case of TLR7, IRF5 also, were to become 
antagonised by a viral subversion mechanism [487].   
It should be noted that the involvement of TRAM in TLR7 signalling does not negate its 
reliance on MyD88. The TLR7 dependent co-immunoprecipitation of TRAM and MyD88 
suggests that TLR7-TRAM signalling is dependent upon MyD88 (Figure 3.19). Thus, a 
remaining question is whether TRAM is required for the interaction of MyD88 with TLR7, as 
it is for the interaction of TRIF with TLR4, or is it the case that TRAM binds downstream of 
MyD88 to act as a linker to the IRF3 pathway. Contrasting with MyD88 deficient cells [40], 
suppression of TRAM does not completely abolish TLR7 signalling (Figure 3.5, 3.16) 
suggesting that there are still transcription factor(s), likely IRF5 and IRF7 via MyD88, 
mediating type-I IFN in the absence of the TRAM-IRF3 pathway. This would therefore 
suggest that TRAM functions downstream of MyD88. If it were upstream of MyD88, TRAM 
deficient cells would be completely unresponsive to TLR7 or TLR9 stimulation, which is not 
the case (Figure 3.5). Thus, it may be proposed that TLR7 signalling in BMDMs may be 
mediated by three MyD88 dependent signalling pathways. These are a TLR7-MyD88-NF-κB 
axis, a TLR7-MyD88-IRF5/IRF7 axis and a novel TLR7-MyD88-TRAM-IRF3 axis which 
complements the IRF5/IRF7 pathway. Future work would include elucidation of the factors 
that modulate TLR7 signalling downstream of TRAM but upstream of IRF3 in this pathway. 
IRF3 is known to be phosphorylated by the combined action of the kinases TBK1 and IKKε 
and would therefore be expected to be involved in any activation of IRF3 [488]. Furthermore, 
confocal imaging of TRAM, TLR7, TLR9 and IRF3 upon stimulation with the corresponding 
TLR ligands would be hugely useful in both visualising the trafficking patterns of these 
proteins during active signalling and also in conforming the roles of TRAM and IRF3 in 
these pathways.  
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If such novel insights can still be made regarding the function of the adaptor TRAM, one of 
the basic tenants of TLR signalling, then one must wonder as to the scale of the ‘novelties’ 
still to be discovered with roles in the host defence against pathogen invasion. One could 
argue that almost all proteins in a cell can potentially play some role in this regard as any 
change to cell homeostasis, be it from a pathogenic, cancerous, aging or autoimmune source, 
can signal to host systems to mobilise in order to revert the cell back to its homeostatic 
equilibrium. The host response to a pathogen for example, could therefore be considered not 
just in terms of the immune response, but should also consider the multitude of ways in 
which cellular process are disrupted and thus respond to threats [489]. Paying attention to 
these processes and how they dictate the balance of survival between say pathogen and host 
could provide many new targets for therapeutic interventions or at the very least bring a 
greater understand of what exactly occurs to a cell during pathogenic insult. 
 
With the above concept in mind, the aim of chapters four and five were to delineate the host 
response to pathogenic insult – not at the level of a single protein, namely TRAM, but on a 
global scale, utilising a whole cell proteomic approach. Proteins whose expression is 
significantly modified in response to infection are considered mediators of host homeostatic 
change and are therefore potential targets for therapies that seeks to restore homeostasis. Two 
respiratory pathogens, one bacterial (B. pertussis) and one viral (HRV16), were chosen as the 
model pathogens owning to their contrasting taxonomy and comparable target in humans, the 
respiratory tract. Humans are also the primary reservoir for B. pertussis and HRV16 and both 
have thus evolved remarkable abilities to stubbornly resist eradication despite advances in 
medical science. The host proteomic response upon infection with each pathogen was thus 
characterised with comparisons between the two also made in order to more succinctly 
illustrate protein responses that are exclusive to either pathogen or that are inclusive of both.  
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Chapter four sought to examine the host whole cell proteomic response to B. pertussis 
infection and is the first time such a study has been attempted. Previously, a transcriptomic 
study using high density DNA microarrays examined the in-vitro host response to B. 
pertussis infection in the same cell-line (BEAS-2B) that was used the current study [181]. 
The researchers investigated the transcriptome of BEAS-2B cells following exposure to B. 
pertussis at a single time point and MOI in order to create an easily controlled and 
reproducible model of the interaction between the pathogen and its target cell type. The 
transcriptomic study found that upon B. pertussis infection for three hours, a dominant pro-
inflammatory response was generated with numerous inflammatory genes upregulated 
including those encoding IL-8, IL-6 and IL-1β [181]. It was interesting that both IL-6 and IL-
1β mRNAs were upregulated as the current work documented copious IL-6 production in 
response to B. pertussis (Figure 4.19), however no detectable IL-1β was detected. It may be 
possible that while IL-β mRNA is upregulated in response to B. pertussis, its secretion at the 
protein level may be somehow inhibited by a B. pertussis virulence factor. A further 
possibility is that BEAS-2B cells either lack, or express low levels of the inflammasome 
machinery required to sense B. pertussis and thus process pro-IL-1β into its mature, secretory 
form. The expression of NLRP12 was shown to be upregulated in response to B. pertussis 
however as no detectable IL-1β was secreted, this suggests that NLRP12 is not a major 
sensor of B. pertussis in BEAS-2B cells, at least with regard to mature IL-1β production.  The 
disconnect between gene and protein expression was a recurring theme in the analysis of hits 
obtained through both 2D-DIGE MS and LFQ MS. Many proteins which were upregulated in 
response to B. pertussis infection such as SOD, TPI, NLRP12 and ferritin were not due to 
increased gene expression (Figures 4.15, 4.9 and 4.11). Similarly, the disconnect between IL-
1β mRNA upregulation in [181] and the lack of secreted mature IL-1β in the current study 
illustrates a key drawback of transcriptomic studies. Dynamic gene expression in response to 
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cell perturbation does not necessarily correlate with protein expression [490]. Inferring that 
this is the case, without verification of corresponding protein levels, leads to false 
conclusions being drawn. Thus, a key benefit of the proteomic approach is simultaneously 
illustrated.  Taking the trancriptomic study at face-value, one could be forgiven for expecting 
both IL-6 and IL-1β to be key effector molecules produced by BEAS-2B cells in response to 
B. pertussis when in fact only IL-6 is secreted in detectable quantities.   
  
Both the transcriptomic [181] and current proteomic studies revealed the upregulation of 
several apoptosis factors with anti-apoptotic genes such as tnfaip3 and api2 dominating in the 
transcriptomic study and more pro-apoptotic proteins such as caspase 3 and caspase 7 in the 
proteomic study (Table 4.1, 4.2). This apparent shift to a pro-apoptotic fate can be explained 
by the different time points used in both studies with the transcriptional study infecting for 3 
hr and the proteomic study for 12 hr. As B. pertussis is known to drive apoptosis in infected 
cells [438, 491], the shift from anti-apoptotic to pro-apoptotic proteins likely reflects the 
detrimental effect the replicating bacteria are having on the host cell viability at the later time 
point of 12 hr. Thus B. pertussis mediated apoptosis of infected cells in likely to proceed in a 
caspase 3 and caspase 7-dependent manner. 
Another interesting pattern was the relatively large contribution that proteins associated with 
cancer and transcriptional/DNA editing processes appear to make to the changes in host 
homeostasis upon B. pertussis infection (Figure 4.12). It is estimated that approximately 15% 
of malignant cancers are attributed to infections with bacteria and viruses [492].  Examples 
include Hylobacteria pyori and gastric cancer and Streptococcus bovis with colon cancer 
[493, 494]. There is no known link between B. pertussis and cancer, however the large 
number of detected proteins with roles in DNA damage repair, DNA and RNA modifications 
and the cell cycle agree with the consensus that bacterial agents are capable of causing or at 
227 
  
least inducing similar pathways involved in tumorigenesis [492]. Pathogens such as B. 
pertussis that are capable of residing within the cell, like tumours, require metabolic 
resources which must be derived from the host. Thus like tumours [495], these requirements 
could potentially be targeted for disruption to supress bacterial replication – particularly 
during chronic infections. B. pertussis, if undetected regularly causes chronic infections [496] 
and this paradigm could potentially be used to target B. pertussis. However, a more useful 
intervention would be against antibiotic resistant bacteria such as methicillin-resistant 
Staphylococcus aerus (MRSA), which is also capable of surviving intracellularly [497]. 
Preventing these bacteria from increasing host intracellular metabolism and subverting it for 
their own needs could inhibit intracellular survival and thus reduce lethality.  
Suppression of a number of protein hits failed to elicit any change in secretion of IL-6 (Figure 
4.19A). However, this does not in any way mean that these proteins have no role to play in 
the host response to B. pertussis. Cytokine secretion is but one effector mechanism used by 
the cell and does not paint a complete picture regarding host response. Other defence 
mechanisms such as NO production could also be monitored as well as levels of bacterial 
replication and host cell death. Even better would be the use of in-vivo studies using mice 
deficient in each protein of interest. Alteration of survival upon loss of one of the protein hits 
would be the ideal illustration of a role for a particular protein in B. pertussis pathogenesis. 
Despite the lack of a cytokine related phenotype upon B. pertussis infection, suppression of 
PPP1Cα and stathmin 1 caused a significant reduction in TLR4 mediated IL-6 secretion 
(Figure 4.19B). The TLR4 ligand, LPS, is a noted virulence factor of B. pertussis however 
whilst B. pertussis is known to be recognised by TLR4, it is a relatively weak activator of this 
PRR compared to other members of the Bordetella family [498]. Thus B. pertussis may 
purposely seek to avoid or suppress the TLR4 response as host proteins stathmin and PPP1Cα, 
both upregulated by B. pertussis, appear to mediate TLR4’s inflammatory response which ma 
228 
  
in turn negatively impact upon B. pertussis survival. Addition of TLR4 agonists as adjuvants 
to B. pertussis vaccine preparations may therefore aid the protective response generated. 
Indeed both acellular and whole cell pertussis vaccines show defective protection against 
disease in TLR4 deficient mice [143]. 
 
Chapter five sought to examine the proteome of BEAS-2B cells in response to infection with 
another respiratory pathogen, HRV16. The aims of the study were to ascertain the proteins 
that may potentially be involved in the host response to viral infection, whether these had any 
effect on the immune response to HRV16 and also to probe similarities observed between the 
proteome alterations upon HRV16 and B. pertussis infection.  
The reduction in the number of HRV16 mediated protein hits with functions in metabolism 
compared to B. pertussis has already been discussed (Section 5.2.2), and serves to illustrate 
the difference in the host response to both pathogens. Another interesting observation was 
that approximately 25 % of protein hits altered upon HRV16 infection were also altered upon 
B. pertussis infection (Figure 5.3). Focusing on these proteins that were identified in both 
studies, 33 %, had previously demonstrated immune function, one quarter had documented 
links to cancer progression and one sixth have known involvements in redox pathways 
(Figure 5.3). Viral and bacterial co-infections in humans have been extensively reported upon 
with one of the best known examples being the synergism between Streptococcus 
pneumoniae and influenza which caused the ‘Spanish flu’ pandemic in 1918 [499]. This 
ability to coexist may be the result of shared patterns of host intracellular modification by 
certain bacteria and viruses thus rendering the cell weakened and amenable to coinfection 
[499]. Additionally, immune subversion mechanisms initiated by bacterial infections could 
increase susceptibility to viral coinfection and vice-versa. Indeed, the propensity for 
coinfection between B. pertussis and HRV was illustrated in a recent Dutch study on a cohort 
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of children who experienced prolonged coughing episodes found that the two most frequent 
pathogens encountered from swabs taken from the children were HRV (32 %) and B. 
pertussis (17 %) [500]. Moreover, the most frequent mixed infection was also HRV and B. 
pertussis which occurred in 10% of cases [500]. Thus it is proposed that the similarities in 
host proteome remodelling observed in response to both B. pertussis and HRV16 infection 
suggests that there are similar pathways utilised by both pathogens to supplement their 
individual replication. Future work will involve perturbing these pathways with the intention 
of curbing either individual pathogens or both. Again, the use of knockout mice combined 
with both individual and co-infection models with a focus on alterations in bacterial or viral 
load and mouse survival in knockout mice compared to WT strains would be the preferred 
model. 
Knockdown of two protein hits that were upregulated upon HRV16 infection, stathmin 1 and 
DJ-1 did not have any effect on IL-6 production in response to HRV16 (Figure 5.9). This 
result mimics that observed upon B. pertussis infection as these two proteins, which were also 
found to be upregulated in response to B. pertussis, did not play a role in B. pertussis 
mediated IL-6 production (Figure 4.19A). Suppression of stathmin 1 and DJ-1 followed by 
stimulation of BEAS-2B cells with a HRV16 PAMP, dsRNA, in the form of poly(I:C) also 
had no effect on either IL-6, RANTES or type-I IFN secretion (Figure 5.9). It therefore 
remains to be seen what roles these proteins play in the host response to HRV16 infection. 
Further studies looking other cellular processes such as iNOS production and metabolism 
could be investigated. As mentioned earlier, alterations to viral replication could also be 
studied upon knockdown of these proteins. One interesting caveat that emerged from the 
poly(I:C) stimulations was that stathmin 1 suppression had no effect on poly(I:C) - TLR3  
mediated IL-6 production (Figure 5.9A). This contrasts with LPS (TLR4) mediated IL- 
production which was significantly reduced upon stathmin 1 knockdown (Figure 4.19B). 
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Thus, it would appear that stathmin 1’s role in TLR signalling is partially exclusive, at least 
to the TLR4 pathway. Stathmin’s role in microtubule formation has already been aluded to 
(Table 4.1, 5.1). It has also been shown that both TLR4 and TLR2 colocalise with alpha-
tubulin and align with microtubules in both dendritic cells and monocytes [501]. Moreover, 
microtubule disruption disturbed TLR2 and TLR4 expression and led to inhibition of IL-12 
production [501]. Thus potential roles in the signalling pathways of other TLRs, particularly 
those capable of trafficking between the plasma membrane and endosomes, such as TLR2 
[502] will have to be investigated in the future in order to further elucidate stathmin 1’s role 
in TLR signalling.  
 
6.2 Future work 
Regarding Chapter 3, there are a number of further experiments that could supplement the 
current data. It was previously attempted to obtain primary WT and TRAM 
-/- 
BMDMs in 
order to confirm the observed phenotypes, however the once shipped, the cells failed to grow. 
This experiement should be attempted again. TRAM’s role in TLR4 signalling has been 
shown to be dependent upon the adaptor TRIF which is immediately downstram of TRAM. 
Therefore, obtaining primary TRIF 
-/-
 BMDMs in order to define TRIF’s role in TLR7 
signalling would also be helpful.  
RNA interference of TRAM in human cells indicated a similar role for human TRAM in the 
TLR7 pathway. However, these experiements looked only at cytokine mRNA induction. 
Measurement of protein secretion by ELISA could not be optimised in time and should be 
examined in future experiments.  
It would be beneficial to provide further confirmation of TRAM’s physical presence within 
the TLR7 pathway and thus TRAM’s trafficking, localisation and protein-protein interactions 
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could be monitored at multiple timepoints using confocal microscopy to probe the position of 
fluorescently-tagged TRAM and other fluorescently-tagged proteins of interest such as TLR7, 
MyD88, TRIF, IRF3, IRF5, IRF7, TRAF6 and TRAF3.  
Finally, it would be interesting to see if the survival of TRAM deficient mice is in any way 
altered compared to WT mice upon infection with a TLR7 activating ssRNA virus. One 
would have to be certain however, that only the TLR7 pathway is being activated. Thus 
perhaps an intra-peritoneal injection of the TLR7 ligand R848 could be attempted and 
survival motiored from here. 
 
Focusing on Chapters’s 4 and 5, again there are numerous experiments that could append the 
present data. Regarding the LFQ MS study of B. pertussis modulated proteins, it was 
disappointing that more proteins known to be involved in innate immune signalling were not 
identified as well as the fact that only two proteins identified by LFQ MS were also found 
using 2D-DIGE MS. Thus it would be useful to further optimise the LFQ MS protocol 
particularly the protein lysis, peptide preparation and the specific protocol used for the Q-
Exactive MS/MS run. Once optimised, this technique could be applied to studying the whole-
cell lysate of HRV16 infected cells also.  
The experiements whereby esiRNA was used to reduce the endogenoud expression of 
selected hit proteins during infection with B. pertussis or HRV16 did produce some 
interesting results however they were limited by the small number of cytokine readouts. It is 
possible to purchase commercially produced cytokine arrays tailored to specific cell types 
(such as the epithelial cells used in the current work) which could simultaneously profile the 
secretion of many cytokines between control and knockdown states upon infection with B. 
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pertussis  or HRV16. This could therefore provide a much broader characterisation of the role 
of the selected proteins in cytokine secretion during an infection scerario.  
Cytokines are not the only possible downstream effector function that could be modulated by 
the selected proteins however. Other processes such as ROS production could also be 
monitored. Additionally, both bacterial and viral load could be tracked in order to see if the 
survival of B. pertussis or HRV16 is being impeded or indeed facilitated by the suppression 
of the selected proteins.  
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Spot 
No. 
Protein Name Fold 
Change 
Accession 
Code 
Mascot 
Score 
MW 
(kDa) 
pI Peptides 
Matched 
Cov 
(%) 
P Value 
1221 Thioredoxin ↑1.5 P10599 194 11.7 4.82 4 34 7.1E-04 
1221 Replication protein A 14 kDa subunit  ↑1.5 P35244 86 13.5 4.96 2 33 7.1E-04 
951 Triosephosphotase Isomerase (TPI) ↑4.4 P60174 297 30.7 5.65 5 29 0.008 
1179 Tubulin-specific chaperone A ↑1.4 O75347 172 12.8 5.25 6 38 0.002 
1120 Stathmin ↑1.5 P16949 142 17.2 5.76 3 21 0.015 
1120 Stathmin-2 ↑1.5 Q93045 86 20.8 8.4 2 10 0.015 
467 Protein disulfide-isomerase ↓1.3 P07237 916 57.0 4.76 25 50 0.015 
103 Transitional endoplasmic reticulum ATPase  ↓1.5 P55072 791 89.2 5.14 19 29 8E-04 
338 heat shock 70kDa protein 9B  ↓1.4 BAD96478 376 73.5 5.87 8 15 0.005 
527 Tapasin ERP57  ↓1.4 3F8U_A 946 54.1 5.61 18 46 1.8E-05 
1312 Superoxide dismutase [Cu-Zn] ↑1.3 Q6NR85 55 15.9 5.7 1 9 9.8E-05 
1199 HGSTP1-1 ↑1.3 4PGT_A 436 23.3 5.43 11 52 0.043 
1434 Ubiquitin-conjugating enzyme E2 N (Ubc13) ↑1.3 P61088 281 17.1 6.13 6 51 5.8E-04 
1347 Cofilin-1 ↓1.7 P23528 256 18.4 8.22 4 42 0.007 
1191 PRDX3  ↑1.3 P30048 238 27.6 7.67 4 18 0.02 
1032 Clic1 ↑1.4 3QR6_A 359 26.9 5.01 9 39 0.001 
997 EB1  ↑1.3 Q15691 446 29.9 5.02 10 45 0.021 
1061 
1019 
 
 
Glutathione S-transferase omega-1 
NLRP12 
 
 
↑1.4 
↑1.3 
 
 
P78417 
NP_150639 
 
 
204 
52 
 
 
27.5 
102 
 
 
6.23 
8.85 
 
 
7 
2 
 
 
24 
13 
 
 
0.017 
Table A1.1: Proteins identified by DIGE/ LC/MS showing changes in expression in response to B. pertussis Infection. All proteins were 
identified using the NCBI and Swiss Prot protein databases and demonstrated a mascot score >52 indicating reliable protein identification.  
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Spot 
No. 
Protein Name Fold 
Change 
Accession 
Code 
Mascot 
Score 
MW 
(kDa) 
pI Peptides 
Matched 
Cov 
(%) 
P Value 
1032 Proteasome subunit beta type-4 ↑1.5 P28070 372 29.1 5.72 9 36 0.005 
826 Annexin A2 ↑1.5 3GPD_R 125 38.5 7.57 2 6 3.7E-04 
1509 Thioredoxin domain-containing protein 12 ↑1.5 O75347 200 19.1 5.27 4 30 0.022 
1444 Mitotic spindle-associated MMXD complex  ↑1.5 Q9Y3D0 84 17.6 5.07 2 26 0.002 
1374 Nucleoside diphosphate kinase A (NME!) ↑1.4 Q96Q81 461 17.1 5.83 18 64 5.8E-06 
1539 Peroxiredoxin-6 ↑1.3 1SOA_A 256 25.0 6 9 44 0.023 
1488 Dj-1  ↑1.3 2RK6_A 490 19.8 6.33 16 66 0.011 
1093 Acyl-protein thioesterase 1 ↑1.3 P18669 89 24.6 6.29 2 8 0.004 
997 Phosphoglycerate mutase 1  ↑1.4 P37837 110 28.7 6.67 2 15 0.025 
806 Transaldolase ↑1.3 P62136 323 37.5 5.26 7 21 0.005 
1382 Serine/threonine-protein phosphatase PP1α ↑1.4 BAA11928 379 37.4 5.74 7 22 0.007 
1415 ER-60 protease ↓1.3 P38657 609 56.7 5.98 13 27 5.9E-05 
1442 Galectin-1  ↑1.3 P25398 260 14.5 5.34 7 44 0.001 
1342 40S ribosomal protein S12 ↑1.4 Q969H8 73 14.5 6.81 3 13 9E-07 
 1325 IL-25 ↑1.3 P09211 235 18.7 6.2 6 27 0.002 
1047 Caspase 3 ↑1.3 O75832 63 21.4 7.67 3 19 0.004 
1087 PSMB10  ↑1.4 Q6IBR6 100 24.4 5.71 3 17 0.011 
1492 Platelet-activating factor acetylhydrolase  ↑1.4 1QUQ_A 80 25.5 5.57 2 12 0.003 
          
          
          
Table A1.1: Proteins identified by DIGE/ LC/MS showing changes in expression in response to B. pertussis Infection. All proteins were 
identified using the NCBI and Swiss Prot protein databases and demonstrated a mascot score >52 indicating reliable protein identification.  
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Spot 
No. 
Protein Name Fold 
Change 
Accession 
Code 
Mascot 
Score 
MW 
(kDa) 
pI Peptides 
Matched 
Cov 
(%) 
P Value 
972 Replication Protein A (Rpa14 And Rpa32) ↑1.3 P06730 260 14.4 5.43 6 44 0.008 
1028 Eukaryotic translation initiation factor 4E ↑1.3 Q9UC36 74 25.0 5.79 2 11 0.047 
1037 Heat shock protein beta-1 ↑1.4 P13693 73 22.7 5.98 1 4 4E-04 
1109 DNA replication complex GINS protein PSF2 ↑1.3 O75947 58 21.4 5.29 1 13 6E-04 
1128 ATP synthase subunit d, mitochondrial ↑1.4 P04632 476 18.4 5.21 12 67 1.4E-04 
1019 Calpain small subunit 1 ↑1.4 Q96L46 485 28.2 5.05 9 51 1.6E-04 
1500 14-3-3 protein epsilon  ↑1.4 Q07021 123 29.1 4.63 3 15 0.004 
886 Complement component 1 Q  ↑1.4 P28066 289 31.3 4.74 8 31 3E-04 
1494 Putative hydrolase RBBP9 ↑1.4 1SOA_A 131 20.9 5.79 2 18 0.017 
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Protein Name Accession Code LFQ Intensity 
(Control) 
LFQ Intensity 
(Infected) 
Matched 
Peptides 
Fold 
Change 
PEP ANOVA 
Elongation Factor gamma  IPI:IPI00000875.7 NaN 26.1588 4 N/A 2.49E-16 N/A 
Sodium/potassium-transporting ATPase  IPI:IPI00006482.1 NaN 25.2055 6 N/A 8.69E-14 N/A 
Adenylyl cyclase-associated protein 1 IPI:IPI00008274.7 NaN 24.056 3 N/A 3.92E-16 N/A 
Exportin-2 IPI:IPI00022744.5 NaN 25.1535 7 N/A 1.03E-20 N/A 
Pre mRNA slicing factor SYF2 IPI:IPI00022963.3 NaN 24.6667 3 N/A 3.93E-13 N/A 
60S ribosomal protein L9 IPI:IPI00031691.1 NaN 25.0996 2 N/A 8.65E-05 N/A 
Pre-rRNA-processing protein TSR2  IPI:IPI00056314.1 NaN 23.5004 2 N/A 0.000226 N/A 
Glucose-6-phosphate 1-dehydrogenase IPI:IPI00216008.4 NaN 26.0543 8 N/A 1.20E-25 N/A 
Caspase-7 IPI:IPI00216674.1 NaN 24.9004 2 N/A 0.001409 N/A 
B-cell receptor-associated protein 31 IPI:IPI00642984.2 NaN 23.1694 4 N/A 1.96E-06 N/A 
Small kinetochore-associated protein IPI:IPI00294680.5 NaN 25.5811 2 N/A 7.50E-05 N/A 
DNA-dependent protein kinase  IPI:IPI00296337.2 NaN 26.1313 19 N/A 1.55E-46 N/A 
Laminin subunit gamma-1 IPI:IPI00298281.4 NaN 25.1725 3 N/A 1.25E-18 N/A 
60S ribosomal protein L7a IPI:IPI00299573.12 NaN 24.8042 2 N/A 0.000365 N/A 
60S ribosomal protein L17 IPI:IPI00413324.6 NaN 25.5323 2 N/A 1.78E-05 N/A 
Ribosome-binding protein p34 (p34) IPI:IPI00396321.1 NaN 25.7962 3 N/A 5.30E-14 N/A 
RACK1 IPI:IPI00848226.1 NaN 25.7188 6 N/A 5.44E-32 N/A 
RNA-binding protein 4 IPI:IPI00003704.4 25.0283 NaN 3 N/A 2.12E-07 N/A 
Protein S100-A13 IPI:IPI00016179.1 26.4933 NaN 2 N/A 1.86E-26 N/A 
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Protein Name Accession Code LFQ Intensity 
(Control) 
LFQ Intensity 
(Infected) 
Matched 
Peptides 
Fold 
Change 
PEP ANOVA 
NUDT15 IPI:IPI00019487.3 24.8133 NaN 3 N/A 6.96E-08 N/A 
Upstream stimulatory factor 2 IPI:IPI00020037.1 25.3726 NaN 3 N/A 7.44E-10 N/A 
Nck-1 IPI:IPI00028065.1 24.7187 NaN 4 N/A 9.56E-20 N/A 
BRO1 domain-containing protein BROX IPI:IPI00065500.3 25.2597 NaN 2 N/A 1.28E-08 N/A 
E3 ubiquitin-protein ligase RNF181 IPI:IPI00292354.8 25.1869 NaN 2 N/A 5.56E-09 N/A 
Caspase activity and apoptosis inhibitor 1 IPI:IPI00303812.7 25.4128 NaN 3 N/A 5.77E-05 N/A 
RNA polymerase-associated protein RTF1  IPI:IPI00303832.6 25.3318 NaN 6 N/A 5.49E-17 N/A 
Kanadaptin IPI:IPI00306749.8 24.5912 NaN 3 N/A 1.00E-08 N/A 
Cx9C motif-containing protein 4 IPI:IPI00446798.1 25.1599 NaN 2 N/A 4.32E-15 N/A 
RNA-binding protein 8A IPI:IPI00001757.1 31.3137 30.9937 10 -0.64 1.98E-228 + 
Serine/arginine-rich splicing factor 2 IPI:IPI00005978.8 32.3223 31.9449 12 -0.75 0 + 
Putative RNA-binding protein Luc7-like 2 IPI:IPI00006932.4 28.1672 28.5935 10 0.85 3.52E-123 + 
UV excision repair protein RAD23 IPI:IPI00008219.1 26.0555 25.4419 8 -1.23 6.40E-18 + 
Intercellular adhesion molecule 1 IPI:IPI00008494.4 24.3462 26.2793 6 3.87 4.29E-26 + 
Serine/arginine-rich splicing factor 6 IPI:IPI00012345.2 31.5658 31.1274 14 -0.88 1.71E-99 + 
Calponin-2 IPI:IPI00910593.1 32.0846 31.7908 17 -0.59 0 + 
Uncharacterized protein C14orf119 IPI:IPI00016726.3 25.4719 26.2364 3 1.53 1.26E-12 + 
SNX15 IPI:IPI00016820.1 26.9393 26.6184 7 -0.64 1.15E-20 + 
U4/U6.U5 Nuclear ribonucleoprotein IPI:IPI00017289.3 27.4412 26.8387 5 -1.21 2.13E-36 + 
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Protein Name Accession 
Code 
LFQ Intensity 
(Control) 
LFQ Intensity 
(Infected) 
Matched 
Peptides 
Fold 
Change 
PEP ANOVA 
SH3-containing Grb-2-like 1 protein IPI:IPI00019169.3 25.9905 24.7994 5 -2.38 4.06E-31 + 
Calreticulin  / ER resident protein 60 IPI:IPI00020599.1 32.4786 31.8841 22 -1.19 0 + 
Superoxide dismutase IPI:IPI00022314.1 26.5621 28.6293 6 4.13 4.54E-57 + 
Zinc finger Ran-binding domain protein 2 IPI:IPI00029400.2 30.5409 30.158 12 -0.77 2.64E-70 + 
Tenascin  IPI:IPI00031008.1 25.256 26.1233 5 1.73 2.16E-27 + 
U6 snRNA-associated Sm-like protein  IPI:IPI00032460.3 27.5791 28.196 3 1.23 7.88E-34 + 
RNA-binding protein IPI:IPI00033561.3 30.6525 29.7869 7 -1.73 1.42E-109 + 
Coiled-coil domain-containing protein 97 IPI:IPI00061777.4 27.8229 27.401 6 -0.84 1.13E-38 + 
40S ribosomal protein S29 IPI:IPI00182289.6 25.5816 26.0145 2 0.87 6.93E-06 + 
Galectin-1 IPI:IPI00219219.3 34.1862 34.5223 16 0.67 0 + 
N-alpha-acetyltransferase 38 IPI:IPI00219871.5 28.4039 27.9208 4 -0.97 6.85E-19 + 
Cdc42 effector protein 3  IPI:IPI00294391.2 26.3264 25.7559 3 -1.14 5.49E-08 + 
TSC22 domain family protein 1 IPI:IPI00301610.9 27.7164 28.2144 8 +1.00 5.10E-69 + 
Protein TSSC4  IPI:IPI00305144.1 29.2542 28.9348 5 -0.64 1.07E-30 + 
Serine/arginine repetitive matrix protein 1 IPI:IPI00328293.3 28.0004 26.944 6 -2.11 2.74E-40 + 
Ferritin IPI:IPI00375676.5 27.9658 29.4761 6 3.02 4.09E-47 + 
Periphilin-1 IPI:IPI00410039.1 26.5231 27.0506 7 1.06 3.41E-31 + 
Transcription elongation factor A protein-like 
3  
IPI:IPI00478127.3 30.6756 30.2284 9 -0.89 3.55E-65 + 
Ferritin heavy chain IPI:IPI00554521.2 31.962 33.7804 16 3.64 1.06E-255 + 
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Protein Name Accession Code LFQ Intensity 
(Control) 
LFQ Intensity 
(Infected) 
Matched 
Peptides 
Fold 
Change 
PEP ANOVA 
Transcription elongation factor A protein-like 
4 
IPI:IPI00647163.1 29.142 28.6857 11 -0.91 3.46E-58 + 
Serine/arginine repetitive matrix protein 2 IPI:IPI00782992.3 30.0636 29.0563 24 -2.01 1.29E-221 + 
 
Suppressor of G2 allele of SKP1 homolog IPI:IPI00828150.1 27.7404 27.4011 6 -0.68 2.53E-70 + 
        
 
 
 
 
 
 
 
 
Table A1.2: Proteins identified by LFQ MS showing changes in expression in response to B. pertussis Infection. All proteins were 
identified using the NCBI and Swiss Prot protein databases and demonstrated a mascot score >52 indicating reliable protein identification.  
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Spot 
No. 
Protein Name Fold 
Change 
Accession 
Code 
Mascot 
Score 
MW 
(kDa) 
pI Peptides 
Matched 
Cov 
(%) 
P Value 
1361 Stathmin ↑1.6 P16949 154 17.2 5.76 3 21 0.009 
1375 Actin-related protein 2/3 complex subunit 5 ↑1.6 O15511 193 16.3 5.47 5 41 0.003 
1383 Prefoldin subunit 5 ↑1.5 O99471 97 17.3 5.93 3 21 0.006 
1345 Superoxide Dismutase (Cu-Zn)  ↑1.7 Q904262A 56 15.9 8.76 2 16 0.009 
1325 DUTP ↑1.6 Q96Q81 254 26.5 9.46 8 30 0.006 
1334 Nucleoside diphosphate kinase A (NME1) ↑1.5 P15531 379 17.1 5.83 14 63 0.012 
1291 Putative hydrolase RBBP9 ↑1.5 O75884 202 20.9 5.79 4 30 0.025 
1250 α/β hydrolase domain-containing protein 14B ↑1.5 Q96IU4 206 22.3 5.94 4 28 0.028 
1550 DJ-1 ↑1.6 ISOA_A 473 19.8 6.33 14 68 0.003 
1549 PRDX3 ↑1.5 P30048 173 27.6 7.67 4 18 0.01 
1326 Lysozyme C ↑1.6 P61626 62 16.5 9.38 1 8 0.045 
1581 Myosin regulatory light chain 12A ↓1.7 P19105 151 19.7 5.67 3 17 0.001 
1417 60S acidic ribosomal protein P2 ↑1.5 P05387 261 11.6 4.42 9 69 0.005 
 1373 Eukaryotic translation factor Eif5a ↑1.6 3CPF_A 321 15.1 5.8 9 40 4.35E-04 
1374 Glia maturation factor beta ↑1.5 P60983 199 16.7 5.19 3 29 0.006 
1265 Heme-binding protein 1 ↓1.3 Q9NRV9 481 21.0 5.71 12 50 0.011 
1492 
1240 
1261 
Glutathione S-Transferase P1 
26S proteasome non-ATPase reg. subunit 10 
Caspase 3 
↑1.4 
↑1.5 
↑1.3 
1QUQ_A 
4PGT_A 
EAX04676 
 
80 
644 
57 
 
25.5 
23335 
21.4 
5.57 
5.43 
7.67 
2 
16 
2 
12 
55 
21 
0.003 
0.003 
0.01 
          
Table A1.3: Proteins identified by DIGE/ LC/MS showing changes in expression in response to HRV16. All proteins were identified using 
the NCBI and Swiss Prot protein databases and demonstrated a mascot score >52 indicating reliable protein identification.  
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Spot 
No. 
Protein Name Fold 
Change 
Accession 
Code 
Mascot 
Score 
MW 
(kDa) 
pI Peptides 
Matched 
Cov 
(%) 
P Value 
1190 RPABC1 ↑1.5 NP_002686 251 24.5 5.69 6 30 0.002 
1154 Phosphoglycerate mutase 1 ↑1.5 P18669 150 28.7 6.67 4 16 0.033 
1518 Unnamed protein product ↓1.3 BAG63158 76 55.7 6.12 3 5 0.022 
1429 40S ribosomal protein S12  ↑1.5 P25398 69 14.5 6.81 3 13 0.022 
1434 HINT1 ↑1.5 P49773 88 13.7 6.43 2 24 0.006 
1651 S-phase kinase-associated protein 1 ↑1.5 P63208 299 18.6 4.4 5 46 0.009 
1254 DNA replication complex GINA protein PSF2 ↑1.5 Q9Y248 128 21.4 5.29 3 24 0.004 
512 Lamin B1 ↓1.5 P20700 758 66.3 5.11 7 32 0.012 
526 MAP3K1 or ASK1 ↓1.6 Q99683 62 154.4 5.52 2 61 0.012 
66 Splicing factor 3A subunit 1 ↑1.5 Q15459 252 88.3 5.15 8 13 0.009 
15 Menin ↓1.7 O00632 54 67.9 6.14 1 2 0.004 
17 Glycogen debranching enzyme ↓1.7 Q9UF08 52 174.6 6.31 2 1 0.005 
21 Tetratricopeptide repeat protein 21B ↓1.6 Q9HAK8 62 150.8 6.53 2 1 0.006 
1411 IL-25 ↑1.4 Q969H8 153 18.7 6.2 4 27 0.02 
1413 Histidine triad nucleotide-binding protein 2 ↑1.4 Q9BX68 147 17.1 9.2 4 36 0.009 
1342 Cofilin-1 ↑1.4 P23528 242 18.4 8.22 5 42 0.031 
1408 Ubquitin-conjugatin enzyme E2 N ↑1.4 P61088 397 17.1 6.13 9 67 0.02 
1192 
963 
Triose phosphate isomerase 
Coiled-coiled domain containing 69 
↑1.4 
↑1.3 
P60174 
EAW61682 
339 
59 
30.7 
34.6 
5.65 
5.49 
8 
2 
27 
7 
0.003 
0.006 
 
Table A1.3: Proteins identified by DIGE/ LC/MS showing changes in expression in response to HRV16 Infection. All proteins were 
identified using the NCBI and Swiss Prot protein databases and demonstrated a mascot score >52 indicating reliable protein identification.  
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Spot 
No. 
Protein Name Fold 
Change 
Accession 
Code 
Mascot 
Score 
MW 
(kDa) 
pI Peptides 
Matched 
Cov 
(%) 
P Value 
1224 Prefoldin subunit 3 ↑1.4 P61758 160 22.6 6.63 4 19 0.033 
1236 Acyl-protein thioesterase ↑1.4 O75608 88 24.6 6.29 2 8 0.022 
1189 NME1-NME2(Nucleoside diphosphate kinase A 
and B) 
↑1.4 NP001018146 340 30.1 9.06 12 36 0.022 
          
          
          
          
          
          
          
          
          
          
          
          
          
          
Table A1.3: Proteins identified by DIGE/ LC/MS showing changes in expression in response to HRV16. All proteins were identified using 
the NCBI and Swiss Prot protein databases and demonstrated a mascot score >52 indicating reliable protein identification.  
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Table A1.4 List of antibodies used 
Antibody Company  
Phospho-IRF3 Cell Signalling 
Total IRF3 Santa Cruz 
IκBα Cell Signalling 
β-Actin Sigma Aldrich 
Lamin A/C Cell Signalling 
NLRP12 Biorbyt 
DJ-1 Biorbyt 
Stathmin-1 Biorbyt 
SOD1 Abcam 
NME1/NME2 Abcam 
GSTO1 Santa Cruz 
Ferritin HC Abcam 
Ferritin LC Abcam 
PPP1Cα Biorbyt 
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Figure A1.1 IRF3 phosphorylation in WT and TRAM deficient iBMDMs in response to 
R848 and LPS stimulation 
 
 
 
Figure A1.2 IRF3 phosphorylation in WT and TRAM deficient iBMDMs in response to 
CpG stimulation 
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Figure A1.3 IκBα degradation in WT and TRAM deficient iBMDMs in response to 
R848 stimulation 
 
 
 
 
Figure A1.4 IRF3 nuclear translocation in WT and TRAM deficient iBMDMs in 
response to R848 stimulation 
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